MAP Kinases Phosphorylate SPF45 and Regulate Its Alternative Splicing Function: Insights onto Phosphorylation-Dependent and -Independent Effects in Ovarian Cancer Cells by Al-Ayoubi, Adnan
Medical University of South Carolina 
MEDICA 
MUSC Theses and Dissertations 
2011 
MAP Kinases Phosphorylate SPF45 and Regulate Its Alternative 
Splicing Function: Insights onto Phosphorylation-Dependent and 
-Independent Effects in Ovarian Cancer Cells 
Adnan Al-Ayoubi 
Medical University of South Carolina 
Follow this and additional works at: https://medica-musc.researchcommons.org/theses 
Recommended Citation 
Al-Ayoubi, Adnan, "MAP Kinases Phosphorylate SPF45 and Regulate Its Alternative Splicing Function: 
Insights onto Phosphorylation-Dependent and -Independent Effects in Ovarian Cancer Cells" (2011). 
MUSC Theses and Dissertations. 16. 
https://medica-musc.researchcommons.org/theses/16 
This Dissertation is brought to you for free and open access by MEDICA. It has been accepted for inclusion in 
MUSC Theses and Dissertations by an authorized administrator of MEDICA. For more information, please contact 
medica@musc.edu. 
MAP kinases phosphorylate SPF45 and regulate its alternative splicing 
function: insights onto phosphorylation-dependent and -independent 
effects in ovarian cancer cells 
By 
Adnan AI-Ayoubi 
A dissertation submitted to the faculty of the Medical University of South 
Carolina in partial fulfillment of the requirement for the degree of Doctor of Philosophy 
in the college of Graduate Studies 
Department of Cell and Molecular Pharmacology and Experimential Therapeutics 
2011 
Approved by: 
Scott T. Eblen, PhD 
Chairman, Advisory Committee 
K I '-.<" f ---, 
~<...~--.!:;:. ~
Kenneth D. Tew, PhD DSc 
Steven A. ~ osen~wei Ph.D _ £2 
~-'~ 
Dennis K. Watson, PhD 
2 
Dedication 
To mom and dad, 
Your endless love, patience, support, guidance and understanding are the reason of my 




I would like to take this opportunity to thank my mentor, Dr Scott T Eblen, for 
giving me the chance to perform research in his lab and pursue my PhD under his 
supervision; thank you for your patience, support and dedication to my education 
throughout the time I spent in Graduate School, for your guidance on the path of 
scientific discovery and philosophy but most of all, for an everlasting friendship. To Dr 
Ken Tew, Dr Steven Rosenzweig} Dr Bryan Toole and Dr Dennis Watson, thank you for 
your willingness to serve on my committee, your continuous guidance, support and 
genuine interest throughout my training. To all the members of the Eblen lab, past and 
present, thank you for your patience, advice and kind words which made this process a 
pleasure. To all the members of the 6th floor Hollings Cancer Center and third floor Basic 
Science Building} past and present, the collegiality, friendships and happy moments will 
always be remembered and cherished. All the staff of the pharmacology department, 
past and present, thank you for handling my orders so diligently and processing them in 
a timely manner which made my work easier. And to all my friends and family, thank 
you for all the support, care and encouragement you keep on providing, I would not 
have been able to make it without you. 
4 
TABLE OF CONTENTS 
DEDICATION ••••••••••••.•••••••.•••••••••••••••.••••••••••••••••.••••••••.•••.•••••••••••.•••••••..•••••••.•.••••••...••••• 2 
ACKNOWLEDGMENTS ••••.••••••••••••••••.••••••.•••••••••••••••••••.•••••••••••..•.•••••..••••••...••••••••••••.•••.. 3 
LIST OF FIGURES AND TABLES .••••.•••.•••...••••••.•••..••••••••...•.•••••.•..•••••••..•••••••...••••.•••.••••.•.. 5 
LIST OF ABBREVIATIONS ..••.•••••.•••••.••••••••••••••.•••••••....•..••••••••••.•••••••••••••.•••.•••..••...••.•••... 7 
ABSTRAc:lr .•.•..••••••••••••••••••••••••••••••.•••••••.•.•.•••.••••••••••.•••••••••.•••••••••••..•.••••..••.•••••••..•••••. :L() 
CHAPTER :L: INTRODUCTION •••....••••••••••.....•.•••••••...•••••••..••••••..••••.•••••.•••••.•••..•••.••••...•. :L2 
Ovarian cancer .............................................................................................................. 13 
MAP KINASE PATHWAY •••••.••.•.••.•..••••.•....•..•..........................••••.•.••..•••...........•......•...•......... 27 
Pre-mRNA splicing and alternative splicing ................................................................... 46 
Splicing factor 4S Kda - SPF45 ...................................................................................... 62 
CHAPTER 2: IDENTIFICATION OF SPF45 AS A NOVEL MAP KINASE SUBSTRATE ••••••...•• 69 
I ntrod uction .................................................................................................................. 70 
Materials and methods ................................................................................................. 74 
Results ........................................................................................................................... 81 
Discussion ...................................................................................................................... 97 
CHAPTER 3: REGULATION OF SPF45 SPLICING FUNCTION BY MAP KINASE 
PHOSPHORYLATION. ROLE OF THR71 AND SER222 IN MODULATING SPF45 FUNCTIONS 
•••••••••.•••••••••••.•••..••••••••••.•••••••••...•.••••••••.•••••••••••...••.•••.•••••••••..•••••••...••••...••••••....•••••..• 1()2 
Introduction ................................................................................................................ 103 
Materials and methods ............................................................................................... 107 
Resu Its ......................................................................................................................... 115 
Discussion .................................................................................................................... 141 
CHAPTER 4: SUMMARY, LIMITATIONS, CONTRIBUITON AND FUTURE DIRECTIONS •. 15:L 
APPENDIX: ERK ACTIVATION AND NUCLEAR SIGNALING INDUCED BY THE LOSS OF 
CELL/MATRIX ADHESION STIMULATES ANCHORAGE-INDEPENDENT GROWTH OF 
OVARIAN CANCER CELLS •••••••••••••••••••••••••..•••••••..•••••••••••••..•••••..••••••.•••••..•••••.•.•••.••••.• :L 73 
REFERENCES .....••....•••••.•...•••.•..•••••••...•••.•••.••••..•••••••..••••••••••••..••••...••••••••••.•.•••.•..•.•... 219 
5 
List of Figures and Tables 
C:ti~J)1rEFl :L •••••••••••••••••••.••••••••••••••••••••••••••••..•.••••••••••••••••..•••••••••••••....•••••••••......••••••••....•• 
FIG 1.1 RAS-MAP KINASE PATHWAY •..•.••.••.•••.•..•.•.••••.••••.•...••..••............•...•.......................... 30 
FIG 1.2 CRYSTAL STRUCTURE OF INACTIVE ERK2 ...................................................................... 41 
FIG 1.3 SPLICEOSOME ASSEMBLY •••.••.•..•.•.•..•.•....•.•..••••••................................•...............•....•.. 48 
FIG 1.4 DOUBLE TRANSESTERIFICATION REACTIONS AND INTRON EXCISION ..................................... 49 
FIG 1.5 SPLICING PATTERNS IN MAMMALIAN CELLS ................................................................... 50 
TABLE 1.1 EOC TYPES AND SIGNIFICANT FINDINGS ................................................................... 18 
TABLE 1.2 TYPE I EOCs AND SIGNIFICANT MOLECULAR CHANGES ................................................. 20 
TABLE 1.3 TYPE II EOCs AND SIGNIFICANT MOLECULAR CHANGES ................................................ 20 
c:ti~J)TIEFl ~ •••••••••••••••••••••••••••.•.••••••••••••••••••.•....••••••••••• 4 •••••••••••••••••••••••••••••••••••••••••••••••••• 
FIG 2.1 SPF45 IS A NOVEL MAP KINASE SUBSTRATE ................................................................... 90 
FIG 2.2 SPF45 IS PHOSPHORYLATED ON THR71 AND SER222 ..................................................... 91 
FIG 2.3 ERK2 ASSOCIATES WITH SPF45 ................................................................................. 92 
FIG 2.4 PHOSPHORYLATION OF SPF45jMUTANTS IN Cos-1 CELLS BY ERK2 MAP KINASE ................ 93 
FIG 2.5 ENDOGENOUS SPF45 IS PRIMARILY PHOSPHORYLATED BY ERK AND JNK IN CELLS .......... 94-96 
c:ti~J)lrEFl :I ................................................................................................................... . 
FIG 3.1 ERK2 PHOSPHORYLATION OF SPF45 DECREASES ITS SPLICING FUNCTION TOWARDS 8FAS .... 132 
FIG 3.2 GENERATION OF SKOV3 STABLE CELLS OVEREXPRESSING SPF45 OR MUTANTS ................. 133 
FIG 3.3 SPF45 DOES NOT CONFER DRUG RESISTANCE TO SKOV3 CELLS ...................................... 137 
FIG 3.4 VALIDATION OF SPF45-INDUCED GENETIC CHANGES IN SKOV3-SPF45jMUTANTSjVECTOR 138 
FIG 3.5 SPF45 REGULATES FIBRONECTIN SPLICING AND INCREASES EDA INCLUSION ....................... 139 
FIG 3.6 MUTATIONS ON THR71 AND SER222 ARE SUFFICIENTTO DISRUPT SPF45 BINDING TO SF1 AND 
SF3s155 ..........•..........•....................•.•..•.•....•.•.•.............•..............•................•.............. 140 
TABLE 3.1 UP-REGULATED GENETIC PATHWAYS INDUCED BY SPF45 OVEREXPRESSION IN SKOV3 CELLS 
•••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••• 0 •••••••••••••••••••••••••••• 134 
TABLE 3.2 DOWN-REGULATED GENETIC PATHWAYS INDUCED BY SPF45 OVEREXPRESSION IN SKOV3 
CELLS •.••••••.•..•.••••••.•••••••..•.•..•.••••.•••..........................•..........••..•••.•.••.•.••••.•..•.•..•••.•..•....... 135 
TABLE 3.3 GENETIC PATHWAYS WITH IDENTIFIED CHANGES IN SPLICING EVENTS ACCOMPANYING SPF45 
OVEREXPRESSION IN SKOV3 CELLS .........•....................•.•..•.•....•.•..•.•.•................•......•.•........• 136 
~F»F»IE~[)I)( ..•••••••......••••••.•.......••••••......•..•••••......•••••.......•••.••...•••••.....•••••....•••••.....••••....•••• 
FIG 1 ACTIVATION OF ERK IN SUSPENDED OVARIAN CARCINOMA CELLS ........................................ 200 
FIG 2 SUSTAINED ACTIVATION OF MEK AND ERK IN SUSPENDED CELLS ........................................ 201 
FIG 3 •...• 0 •••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••• 0 •••••• 0 •••••••••••••• 0 ••••••••••••••••••••• 202 
FIG 4 RE-ATTACHMENT OF SKOV-3 CELLS TO AN EXTRACELLULAR MATRIX RESTORES DOWN-REGULATION 
OF ERK ACTiViTy •...•...........•.•........•••.•.••.•..•.•.•..•••.•........ 0 ••••••••••••••••••••••••••••••••••• 0 •••••••••••••• 203 
FIG 5 SUSTAINED ACTIVATION OF ERK IN SUSPENDED CELLS IS NOT DUE TO LOSS OF PHOSPHATASE 
ACTiViTY ..........•...••.•.••..••••..•••.•.•.•. 0. 0 ••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••• 0.000 '0' 0 ••••••••• 204 
6 
FIG 6 ACTIVATION OF ERK IS SUSPENDED OVARIAN CELLS OCCURS THROUGH AN AUTOCRINE MECHANISM 
..................................................................................................................................... 205 
FIG 7 ERK NUCLEAR SIGNALING IS ENHANCED IN SUSPENDED OVARIAN CANCER CELLS ..................... 206 
FIG 8 INHIBITION OF ERK ACTIVATION IMPAIRS ANCHORAGE INDEPENDENT GROWTH ..................... 207 
7 
List of abbreviations 
The following is a simplified list of the most common abbreviations used 
throughout this dissertation. The list is not conclusive, however all abbreviations are 
described within the corresponding text. 
3'ss 3' Splice Site 
5'ss 5' Splice Site 
Akt/PKB Serine/Threonine Protein Kinase 
ATXNl Ataxin 1 
BPS Branch-Point Sequence 
eDNA Copy Deoxyribonucleic Acid 
ClK1/2/3/4 Cdc2-like Kinase 1/2/3/4 
EGF Epidermal Growth Factor 
EGFR Epidermal Growth Factor Receptor 
EOC Epithelial Ovarian Cancer 
ErbB2/Her2/neu V-Erb-B2 Erythroblastic leukemia Viral Oncogene Homolog 2 
ERK Extracellular Regulated Kinase 
ERK1b/1c Extracellular Regulated Kinase Splice Variants 1b/1c 
ER~ Estrogen Receptor Beta 
ESE/ESS Exonic Splicing Enhancer/Suppressor 
EST Expressed Sequence Tag 
Fas/FasL CD95/CD95l- Death Receptor/ligand 
FGFR Fibroblast Growth Factor Receptor 
FN Fibronectin 
FN-EDIIIA/FN-EDA Fibronectin-Extra Domain A 
FN-EDIlIB/FN-EDB Fibronectin-Extra Domain B 
GAP Gtpase Activating Protein 
GEF Guanine Exchange Factor 
H202 Hydrogen Peroxide 
hnRNP Heterogenous Nuclear Ribonucleoprotein 
HVR Hypervariable Region 
Il-l Interleukin 1 
imp~ Importin Beta 
ISE/ISS Intronic Splicing Enhancer/Suppressor 
JNK C-Jun N-Terminal Kinase 
8 
KSR Kinase Suppressor Of Ras 
MAP2K Mitogen Activated Protein Kinase Kinase 
MAP3k Mitogen Activated Protein Kinase Kinase Kinase 
MAPK Mitogen Activated Protein Kinase 
MEK MAPK/ERK Kinase 
MEKK1/2/3/4 MAPK/ERK Kinase Kinase 1/2/3/4 
MKK3/6 MAPK Kinase 3/6 
MKP MAPK Phosphatase 
NES Nuclear Exclusion Signal 
NLS Nuclear Localization Signal 
NMDA N-Methyl D-Aspartate 
NPC Nuclear Pore Complex 
OSE Ovarian Surface Epithelium 
p38 Protein 38 Kda Protein Kinase 
PAKl P21 Protein (Cdc42/Rac) Activated Kinase 1 
PDGFR-(3 Platelet-Derived Growth Factor Beta 
PGK-l Phosphoglycerate Kinase 1 
PI3K Phosphatidylinositol 3-Kinase 
PKA Protein Kinase A 
PKC Protein Kinase C 
PLCE Phospholipase C Epsilon 
PLD Peggylated Liposomal Doxorubicin 
PMA Phorbol-12-Myristate-13-Acetate 
PP2A Protein Phosphatase 2A 
pre-mRNA Pre-Messenger Ribonucleic Acid 
PTB Polypryimidine Tract Binding Protein 
PTMs Post-Translational Modifications 
Rac Ras-Related C3 Botulinum Toxin Substrate, Rho Family, Small GTP 
Binding Protein 
Raf Rapidly Accelerated Fibrosarcoma, Serine/Threonine-Specific Protein 
Kinase 
RalGDS Ral Guanine Nucleotide Dissociation Stimulator 
Ras Rat Sarcoma Viral Oncogene Homolog, Small GTP Binding Protein 
RRM RNA Recognition Motif 
RSK Ribosomal S6 Kinase 
RTK Receptor Tyrosine Kinase 
Sam68 Src-Associated In Mitosis, 68 Kda 
SAP Spliceosome Associated Protein 
SCAl Spinocerebellar Ataxia 1 
SELEX Systematic Evolution Of Ligands By Exponential Enrichmen 
9 
SF domain SPF45 Like Domain 
SFl Splicing Factor 1 
SF2/ASF Splicing Factor2/ Alternative Splicing Factor 
SF3b155 Splicing Factor 3b 155 Kda 
Shc (Src Homology 2 Domain Containing) Transforming Protein 1 
SMN2 Survival Of Motor Neuron 2, Centromeric 
snRNP Small Nuclear Ribonucleic Protien 
Sos Son Of Sevenless 
SPF45 Splicing Factor 45 Kda 
SPF4SAA SP F4S-Th r7lAI aSer222Ala 
SPF4S DD SPF4S-Thr71AspSer222Asp 
SRC-l (Schmidt-Ruppin A-2) Viral Oncogene Homolog (Avian}-l , Tyrosine 
Kinase 
SRp40 Serine/Arginine Rich Protein 40 Kda 
SRp9G8 Serine/Arginine Rich Protein 9G8 
SRPK Serine/ Arginine Rich Protein Kinase 
STAT Signal Transducers And Activators Of Transcription Protein 
SXL Sex Lethal Protein 
TGFa Transforming Growth Factor Alpha 
TGF~ Transforming Growth Factor Beta 
TNFa Tumor Necrosis Factor Alpha 
TP53,pS3 Tumor Protein 53 Kda, Tumor Suppressor Protein 
U2AF/6S/35 U2 Auxilliary Factor/6S Kda Subunit/35 Kda Subunit 
UHM U2AF Homology Motif 
ULM UHM-Ligand Motif 
UV Ultraviolet Radiation 
VEGFR Vascular Endothelial Growth Factor Receptor 
10 
Abstact 
Alternative pre~mRNA splicing increases proteome diversity and is important in 
the behavior of cells in health and disease. The processes that regulate alternative pre-
mRNA splicing are diverse and include regulation of splicing factors by phosphorylation. 
Here we report that the pre-mRNA alternative splicing factor SPF45 is a novel substrate 
of ERK, JNK and p38 MAP kinases in ovarian cancer cells. Using mutational analysis and 
phospho-specific antibodies, we demonstrate that MAP kinases phosphorylate SPF45 on 
Thr71 and Ser222 and that phosphorylation in cells is induced by a number of 
extracellular stimuli including PMA, EGF, serum, H20 2 and UV. Exon 6 of the death 
receptor Fas/CD95 has been shown to undergo alternative splicing in the presence of 
SPF45. Using a Fas minigene assay, we show that ERK2 and p38 inhibit SPF45 alternative 
splicing activity towards Fas, dependent upon these two phosphorylation sites. Other 
than Fas, no other pre-mRNA targets of SPF45 have been reported in mammalian cells. 
We generated SKOV3 cells stably-overexpressing wild-type SPF45 or a phosphorylation 
site mutant and performed an exon and gene array analysis to identify novel SPF45 
splicing targets and genes whose expression is changed downstream of SPF45 splicing 
activity, respectively. From this analysis, 139 potential splicing targets and over 150 
genes with altered expression were identified. We focus on four genes for validation 
with emphasis on ErbB2 and fibronectin. We show that SPF45 downregulates cellular 
proliferation in SKOV3 cells in a phosphorylation-dependent manner. Furthermore, we 
demonstrate that SPF45 regulates fibronectin alternative splicing, enhances inclusion of 
11 
FN-EDIIiA region, and affects cellular adhesion to fibronectin matrix. We also assess 
SPF45 binding to SFl and SF3b15S, essential components of the spliceosome, as well as 
the impact of Thr71 and Ser222 mutations on this interaction. Finally, we determine the 
effect of SPF45 overexpression in SKOV3 cells on their drug resistance profile. This study 
provides a link between MAP kinase signaling and splicing factors and identifies the role 
of this interaction in regulating molecular processes in ovarian cancer cells. Additionally, 
it provides the basis to investigate the role of SPF45 in ovarian cancer and to produce 
successful therapeutic interventions targeting SPF45-mediated effects. 
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Chapter 1: Introduction 
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Ovarian Cancer 
The most recent statistics indicate that ovarian cancer is the second most 
common yet deadliest gynecological malignancy and ranks as the fourth leading cause 
of cancer death among women in the western world (Jemal 2009) surpassing mortality 
from both endometrial and cervical cancer combined (Ozols 2004). The etiology and 
pathogenesis of the disease are still poorly understood compared to other forms of 
cancer, primarily due to a lack of a progression model that can accurately explain the 
course of the disease (Shih Ie 2004). Ovarian cancer is usually deSignated as epithelial 
ovarian ~ancer (EOC) since 90% of ovarian tumors are believed to originate from the 
ovarian ~urface epithelium (OSE) (Auersperg 2001), with granulosa cells accounting for 
most of the rest, and a rare contribution from stromal or germinal cells (Auersperg 
2001). The 5-year survival rate for ovarian cancer patients can be extremely good if 
detected early (- 90% FIGO stage lA, IB), however it declines raidly with increased stage 
(32.5% FIGO IIIC, 18.6% FIGO IV) when unfortunately most patients (> 55%) are 
diagnosed (Heintz 2006). 
Risk factors 
The risk factors for developing ovarian cancer can be divided into three main 
categories: hormonal, genetic and environmental (Chen 2010). 
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Hormonal factors - such as early menarche or late menopause)' nulligravidity, 
infertility, endometriosis (mainly endometrioid and clear cell ovarian cancer) and 
postmenopausal estrogen therapy. 
Genetic factors - such as family history of ovarian cancer, BRCA1/2 mutations and 
Lynch syndrome. 
Environmental factors - such as talc powder, cigarette smoking (mainly mucinous 
ovarian cancer) and obesity. 
In contrast to the aforementioned risk factors, multiple pregnancies, oral 
contraceptives, tubal ligation), hysterectomy and oophrectomy, and breastfeeding are 
considered protective factors from developing ovarian cancer. Based on these 
observations and other indications, two theories have been proposed to explain the 
pathogenesis of ovarian cancer and are discussed later in this chapter. 
Clinical manifestations, physical exam and diagnostic evaluation 
Epithelial ovarian cancer is primarily a disease of menopausal and post-
menopausal women. It typically manifests between the ages of 40 and 65, unlike the 
non-epithelial varieties which tend to be more common in younger population. One of 
the main hurdles in detecting ovarian cancer is the dull and vague presentation of 
symptoms that often leads to delayed discovery)' and unfortunately at an advanced 
stage. The most common symptoms include: abdominal distention, nausea and 
anorexia. It is suggested that a frequent and more severe presentation of these 
symptoms should prompt ovarian cancer in the differential diagnosis (Chen 2010). 
Equally, an adnexal mass palpated during pelvic or rectovaginal examination should also 
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prompt further workup to rule out ovarian cancer (Chen 2010). Ultrasound sonography 
is the tool of choice for diagnostic evaluation of malignant growth versus ovarian cysts, 
the former of which requires further surgical intervention. 
Etiology of epithelial ovarian cancer - Proposed hypotheses 
Two main theories have been proposed and accepted to explain the origin of 
EOC. The first theory, proposed by Fathalla (Fathalla 1971), also known as lithe incessant 
ovulation" theory, is based on observations of development of adenocarcinoma of the 
ovaries of domestic fowls that are maintained at a continual ovulation rate without 
seasonal rest. Epidemiological studies point to strong relationship between the 
development of ovarian cancer and nulliparity compared with a lower risk for multiple 
pregnancies especially a younger age of first pregnancy; equally, there is higher 
incidence of ovarian cancer associated with fertility treatment regimens that induce 
hyperovulation compared to a protective effect associated with oral contraceptives 
(Cramer 1983, Greene 1984). Due to an increased rate of wound healing and repair of 
the surface epithelium, the hypothesis postulates that adenocarcinoma of the OSE is 
induced by the formation of foci of genetic mutations known as "inclusion cysts" 
providing a fertile ground for tumor initiation and growth at the sites of ovulation, 
which is greatly increased by a higher rate of ovulation similar to the cases of nulliparity 
and fertility treatment. The hypothesis is also supported by observations of malignant 
progression of rat OSE that are extensively subcultured (Godwin 1992, Testa 1994) and 
an increase in inclusion cysts and changes of ovarian surface epithelium in women with 
higher risks of ovarian cancer (Feeley 2001, Schlosshauer 2003). 
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The second hypothesis, developed by Cramer and Welch (Cramer 1983), is 
known as "the gonadotropin theory". The process of ovulation is under strict hormonal 
regulation by pituitary-secreted gonadotropins, which by themselves have no 
tumorigenic effect on ovarian epithelial cells grown in culture (Ozols 2004), although 
they cause a disruption of the ovarian epithelial basement membrane altering tissue 
regeneration and cellular signaling (Roland 2003). Additionally, ovulation constitutes an 
inflammatory-like process that culminates in cen rupture {Espey 1994}. Based on these 
observations and the fact that inflammation is one of the hallmarks of cancer (Hanahan 
2000) that increase mutagenic alterations, persistent gonadotropins secretions in the 
body even after menopause, along with any other potential source of inflammation are 
thought to be carcinogenic and lead to the development of ovarian cancer. 
Interestingly, a third hypothesis/theory has emerged in the last decade 
implicating the fallopian tube as a potential source for serous ovarian adenocarcinoma. 
Studies by Piek et al identified tubal intraepithelial carcinoma (TIC) in fimbriae from 
patients who underwent elective bilateral salpingo-oophorectomy due to high risk of 
ovarian cancer (Piek 2001). Furthermore, a study by Carcangiu et al identified 
hyperplastic changes in prophylactically resected fallopian tubes of BRCA1 mutation 
carriers (Carcangiu 2004). Furthermore, TICs are identified in more than 50% of cases 
with ovarian cancer, beside shared mutations in TP53 of TICs and adjacent bulky ovarian 
masses (Kindelberger 2007). 
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Histopathology 
As mentioned earlier, the majority of ovarian cancer cases are of epithelial 
origins, therefore the discussion will be limited to the different histopathological types 
of EOC. EOCs are divided into the following subtypes: serous, mucinous, endometrioid, 
clear cell, transitional cell {Brenner typeL squamous and mixed epithelial based on their 
resemblance to the epithelia neighboring the ovaries (Seidman 2002, Scully 1999) with 
each of these subtypes further divided into benign, borderline and malignant. The most 








borderline and Endosalpingeal. 75% high-grade, 25% low-
grade (Ben-Baruch, 1996). Low-grade less 
responsive to CRx (Schmeler 2008, 
Gershenson 2009) 
borderline and Endocervival. Forms largest ovarian tumors 
with a median diameter of 18 to 20 cm 
(Seidman 2002) 
Endometrioid (benign, borderline and 
malignant) 
Endometrial. Foci of endometriosis: 
precursor lesions (Heaps 1990, McMeekin 
1995). Better survival than serous (Storey 
2008). 
Epithelial-stromal and stromal 
Clear cell (benign, 
malignant) 
borderline and Mullerian. (Also called mesonephroid). May 
arise from endometriosis (Scully 1998). 
Lower response rate to platinum- and 
taxane-based CRx (Behbakht 1998, Goff 
1996) 
Transitional cell (benign, borderline and 
malignant) 
Non-Brenner transitional cell 
Squamous cell tumors 




Table 1.1 EOC types and significant findings 
Transitional. Benign - small solid masses 
within stroma. Intermediate - multicystic, 
low malignant potential. Both unilateral. 
Malignant - atypical features and invasive 
characteristics. 
Squamous 
Mixed. Two or more distinct histologic 
types. Presence of serous carcinoma or 





Genetics of Ovarian Cancer/Dualistic model of ovarian carcinogenesis 
According to Robert Kurman, director of the division of gynecologic pathology at 
Johns Hopkins, EOC tumors are divided into types I and II based on the histological 
presentation and molecular aberrations found (Shih 2004). Type I tumors tend to follow 
an indolent course and develop gradually from precursor lesions, developing from 
cystadenomas and adenofibromas, progressing to borderline malignancies then finally 
becoming low grade tumors. They are also associated with several signaling pathways 
and genetic mutations most noticeable of which are K-Ras and B-Raf mutations. In a 
way, type I tumors are reminiscent of the progression model of colorectal 
adenocarcinoma; unfortunately, they represent a minority of ovarian cancer cases (Shih 
2004). Type II tumors, on the other hand, are more common and are associated with an 
aggressive and fast course, which prevents the detection of precursor lesions if any. At 
times, they are thought to develop de novo (Shih 2004). Unlike type I tumors, there are 
no noticeable changes in signaling pathways, but TP53 mutations are observed in at 
least 80% of cases and seem to present a unifying feature of type II tumors. The 
following two tables (tables 1.2 and 1.3) summarize the main characteristics of these 
two types. 
Type I tumors 




Clear cell carcinoma 
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Common molecular genetic 
alterations 
BRAF or KRAS mutations 
KRAS mutations 
8-catenin gene mutations 
Microsatellite instability 
lOH or mutations of PTEN 
KRAS mutations 
TGF-B RII mutation 
KRAS mutations 
Microsatellite instability 
Table 1.2 Type I EOCs and significant molecular changes. Adapted from Shih and 
Kurman . Ovarian tumorigenesis: a proposed model based on morphological and 
molecular genetic analysis. Am J Pathol 2004. 
Type II tumors 
High-grade serous carcinoma 
Malignant mixed mesodermal tumor 
(carcinosarcomas) 
Common molecular genetic 
alterations 
p53 mutations 
HER2/neu gene overexpression 
AKT2 gene overexpression 
Inactivation of p16 gene 
p53 mutations 
Table 1.3 Type " EOCs and significant molecular changes. Adapted from Shih and 
Kurman. Ovarian tumorigenesis: a proposed model based on morphological and 
molecular genetic analysis. Am J Pathol 2004. 
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Chemotherapy for epithelial ovarian cancer 
The standard of care for patients newly diagnosed with EOC depends on the 
stage of the disease upon presentation. 75% of patients are diagnosed at an advanced 
stage, usually stage III (dissemination into peritoneal cavity or lymph node involvement) 
or IV (disseminated to more distant tissues). For these patients, surgical debulking 
followed by chemotherapy (taxanes and platinum compounds) remains the method of 
choice (Young 1983). For the remaining 25% of patients (stages I and II, I being restricted 
to the ovary while II is in the pelvic cavity), surgery alone is the main approach (Young 
1990, Heintz 2006), with further chemotherapy indicated in high-risk stages I or II in 
order to avoid relapse. Optimal debulking (residual tumors < 1cm) has been associated 
with improved relapse rates (Herzog 2010) however the majority of these patients 
develop recurrent refractory disease from which they ultimately die. In the following I 
will discuss the two main anti-neoplastic agents employed for ovarian cancer and then 
approach recurrent ovarian cancer and the different modalities used. 
Platinum compounds 
Before the introduction of platinum compounds, cyclophosphamide and 
doxorubicin were the drugs of choice for cancer patients. Serendipitously discovered to 
have anti-growth effects (Rosenberg 1973, 1985), cisplatin represents the prototype of 
platinum compounds. Cisplatin is composed of a platinum atom complexed to two 
ammonia and two chloride atoms in a square planar geometry. Cisplatin inhibits tumor 
cells growth and it has been postulated that the central platinum atom binds the DNA 
forming diaminoplatinum adducts causing cross-links and disrupting the DNA structure 
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(Huang 1994, McGuire 1998). Addition of cisplatin to the established chemo regimens 
resulted in a substantial improvement in response rates (Omura 1986, Thigpen 1994). 
Due to its undesirable side effects such as neurotoxicity, nephrotoxicity, ototoxicity and 
gastrointestinal toxicity (Ozols 1984), chemical modifications of the cisplatin led to the 
development of several other platinum compounds including carboplatin and 
oxaliplatin. Carboplatin has equal efficacy to the parent compound (ICON2, 1998) with 
lesser associated side effects, except for an increase in myelosuppression that can be 
dose-limiting (Ozols 1989). Oxaliplatin is active in ovarian cancer and overcomes 
cisplatin resistant tumors in vitro (Vaisman 1998). The main side effect of oxaliplatin is 
the development of peripheral neuropathy that is cumulative and dose-limiting (Chollet 
1996). 
Taxanes 
Paclitaxel represents the parent molecule in this family, and was first isolated 
from the bark of the pacific yew tree Taxus bre/ivolia (Wani 1971). Paclitaxel works by 
promoting microtubule formation, inhibiting the disassembly of J3-tubulin subunits, 
leading to aberrant microtubules-derived structures and arrested mitosis (Rowinsky 
1993). Chemically, it has a complex molecular structure and is currently obtained as a 
semi-synthetic product from 10-desacetylbaccatin precursor extracted from the yew 
tree leaves. Paclitaxel displays preference to malignant tumors of epithelial origin and 
occupies a central role in the treatment of cisplatin-refractory ovarian cancer (Rowinsky 
1995). Modification of two side chains on paclitaxel led to the development of 
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docetaxel, with enhanced clinical response in the therapies of ovarian and breast 
cancer. 
Recurrent epithelial ovarian cancer 
Currently, 70-80 % of patients with ovarian cancer are detected at an advanced 
stage, usually III or IV, with a recommended management of cytoreductive surgery 
followed by combination chemotherapy of platinum compounds and taxanes. Unlike 
other types of cancer, where diagnosis at an advanced stage deters surgery, the 
combination of surgery and chemotherapy has shown an advantage over chemotherapy 
alone, leading to remission in around 80% of cases (NIH Consensus Conference 2005). 
Unfortunately, relapse rates are as high as 90%, and cancer resurges with the added 
disadvantage of drug resistance. The decision for managing these patients depends on 
their response to the first-line treatment (Thigpen 1993), which leads to categorizing 
patients into platinum-sensitive and platinum-resistant. While platinum-sensitive 
patients usually have a very favorable response to platinum in their first round of 
chemotherapy, platinum-resistant patients have the following characteristics: i. 
platinum-refractory phase, where patients progress while on platinum therapy ii. at best 
these patients have a stable response while on their first round of chemotherapy and iii. 
they tend to relapse less than six months following the completion of the first round of 
therapy (Herzog 2010). Unfortunately, the response of this category to second-line 
platinum therapy is dismal and these patients are usually treated with non-cross 
resistant anti-neoplastic agents. Additionally, since a cure is almost unattainable, and to 
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preserve a decent quality of life for these patients, palliative therapy is more common 
than an aggressive regimen that has no obvious benefit. 
In the platinum-sensitive category, a higher treatment-free interval is associated 
with a better outcome and helps in the decision of the second-line regimen. A phase II 
study showed that addition of platinum compound (cisplatin) to cyclophosphamide and 
doxorubicin regimen has a better response than the single agent paclitaxel in treatment 
of recurrent EOC (Cantu 2002) and a recent randomized phase III trial showed an 
advantage of combination of carboplatin and Qegylated !iposomal doxorubicin (PLD) to 
carboplatin alone (59 vs. 28 percent) in recurrent ovarian cancer treatment (Markman 
2010). Additionally, it was found in the same study that the combination of carboplatin 
with PLD is associated with lesser alopecia and chronic neurotoxicity as well as 
decreased hypersensitivity due to fewer infusion reactions compared to the 
combination of paclitaxel and carboplatin. Altogether, promising outcomes are expected 
in combination therapy as a second-line treatment, demonstrating the efficacy of 
inclusion of platinum compounds in the regimens. In the following, a brief overview of 
the chemotherapeutic agents under investigation in the second-line management of 
EOC, especially non-platinum non-taxane cross-resistant, is provided. 
Etoposide belongs to the family of podophyllotoxins that inhibit topoisomerase II 
causing DNA strands breaks. Oral etoposide offers an advantage in regimen scheduling 
compared to intravenous administration and causes a 27% response rate in platinum-
resistant patients (Slayton 1979). Toxicity includes myelosuppression (neutropenia) and 
gastrointestinal symptoms (nausea and vomiting) (Rose 1998). Because of its highest 
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response rate compared to other antineoplastics, it is currently employed as the first-
line of therapy of recurrent EOC after failure of platinum and taxane therapies. 
Doxorubicin is an anthracycline antibiotic obtained from Streptomyces peucetius. 
The quinone and hydroquinone moieties allow for electron transfers promoting 
formation of free radicals. Several mechanisms have been proposed to explain 
doxorubicin actions including: DNA intercalation, topoisomerase II inhibition and 
formation of free radicals, all of which lead to destruction of DNA integrity. A pegylated 
liposomal formulation of doxorubicin is employed in the treatment of EOC, and a 17% 
response rate is observed with PLD monotherapy in platinum- and taxane-resistant EOC 
(Lorusso 2004, Thigpen 2005). Major toxicities are stomatitis and "hand-and-foot" 
syndrome. 
Topotecan is a camptothecin analog that acts by inhibiting topoisomerase I and 
is active against both platinum-sensitive and -resistant cancer. Myelosuppression is a 
dose-limiting toxicity (neutropenia). Compared to PLD, topotecan has a similar response 
rate (Gordon 2001); however the myelosuppression induced by topotecan favors PLD. 
Gemcitabine is a fluorinated analog of cytidine that acts an inhibitor of DNA 
synthesis during the S phase. Upon conversion to di- and tri-phosphate metabolites} it 
prevents the incorporation of dNTPs into the nascent DNA. The tri-phosphate 
metabolite is also incorporated into the DNA causing chain termination. In treatment of 
recurrent EOC} gemcitabine is active against both platinum- and taxane-resistant disease 
(Markman 2003} Rose 2003). Compared to PLD} no difference in response rate is 
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observed (Mutch 2007); however due to lesser cytotoxicity, it represents a tolerable 
alternative to PLD in women with platinum-resistant EOC. 
Vinorelbine is a semi-synthetic analog of vinblastine, a vinca alkaloid. Vinca 
alkaloids are mitotic spindle inhibitors and act by binding tubulin and preventing 
polymerization. Response rate to vinorelbine in EOC-patients refractory to platinums 
has been variable with no obvious advantage (Bajetta 1996, Burger 1999 and 
Rothenberg 2004). 
Ifosfamide is a nitrogen mustard prod rug that is converted enzymatically in the 
liver to its active electrophilic metabolite which attacks the N7 nitrogen of guanine, 
forming covalent bonds resulting in DNA cross-linking. In treatment of recurrent 
platinum-resistant EOC, ifosfamide is moderately active (Baur 2006). Toxicity includes 
hematologiC, renal and central nervous system such as disorientation, hallucinations, 
somnolence and agitation (Herzog 2010). 
Pemetrexed is an antifolate prodrug metabolized to its active polyglutamate 
forms which inhibit THF4-dependent enzymes. Pemetrexed monotherapy showed a 21% 
response rate in platinum-resistant EOC despite the severe toxicity that could be 
associated with its administration (Vergote 2009) and folic acid and vitamin B12 are 
required supplements during treatment. 
Anti-hormone therapy, similar to that used with other hormone-dependent 
cancers like breast and prostate, has been tested in ovarian cancer using tamoxifen - a 
selective estrogen receptor modulator - , and letrozole and anastrazole- aromatase 
inhibitors. Several trials and one meta-analysis showed that the response to hormone 
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therapy in ovarian cancer is, at best, modest (Williams 2001, Smyth 2007 and Argenta 
2009) 
Bevacizumab is a humanized vascular endothelial growth factor (VEGF) -
monoclonal antibody. Several phase II trials showed improved response rates in 
combination with other chemotherapeutic agents (Burger 2007, Cannistra 2007, Chura 
2007, Micha 2007, Spannuth 2008), however, the high potential for GI perforation keeps 
it as a last-line of treatment (3 rd, 4th or even 5th-line of treatment). 
Intraperitoneal chemotherapy can provide, theoretically, a several fold increase 
of drug concentration at the site of a tumor with the feasibility of overriding systemic 
toxicity. Its role in ovarian cancer therapy remains controversial as it hasn't produced an 
advantage over intravenous therapy (Markman 1991) and has been limited to 
microscopic rather than macroscopic disease (Feun 1998, Berek 1999). Further clinical 
trials are needed in order to establish the true role of IP therapy. 
Ovarian Cancer and Intracellular Signaling 
As in many cancers, several signaling cascades are altered in ovarian cancer 
leading to the different pathological phenotypes expressed by these cells. ERKjMAP 
kinase and PI3Kj Akt pathways have both received special attention in ovarian cancer for 
their involvement in survival, development, differentiation and migration, among other 
functions. In fact, Ras or B-Raf activating mutation occur in two thirds of low grade 
ovarian tumors and 16% of high grade tumors (Singer 2003 alb, Ho 2003). Additionally, 
activation of ERK/MAP kinase has been observed in 80% of low grade ovarian tumors 
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and 40% of high grade tumors (Hsu 2004) indicating the existence of mechanisms, 
different than upstream Ras or Raf mutational activation, responsible for elevated 
signaling through this pathway and pointing to its importance in ovarian tumors. In this 
dissertation I will focus on the MAP kinase pathway and provide a summary of the major 
components of this cascade, as well as the therapeutic strategies targeting this pathway. 
MAP Kinase pathway 
The discovery of the MAP kinase pathway (Fig 1.1) in the lab of Tom Sturgill 
(Rossomando 1989) about 20 years ago, marked a breakthrough in the field of signal 
transduction. The MAP kinase pathway was initially described as a linear cascade of 
sequentially activated protein kinases with "Iittle or no cross-reactivity" and the 
namesake MAP kinase as a "unifying explanation of most, if not all, nonnuclear 
oncogenes" (Seger 1995). Our view of the pathway has changed and evolved over the 
last twenty years with increasing complexity and cross-talk between the different 
signaling cascades; however, the linear representation of the pathway remains the best 
start to examine and understand its different details. In its simplest topology, the MAP 
kinase pathway is a sequentially activated pathway of three conserved protein kinases 
that convey an extracellular signal in the form of phosphorylation events (Tanoue 2003). 
Four pathways have been well described in mammalian cells: ERK1/ERK2, p38a/~/v/{j, 
JNK1/2/3 and ERK5 MAP kinase pathways. ERK pathways are preferentially activated by 
growth factors, phorbol esters and adhesion, while JNK and p38 MAP kinases are 
preferentially activated by cytokines and stress. In response to these extracellular cues, 
receptor tyrosine kinases, G-protein coupled receptors and integrin receptors recruit a 
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small GTP-binding protein to the cell membrane (Ras superfamily) that recruit a MAP3K, 
the first kinase in the cascade. Activated MAP3K leads to the sequential 
phosphorylation, and thereby activation, of MAP2K and finally the namesake MAPK that 
phosphorylates a plethora of targets across the cell, from the cell membrane to the 
nucleus. In the following, we will focus on the ERK1/2 MAP kinase pathway and then 























Fig 1.1 Ras-MAP kinase pathway A simplified and linear overview of the ERK/MAP 
kinase pathway topology. 
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Ras belongs to a family of small G-proteins that alternate between an inactive 
GDP-bound and an active GTP-bound state (Shih 1980) due to an intrinsic GTPase 
activity. Transmembrame receptor activation by extracellular stimuli induces a 
conformational rearrangement that recruits the molecule adapters Grb2, Shc and 
guanine-nucleotide exchange factor SOS which in turn binds and recruits Ras to be 
activated at the cell membrane (Olivier 1993, Rozakis-Adcock 1993, Buday 1993 and 
Egan 1993). An intricate interplay between guanine-nucleotide exchange factors (GEFs), 
GTPase-activating proteins (GAPs) and guanine nucleotide dissociation inhibitors (GDls) 
is believed to have a major role in activating Ras (reviewed in Konstantinopoulos 2007). 
Four main isoforms of Ras have been described: K-Ras4A, K-Ras4B, H-Ras and N-Ras. 
Except for the C-terminal 23-24 amino acids, known as the hypervariable region (HVRt 
all isoforms share a near identical homology (Dhar 1982, Tsuchida 1982, Shimizu 1983). 
Ras proteins are subject to lipid modifications in their C-termini (prenylation and 
palmitoyilation) that target the proteins for cell membrane anchoring and subsequent 
activation (Sefton 1982, Casey 1989, Hancock 1989). It is also believed that lipid 
modifications of Ras target it for microlocalization on the cell membrane (Boyartchuk 
1997, Prior 2001). 
Among the first evidences into the role of Ras in cancer is the finding of its ability 
to mediate cellular transformation in NIH 3T3 cells (Ellis 1981). In 1982, Channing Der 
showed an elevated expression levels of K-Ras and H-Ras in human bladder and lung 
carcinoma cell line and identified their role in transforming cells (Der 1982) while Luis 
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Parada, then in the lab of Bob Weinberg, demonstrated H-Ras as the oncogene in EJ 
human bladder carcinoma (Parada 1982). Further studies demonstrated Ras to be 
activated in about 30% of all human cancers, with the highest activation observed in 
pancreatic cancer (90%) - arguably the worst kind of cancers -, in colon and thyroid 
(SO%)} in lung cancers (30%) (Malurnbres 2003). Elevated Ras activation in cancer can be 
attributed to two main processes: i. activating mutations and ii. continuous Ras 
activation via upstream stimulation. Concerning the former, several Ras mutations have 
been described in a variety of diseases; however mutant K-Ras genes encoding proteins 
harboring the single amino acid mutation at G12 or Q61 (or their homologs on the other 
Ras isoforms) are reserved for cancer cells (Taporowsky 1983, Shimizu 1983 and Fasano 
1984). Ras G12/Q61 are GAP-insensitive therefore they maintain a GTP-bound state and 
remain activated in a stimulus-independent manner (Adari 1988). Alternatively, Ras is 
activated by aberrant upstream stimulation. For instance} several receptor tyrosine 
kinases (RTKs) such as EGFR and ErbB2 are either overexpressed or mutationally 
activated in several human cancers leading to subsequent Ras-Raf-MEK-ERK activation 
(Lynch 2004} Stephens 2004 and Grandis 2004). Additionally, continuous Ras activation 
leads to transcriptional activation of transforming growth factor a (TGF a), heparin-
binding-EGF and amphiregulin (McCarthy 1995, Gangarosa 1997 and Schulze 2001) 
which are natural EGFR ligands leading to a positive feedback loop activation of Ras/ERK 
pathway. 
While the Raf-MEK-ERK axis is the main effector target of Ras activation, other 
pathways can be induced by Ras activation. In particular, PI3KjAkt, Tiam1jRac, RalGDS 
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and PLCE are additional pathways activated by oncogenic Ras and have a strong impact 
on tumorigenesis {reviewed in Repasky 2004, Shaw 2006}. Accordingly, targeting the 
Ras/ERK pathway for inhibition might not suffice for a complete abrogation of Ras 
oncogenic effects. Alternatively, developing specific inhibitors for ERK targets might 
represent a more efficient strategy in inhibiting Ras/ERK-mediated effects in cancer. 
Further discussion on different inhibitors of the Ras/ERK cascade is provided later in this 
chapter. 
Raf 
The regulation of the MAP kinase pathway at the Raf level is very complex and 
remains under extensive investigation. Raf is a serine/threonine (S/T) kinase that exists 
under 3 main isoforms: A-Raf, B-Raf and Raf-l (or C-Raf). Activation of Ras at the cell 
membrane initiates a complex series of phosphorylations and dephosphorylations of Raf 
where it constitutes a relay for several pathways like PI3K/ Akt, Src, PKA, PKC and PP2A 
(reviewed in McCubrey 2006), self-dimerization or heterodimerization with the Raf-like 
protein kinase-suppressor of Ras (KSR) (Xing 1997), and association/disassociation with 
scaffolding proteins like HSP90 and RKIP (Blagosklonny 2002, Corbit 2003). Of the three 
isoforms, B-Raf is mutated most in cancer cells; more than 30 mutations of B-Raf, 
clustered within the kinase's activation loop and P-Ioop, have been reported (Wan 
2004). Interestingly, B-Raf(V599) is the most common mutant isoform and its basal 
kinase activity exceeds 400-folds that of the wild type kinase (Wan 2004) leading to a 
sustained ERK/MAP kinase pathway activation independent of Ras and Src function 
(Marais 1997, Brose 2002 and Davies 2002). Also, Src-dependent activating residues on 
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Raf-l and A-Raf are replaced by the negatively charged aspartic acid residues, mimicking 
a continuously phosphorylated enzyme and giving B-Raf a higher basal activity to 
activate MEK/ERK than A-Raf or RAf-1 (Marais 1997). B-Raf mutations are reported in up 
to 70% of melanomas, 50% in thyroid cancer, 22% in colon cancer and 30% in ovarian 
cancer (Davies 2002, Garnett 2004 and Libra 2005). It is interesting to notice that, in 
ovarian cancer, K-Ras and B-Raf mutations are mutually exclusive (Singer 2003) as either 
mutation is sufficient for Raf-MEK-ERK activation. The exact role of B-Raf in 
tumorigenesis remains to be determined as introdUCing B-Raf mutants into cells does 
not initiate neoplastic transformation and hence a maintenance role for B-Raf is 
predicted in these cancers (Rajagopalan 2002, Vuen 2002). 
MEK 
MAP/ERK kinase (MEK1/2) is the direct activator of ERK/MAP kinase. It is a dual 
specificity tyrosine and serine/threonine (V /5/T) kinase (Alessi 1994) that is activated by 
Raf upon phosphorylation on S218 and S222 (or 5er217 and Ser221) (Alessi 1994). MEK 
is also phosphorylated on 5298 by PAKl in order for Raf to phosphorylate MEK in 
response to integrin adhesion (Coles 2002, Slack-Davis 2003). MEK is inhibited by a 
negative feedback phosphorylation on T292 by ERK (Brunet 1994b, Eblen 2004). In the 
ERK/MAP kinase pathway, MEK targets a unique substrate, namely ERK1/2 (Crews 
1992). This feature in the ERK pathway allows for specific inhibition of ERK by 
pharmacologically targeting its upstream activating kinase MEK1/2. Interestingly, unlike 
Ras and Raf, there are no known activating mutations of MEK in cancer. However, 
mutation of Ser218/222 in MEK1 to Asp or Glu generates a constitutively active MEK1 
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that is oncogenic in fibroblasts (Brunet 1994a). Recently, mutations on F35S and Y130 in 
MEK1 and F57C in MEK2 have been identified as part of the cardio-facio-cutaneous 
syndrome (Rodriguez-Viciana 2006), but have no implications on cancer. Also, a recent 
activating mutation of MEKl (F129L) has been identified and is proposed to impart an 
acquired resistance to MEK inhibitors (Wang 2011). 
In resting cells, MEKs are known to localize to the cytoplasm due to a nuclear 
export signal (NES) on their N-termini (Fukuda 1996, Jaaro 1997). Additionally, 
interactions with scaffolding proteins and cytoplasmic anchors such as MP1, KSR1, Sefl 
and paxillin confine MEKs to endosomes, the plasma membrane, outer Golgi membrane 
and cytoskeleton, respectively (Shaeffer 1998, Kornfeld 1995, Therrien 1995, Torii 2004 
and Ishibe 2003). More recently, MEKs were shown to localize to the mitochondrial 
membranes and lumen (Poderoso 2008), however the significance of this localization 
remains poorly understood. Although mainly localized to the cytoplasm, MEKs are 
subject to continuous and rapid shuttling in and out of the nucleus in response to 
stimulation (Jaaro 1997, Tolwinski 1999 and Yao 2001). In the nucleus, MEKs interact 
with inactivated ERKs through their 0 and CD domains (described below) and are 
subsequently exported via the NES/exportin system into the cytoplasm (Adachi 2000). In 
that regard, MEKs explain the transport process for ERK out of the nucleus and provide a 
cytoplasmic anchor for inactive ERKs. 
ERK represents the last tier in the core MAP kinase pathway. Two isoforms of 
ERK exist, ERKl (p44 MAPK; 44 KDa) and ERK2 (p42 MAPK; 42 KDa) with 83% amino acid 
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homology (Owaki 1992). Additionally, two additional splice variants of ERK1 have been 
described. The first, ERKlb, is a 46 KDa protein with a 26 amino acid insertion between 
residues 340 and 341 of ERK1 and expresses similar kinetics of activation to the main 
ERK isoforms, however with a tissue specific distribution and higher response to osmotic 
stress (Boulton 1991, Yung 2001). The second splice variant is ERK1c, a 42 KDa protein 
with slower kinetics than ERK1/2, and displays high density in the Golgi apparatus where 
it is implicated in Goigi fragmentation (Aebersold 2004, Jesch 2001). 
ERK1/2 are activated by phosphorylation of the TEY motif (202/204 or 185/187) 
by the dual specificity kinase MEK (Boulton 1991). As an enzyme, ERK is a 
serine/threonine kinase and phosphorylates a plethora of substrates distributed around 
the cell, from the cell membrane (CD120a, calnexin), to cytoskeletal proteins and 
kinases (neurofilaments, paxillin, RSK, MSK), all the way to transcription factors in the 
nucleus (SRC-1, Elk1, MEF2, c-Fos, c-Myc, STAT) (reviewed in Yoon 2006). To date, more 
than 160 substrates of ERK have been reported, mediating its diverse functions in 
cellular proliferation, development and migration. Obviously, such a diverse response 
from ERK activation requires a tight control of substrate phosphorylation in order to 
maintain a high fidelity signal. Regulation through kinases scaffolds, protein 
phosphatases and localization represent the major routes to reach this end. 
ERK1/2 are predominantly located in the cytoplasm of quiescent cells and 
translocate to the nucleus upon activation. In the cytoplasm of resting cells, around 50% 
of ERKs are bound to microtubules (Reska 1995). ERK1/2 also localize to focal adhesions 
and adherens junctions where they are necessary for paxillin phosphorylation during cell 
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migration (Ishibe 2003). Three mechanisms have been elucidated describing ERK1/2 
nuclear translocation through the nuclear pores: i. passive diffusion of a monomer, ii. 
active transport of an ERK1/2 dimer (both phosphorylated and unphosphorylated) and 
iii. nuclear pore complex (NPC)-mediated translocation via active, cytosol- and ATP-
independent mechanisms (Khokhlachev 1998, Adachi 2000, Matsubyashi 2001 and 
Whitehurst 2002). As it doesn't have either a nuclear localization (NLS) or export signals 
(NES) of its own .. ERK is anchored in the cytoplasm by binding the N-terminus of MEK1/2 
(Fukuda 1996) which is disrupted upon ERK1/2 phosphorylation, inducing ERK1/2 
translocation to the nucleus {Fukuda 1997}. ERK1/2 is dephosphorylated in the nucleus 
by MAP kinase phosphatases (MKPs), which causes its association with MEK1/2 for 
shuttling back to the cytosol (Tanoue 2000). 
When localized to the nucleus, ERKs are kept under tight spatiotemporal control 
by several molecules that act as scaffolds, which act to anchor kinases within close 
proximity in certain areas of the cell in a way to achieve localized response in a stimulus-
specific manner and integrating different signals within controlled microdomains (Elion 
2001, Kolch 2005). Several cytoplasmic scaffolds have been identified, including KSR, 
MP1, ~-arrestins and Sef. KSR interacts with Raf-1, MEK1/2 and ERK1/2 and is 
translocated with MEK1/2 to the plasma membrane, bringing the Raf-MEK-ERK in close 
proximity for increased signaling efficiency (Sundaram 1996, Therrien 1996). MPl binds 
to MEK1/2 and ERK1/2 in endosomes, enhancing their interaction and ERK1/2 signaling 
in response to EGF (Schaeffer 1998, Teis 2002). B-arrestins improve Raf-MEK-ERK 
signaling in endosomes downstream of G protein coupled receptors (Luttrell 2001) and 
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Sef colocalizes with active ERK1/2 and MEK1/2 on Golgi membranes, preventing 
signaling to the nucleus (Torii 2004). Altogether, these molecules provide examples of 
regulation and control of ERK signaling through ERK localization. 
Phosphatases also control ERK signaling and play an essential role in positive and 
negative regulation of ERK signal propagation. Similar to MAP kinases, phosphatases are 
also governed by localization-mechanisms within the cell, hence they convey their 
effects in a stimulus- and spatial distribution-dependent manner. Protein phosphatase 
2A PP2A binds KSR and dephosphorylates it along with Raf-l, removing an inhibitory 
phosphorylation on the latter and allowing Ras-Raf activation in response to growth 
factor stimulation (Dougherty 2005). The nuclear phosphatase DUSPs is a specific ERK-
phosphatase and behaves as an inhibitor of the kinase but also as a nuclear anchor 
{Mandl 2005}. Phosphatases are also regulated by phosphorylations in the vicinity of the 
ERK interaction region. Hematopoietic protein tyrosine phosphatase {He-PTP} 
dephosphorylates ERK1/2 only when an inhibitory phosphorylation on Ser23 in the 0-
domain is removed (Gjorloff-Wingren 2000). STEP, a striatal neuron specific 
phosphatase, dephosphorylates ERK1/2 in response to NMDA receptor activation, which 
activates calcineurin to dephosphorylate and subsequently activate STEP (Paul 2003). 
Phosphatases are diverse and represent a crucial level of regulation and maintenance of 
a high fidelity signal transducing extracellular cues, their discussion is however beyond 
the scope of this work. 
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Docking interactions: D~ DfF and CD motifs 
Since all MAP kinases share a common substrate consensus sequence, separate 
motifs within the different proteins, both enzymes and substrates, are necessary to 
achieve a higher fidelity of binding and phosphorylation. Four motifs have been 
described: 0, DEF, CD and ED motifs. The D-domain consists ot a cluster of basic 
(positively charged) residues in the vicinity of an lXL motif, either upstream or 
downstream of the phosphorylation site (Yang 1998). D-domains are thought to 
enhance substrates recognition and to improve signaling specificity. They have been 
described in MAP kinase regulatory proteins, such as MAPKKs (MEK1/2), phosphatases 
(STEP, MKPs) and scaffolding proteins (KSR) and are believed to enhance the 
propagation and regulation of the signal specificity and fidelity similar to MAP kinase 
substrates (reviewed in Enslen 2001). The DEF motif (Docking site for ERK and £XFP) 
forms another class of interacting domains: the (F/Y)X(F/Y)P sequence is found in 
several transcription factor substrates of ERK1/2 across different species and is believed 
to be an ERK specific sequence (Jacobs 1999). The FXFP motif tends to be C-terminal to 
the phosphoacceptor site, and it is not mutually exclusive from the D-domain; in fact, 
together (such as in Elkl and KSR) they strengthen substrate recognition and binding 
(Jacobs 1999, Fantz 2001, Murphy 2002). While the DEF interacting module on ERK has 
not been identified yet, hydrophobic sequence in and downstream of the common 
docking {CD} motif has been shown to mediate ERK, p38 and JNK interactions with the 
D-domains (Rubinfeld 1999, Tanoue 2000). It is separate from the kinase active site but 
lies in its vicinity, and consists of a cluster of acidic residues (negatively charged) 
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surrounded by hydrophobic residues (Rubinfeld 1999 and Tanoue 2000) mediating 
electrostatic and hydrophobic interactions with the D-domain residues, respectively. Fig 












Fig 1.2 Crystal structure of inactive ERK2 bound to ATP, above, was resolved in the lab 
of Elizabeth Goldsmith {Zhang 1994}. 
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P38 MAP kinase module 
Similar to the ERK/MAP kinase pathway, the p38 pathway is a three-tiered 
cascade (Han 1994, Lee 1994) consisting of several MAP3Ks including MEKK1/2/3/4, 
MLK2/3, ASK1 and TAK1 that are activated in response to environmental stresses such 
as UV irradiation, osmotic pressure, oxidative stress, ischemia and inflammation along 
with its cytokines such as Il-1 and TNFa (reviewed in Roux 2004). Consequently, 
MAP3Ks phosphorylate the dual specificity kinases MAP2Ks, MKK3 and MKK6, to finally 
activate the four isoforms of p38a/~/v/o MAP kinase (Han 1993, 1994, Freshney 1994, 
Rouse 1994, Lechner 1996). P38 is a serine/threonine kinase and is activated by 
phosphorylation on the TGY motif in its activation loop (Han 1995, Wang 1997). 
Structurally, p38 shares around 50% homology with ERK, however, it differs in the 
length of its activation loop suggesting a potential explanation for the discrepancy of 
substrate specificity (Wilson 1996). Similar to ERK, p38 substrates are found around the 
cell (Raingeaud 1995, Ben-Levy 1998). P38 is strongly involved in immune and 
inflammatory processes and is activated in macrophages and neutrophils (Dna 2000). 
Accordingly, it is not surprising that several p38 inhibitors in development are being 
targeted towards autoimmune and inflammatory diseases. P38 inhibitors are discussed 
later in this chapter. 
JNK module 
In the same pattern as ERK and p38, the JNK subfamily is a three-tiered cascade 
that shares similar activating stimuli with p38 MAP kinases. Environmental stresses and 
inflammation are the main activators of the pathway which is commonly turned on with 
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p38 by phosphorylating MEKK1/2/3/4, MLK2/3, ASKl and TAKl but also separately by 
activating TAO-l/2 and ASK2 (reviewed in Bogoyevitch 2010). At the MAP2K levet MKK4 
and MKK7 mediate the upstream signal to phosphorylate JNK1/2/3 on the TXY motif 
where X is a proline. MKK4 also phosphorylates p38 in some cell types, suggesting a role 
for MKK4 in integrating signals from two pathways activated by similar cues (Derijard 
1995). Although it is localized throughout the cell, JNK is involved in the phosphorylation 
and activation of transcription factors such c-jun, ATF-3, STAT-3 and HSF-l. Despite the 
fact that JNK shares a similar implication in inflammation as p38, more inhibitors of the 
latter managed to reach clinical trials (Roberts 2007). 
Pharmacological inhibition of MAP kinases 
Due to their centrality to oncogenic and mitogenic extracellular signals, the MAP 
kinase pathways have been under extensive investigation for pharmacological 
inhibition, with Ras/Raf/MEK/ERK and p38 MAP kinase cascade being the most alluring 
targets for intervention. The majority of inhibitors are discovered by in vitro screens of 
protein kinases or in cells assays, and have focused on exploiting the ATP-binding 
domain of protein kinases, to generate ATP-mimetic molecules that work by competitive 
ATP inhibition. A major drawback of this approach is the non-specific inhibition of other 
kinases since most of these proteins share a similar topology like the one described 
above for ERK. Pharmacological inhibitors have been synthesized to inhibit the pathway 
at each tier of the canonical sequence Ras~MAP3K~MAP2K~MAPK. 
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Inhibitors oj Ras 
Ras mutations are common in several cancers, including pancreatic, colon, lung, 
gall bladder and thyroid cancer (Rowinsky 1999) and altogether account for 30% 
mutations in human cancer (Bos 1989). Ras inhibitors have focused on a common 
property to all Ras isoforms - the CAAX box (Giehl 2005, Roberts 2007). The CAAX box is 
a common motif in the hypervariable region of Ras proteins that is subject to lipid 
modification responsible for anchoring the proteins to the cell membrane. Prenylation 
(addition of farnesyl group) is the most common modification to the (-terminus of Ras. 
Targeting farnesyltransferase for inhibition, the enzyme that catalyzes this modification, 
is the main approach followed to inhibit Ras anchoring to the cell membrane; however, 
the discovery that K-Ras is the most commonly mutated isoform in cancer decreased the 
interest in FTls because K-Ras undergo geranyl geranylation, another lipid modification 
that compensates for the loss of farnesylation (Adjei 2001, Rajagopalan 2002). 
Inhibitors oj Raj 
Raf, a serine/threonine kinase that occupies the middle tier of the canonical 
ERK/MAPK pathway, is under extensive regulation by no less than 13 regulatory 
phosphorylations (Steelman 2004), which makes it an important crossroad for several 
signaling pathways. Raf is heavily involved in cancer, and is reported to be mutated 
(mainly B-Raf) in approximately 30% of solid cancers (Bos 1989) making it a valid to 
target Raf for inhibition. The first successful inhibitor of Raf to reach clinical trials is 
BAY439006, also known as Sorafenib, a small molecular weight inhibitor shown by 
crystallographic data to bind an overlapping region of the ATP-binding domain on Raf 
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and interestingly, the mechanism of inhibition is non-ATP competition (Wan 2004). 
However, like most kinase inhibitors targeting the ATP-binding domain, Sorafenib shows 
a promiscuous behavior towards other kinases, mainly receptor tyrosine kinases like 
VEGFR-2/3, PDGFR-~, c-KIT and FGFR-1 (Wilhelm 2004). Sorafenib is currently exploited 
in several clinical trials for its RTK inhibitory effects, however, the crystallographic 
resolution of B-Raf led to the development of more specific inhibitors, such as PLX4032, 
which is currently showing promising Raf inhibition in Phase I melanoma clinical trials 
(Wellbrock 2010). 
Inhibitors of MEK 
Other than an enhanced activity in several types of cancer, MEK has not been 
shown to be overexpressed or mutated in cancer (Hoshino 1999). Arguably, targeting 
the ERK/MAP kinase pathway at the MEK level is perhaps the most effective route to 
achieve strong ERK inhibition as MEK and ERK represent a unique feature among protein 
kinases: one enzyme-one substrate duo (Seger 1992). PD98059 and U0126 are two small 
molecule inhibitors of MEK1/2 identified by in vitro and cell-based screen for inhibitors 
of ERK activation, respectively (Dudley 1995, Favata 1998). Both inactivate MEK by 
allosteric interactions, non-competitive with ATP-binding (Davies 2000). Another family 
of MEK inhibitors is identified from microbial extracts. This discovery led to the 
development of two small molecules, Ro092210 (Williams 1997) and L783277 (Zhao 
1999) that contain an active ketone moiety shown to inhibit MEK1/2 competitively with 
ATP. Currently, several MEK inhibitors are in clinical development including AZD8330, 
GSKl120212, and R05126766. Recently, AZD6244 (Selumetinib), a non-ATP competitive 
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MEK inhibitor has shown promising results in phase II clinical trials of colorectal, 
hepatocellular, non-small-cell lung, and melanoma tumors (Davies 2007, Hersey 2009, 
Hainseworth 2010 and Bennouna 2010). 
Inhibitors of JNK and p38 MAP kinase 
P38 has received the most extensive attention among the MAP kinases from the 
pharmaceutical industry due to its involvement in inflammatory diseases and several 
inhibitors have entered clinical trials for rheumatoid arthritis and psoriasis (Lee 2000). In 
fact, p38 inhibitors have shown promising efficacy in animal models as well as clinical 
trials of arthritis and inflammatory lung disease such as: rheumatoid arthritis (e.g. vx-
745, Scio-469, Ro-320-1195), psoriasis (e.g. HEP 689), COPD (e.g. GSK-681323) and 
Crohn's disease (e.g. GSK-681323, RWJ-67657). Equally, several JNK inhibitors are also 
developed and their involvement in the therapy of inflammatory diseases exceeds their 
use in cancer. Examples of JNK inhibitors currently in clinical trials include CC-401, CNI-
1493 and CEP-1347. The list of kinase inhibitors is extensive and is beyond the topic of 
this dissertation; the reader is directed to the following reviews for further information 
concerning these pharmacological agents (Adcock 2006, English 2002). 
Pre-mRNA Splicing and Alternative Splicing 
Eukaryotic genes almost entirely consist of interrupted coding nucleotide 
sequences called "exons" and non-coding sequences called "introns". Pre-mRNA 
splicing is the molecular process that leads to intron removal and subsequently, ligation 
of exons to form the mature messenger RNA (mRNA) which is transported to the 
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cytoplasm for translation and protein synthesis. The general mechanism of intron 
removal and exon ligation has been well characterized in its broadest terms. It consists 
of a sequential formation of a multiprotein-nucleic acid complex known as the 
spliceosome followed by a stepwise removal of the two intronic borders. Nearly all 
introns are flanked by a GU dinulceotide at the 5' splice site (ss) and an AG dinucleotide 
at the 3' splice site (Grabowski 1984, Krainer 1984, Ruskin 1984). The 3' ss is preceded 
by a polypyrimidine tract that separates it from an important adenine known as the 
branching point in the branching point sequence (BPS) essential for the first catalytic 
step (Padgett 1984). 
An efficient and precise splicing reaction requires the exact recognition of the 
borders of each intron/exon, a process accomplished by the spliceosome. The latter is a 
large complex, consisting of 5 small nuclear ribonucleoproteins (snRNPS, U1, U2, U4/U6 
and US) and more than 150 associated auxiliary proteins that coordinate the efficient 
binding and recognition of the splice sites, as well as catalyzing the trans-esterification 
reactions. As the spliceosome assembles, U1 binds to the 5' splice site while splicing 
factor 1, SF1 (also known as mammalian branch point binding protein mBBP) binds the 
adenine in the branch-point sequence (BPS), forming the E' complex (Michaud 1991). E' 
complex is converted to the E complex by binding of the U2snRNP auxiliary factor 
(U2AF) to the polypyrimidine tract and the 3' splice site via the 65KDa and 35KDa 
subunits, respectively (Seraphin 1989, Michaud 1993). U2AF facilitates U2snRNP 
recruitment to the adenine in the BPS replacing SF1 in the first ATP-dependent step of 
the spliceosome formation (Frendewey 1987, Konarska 1987, Jamison 1992) forming 
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complex A and inducing a conformational rearrangement facilitating the recruitment of 
the tri-snRNP US/U4/U6 (Konarska 1987, Cheng 1987). US binds the upstream exon at 
the 5' splice site while U6/U4 binds U2 forming complex B1, which is rapidly replaced by 
complex B2 upon U1 release and U5 and U6 binding the 5' intronic splice site (Cheng 
1987, Lamond 1988). Extensive remodeling and rearrangements lead to the formation 
of the catalytic C complex. At this point, U4 is released, the spliceosome is fully mature 
and intron splicing occurs via a stepwise two trans-esterification reactions. The 
phosphodiester bond at the 5' splice site is cleaved by a nucleophilic attack of the 2'-OH 
of the adenine (A) at the BPS resulting in two intermediates, the upstream exon with a 
free 3'-OH on a guanosine and a lariat structure consisting of the downstream exon and 
the intron coiled on itself by 2', S'-phosphodiester bond. The free 3'-OH on the 
upstream exon subsequently liberates the lariat intron by another nucleophilic attack in 
a 3' ,5'-phosphodiester bond on the 3' splice site leading to the release of the lariat 
intron and ligation of the upstream and downstream exons. This process continues on 
all intronic sequences until the mature mRNA is formed and ready for translation. The 
different steps in spliceosome assembly are depicted in Fig 1.3 and the two nucleophilic 
transeterification reactions are depicted in Fig 1.4. 
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Fig 1.3 Spliceosome assembly Pre-mRNA alternative splicing is a multi-step mega-
reaction that includes several intermediate complexes involving a large number of 
proteins/nucleoproteins. 
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Fig 1.4 Double transeterification reactions and intron excision In the 1st reaction, the 
2' -OH group of the BPS Adenine cleaves the phosphodiester bond at the 5' ss. In the 2nd 
reaction, the 3' -OH on the free upstream exon cleaves the lariat intron and joins the 
downstream exons at the 3'ss by a 2nd nucleophilic attack. 
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Alternative splicing 
Alternative splicing is the process of generating two or more transcripts of the 
same gene from a common pre-mRNA sequence. In eukaryotes, alternative splicing is a 
common mechanism for generating a wide array of protein products involved in diverse 
cellular functions that range from sex determination to growth, differentiation and even 
apoptosis. It has been estimated in the recent literature, based on bioinformatics 
analysis of expressed sequence tags (ESTs) and cDNA datasets, that 95-100% of pre-
mRNAs undergo alternative splicing yielding multiple mRNAs (Wang 2008, Pan 2008). 
Alternative splicing gained substantial interest after the discovery that mutations in no 
less than 15%, and up to 50% of human genetic diseases involve changes in alternative 
splicing, either in the consensus sequence or in weak regulatory regions within the 
introns and/or exons, and dictate the fate of the final isoform produced (Matlin 2005). 
Similar to constitutive splicing, the process is carried out by the spliceosome; however, 
differences between weak and strong sequences on the pre-mRNA, called cis-factors, 
and the relative concentrations of several spliceosome associated proteins (SAPs), 
known as trans-factors, playa crucial role in determining the outcome of splicing. 
Additionally, the interplay between the cis and trans factors is subject to post-
translational modifications, which increases the complexity of the system. Ultimately, 
introns and exons forming the nascent pre-mRNA are cut and ligated in a multitude of 
combinations generating several transcripts that are translated by increased proteomic 
diversity. Several patterns of alternative splicing exist, with the most common modules 
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being alternative 5' or 3' splice-site selection, mutually exclusive exons, cassette-exon 
inclusion or skipping, and intron retention (Nilsen 2010) and are depicted in Fig 1.5. 
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Cassette exons Alternative 3' splice sites 
Mutuallay exclusive exons Retained intron 
; ..... 
Alternative 5' splice sites 
Fig 1.5 Splicing patterns in mammalian cells Different combinations of splicing and 
ligation can potentially generate a countless amount of transcripts. Of the multiple 
patterns of alternative splicing, cassette exons splicing pattern is the most identified and 
most studied form of alternative splicing. 
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Regulation of pre-mRNA splicing 
A major requirement for an efficient splicing reaction is the ability of the 
spliceosome to differentiate exons from introns, a process known as exon definition, 
which is mainly dictated by the presence of three short sequence cis elements: the 5' 
splice site, the 3' splice site and the branch point. Although intronic sequences are 
spliced-out and removed from the pre-mRNA, their relative length compared to average 
exons (50-250 nt) supports the hypothesis that splicing occurs by exon definition first, 
subsequently converted to intron definition with cross-bridging between Ul and U2 
snRNPs on opposite sides of an exon. As such, controlling splice sites selection, either by 
facilitating or inhibiting their recognition, is an important step in the regulation of 
splicing. In yeast, the consensus of splice sites selection is strictly followed while higher 
eukaryotes represent a more challenging case and divergence from the consensus is 
observed (Burset 2000, 2001). To improve exon control and recognition, additional 
elements known as exonic or intronic enhancers (ESE or ISE) and exonic or intronic 
silencers (ESS or ISS), depending on their location and impact on splicing, are present in 
the pre-mRNA. Two major classes of splicing factors, arginine-serine rich (SR) proteins 
and heterogeneous nuclear ribonucleoproteins (hnRNPs), bind the regulatory elements 
mentioned above to modulate splicing. 
SR proteins 
The serine and arginine rich proteins (SR proteins) are an essential family of 
constitutive splicing factors with abilities to bind RNA specific sequences and to 
modulate protein-protein interactions. SR proteins are recognized for their role as 
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molecular adapters between the pre-mRNA and the spliceosome. SR proteins are highly 
conserved and consist of one or two N-terminal RNA recognition motifs (RRMs) and a C-
terminal domain rich in repeating sequences of arginine and serine residues (RS 
domain). RRM domains are approximately 80 amino acid in length (Nagai 1990), and 
function in RNA binding (Nagai 1995). SELEX protocols (systematic evolution of ligands 
through exponential enrichment; Tuerk 1990) identified purine-rich exonic enhancer 
elements as preferred binding sites for individual SR proteins (Tacke 1999). The C-
terminal RS domains are highly conserved among the SR proteins (Zahler 1992, Birney 
1993) and function in cellular localization through protein-protein interactions with 
other RS-containing proteins (Caceres 1997, Kataoka 1999, Lai 2000, 2001). Additionally, 
RS domains are necessary for mediating protein-protein interactions with the 
spliceosomal machinery (Wu 1993, Kohtz 1994, Graveley 1998). As mentioned above, 
higher eukaryotes tend to diverge from the consensus exon definition, and SR proteins 
have been determined as crucial factors in identification of enhancer sequences within 
the exons or introns and facilitation of the interactions between the upstream 3' and 
the downstream 5' splice sites surrounding an exon (Berget 1995). SR proteins are also 
involved in intron bridging, the process of converting the exon definition into intron 
definition, which leads ultimately to intron removal and ligation of exons (Wu 1993, 
Abovich 1994, 1997 and Berglund 1997). It is noteworthy to mention that most SR 
proteins were discovered by their accidental reactivity to a monoclonal antibody, 
mAb104, mounted against active sites of RNA pol II on loops of the lampbrush 
chromosomes and germinal vesicles (Roth 1990). Altogether, the combination of the 
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RRM and RS domains functions support the role of SR proteins as facilitators of splicing: 
through binding E5Es and mediating critical protein-protein interactions, SR proteins 
strengthen weak splice sites, dictating the outcome of pre-mRNA splicing. 
HnRNPs 
Another group of essential modulators of the splicing process are the 
heterogeneous nuclear ribonucleo,Qroteins (hnRNPs). HnRNPs contain one or two RNA 
recognition motifs (RRMs) that mediate their binding to the pre-mRNA. The process of 
specific hnRNPs binding to pre-mRNA is not fully understood and still under debate; 
whereas some hnRNPs bind in a sequence-specific fashion, many others bind randomly_ 
HnRNPs are involved in several layers of gene expression and RNA processing including 
transcription, polyadenylation, stabilizing mRNA structure, shuttling of mRNA to the 
cytoplasm as well as pre-mRNA splicing. A (-terminal glycine G-rich motif" involved in 
protein-protein interactions within the spliceosome, is commonly found in several 
hnRNPS, although not universally. In contrast to SR proteins which function in enhancing 
splicing, hnRNPs act as splicing repressors by binding to silencing sequences within the 
introns and exons (ISS and ESS). More than 25 hnRNPs have been identified to date 
(Dreyfuss 1993), of which SXL, PTB (also known as hnRNP I) and hnRNP A/B family have 
shown to have the strongest involvement in modulating splicing. Two hypotheses are 
advanced to explain the inhibitory effect of hnRNPs in both of which they sterically 
encumber the interaction between positive enhancers or splicing factors to the pre-
mRNA. In the simplest form, repressor proteins directly antagonize enhancers by 
binding either close to a splice site or to ESE/ISE. PTB for instance, competitively binds 
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the polypyrimidine tract blocking U2AF (Singh 1995, Spellman 2006). Similarly, SXL binds 
the polypyrimidine tract of an upstream cryptic 3' splice site preventing U2AF binding, 
thereby activating a downstream 3' splice site (Lin 1995, Lallena 2002). Another example 
of direct steric hindrance comes from FOXl and FOX2, splicing factors expressed 
specifically in the heart, brain and skeletal muscles, which bind an ISS preventing SFl 
binding to the branch point of the calcitonin-related polypeptide-a, CALCA, hence 
inhibiting E' complex formation (Zhou 2008). On the other hand, simple steric hindrance 
fails to explain the inhibitory effect of hnRNP Al on its own exon 7B inclusion. The 
exonic sequence suppressor (ESS) is > 100 nt far from the enhancers. Oligomerization of 
Al through the C-terminal G-rich domain extends the inhibitory effect of Al towards the 
enhancer sequence and probably mediates a conformational rearrangement leading to 
the A1 observed effect (Del Gatto-Konczak 1999); a similar hnRNP Al effect has been 
shown for exon 7 exclusion of SMN2 (Kashima 2007). 
Combinatorial control 
SR proteins and hnRNPs interactions with the pre-mRNA and the spliceosome 
provide an attractive and somewhat simplistic view of the process of splicing regulation; 
however, a combinatorial effect of these RNA-associated proteins is more likely to 
represent a closer look into the real mechanisms of regulation. Several ways help 
accomplish that combination. The simplest and most studied form is the effect of 
relative abundance of enhancers and inhibitors. HIVl tat exon 3 inclusion is influenced 
by the amount of the inhibitor hnRNP A1 and enhancer SF2/ASF - an SR protein -
through interplay of their binding to their respective sequences (Zhu 2001). SF2/ ASF and 
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hnRNP Al provide similar opposing effects on (3-tropomyosin exon 6B inclusion (Expert-
Bezancon 2004). The picture becomes more complicated when proteins within the same 
family display antagonistic influences. There are many examples of functional 
antagonism within SR proteins, as well as hnRNPs. For instance, SRp20 self-regulated 
splicing is antagonized by SF2/ ASF (Jumaa 1997), SRrp86 is antagonized by SRp9G8 (Li 
2003) and SRrp86 itself has antagonistic effects: it enhances SRp20 while repressing 
5C35, SF2/ASF and SRp55 (Barnard 2000). Functional antagonism is also observed 
among hnRNPs: PTB and CELF (CUG-BP and ETR3-like factors) have opposite effects on 
Q-actinin (Suzuki 2002, Gromak 2003) and cardiac troponin-T (Charlet-B 2002). 
Regulation of splicing factors activities by phosphorylation/signaling 
Adding an extra layer of complexity, post-translational modifications of splicing 
factors are also complicit in modulating their activities and hence affecting both 
constitutive and alternative splicing. Phosphorylation, glycosylation and methylation are 
documented post-translational modifications (PTMs) on splicing factors (Soulard 1993, 
Rho 2007, Stamm 2008, Sinha 2010) and are implicated in regulating their functions. In 
this subsection, I will focus on the phosphorylation PTMs as they are most pertaining to 
this dissertation and the reader is directed to the references above for more 
information regarding the other forms of PTMs. As discussed earlier under this section, 
proteins and nucleic acids within and around the spliceosome are governed by weak 
hydrophobic and electrostatic protein-protein, protein-RNA and RNA-RNA interactions, 
which lead in a sort of "organized chaos" to a highly specific pattern of splicing. It is 
believed that this type of weak interactions is necessary to allow smooth and efficient 
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transitions in a highly complex and dynamic system. In that context, phosphorylation of 
splicing factors plays an important role in "bending and twistingll these interactions to 
modify the splicing outcome. Traditionally, phosphorylation modifications are studied 
on the two major classes of splicing protein regulators, namely the SR proteins and 
hnRNPs. In what follows, I will address the roles that phosphorylation is identified to 
. play in splicing, giving examples in each case. With respect to the role of the MAP kinase 
pathway in signaling to splicing factors, Sam68, remains the sole ERK/MAP kinase direct 
substrate implicated in splicing so far (Matter 2002). One of the earliest evidences of the 
involvement of protein phosphorylation in splicing is the fortuitous identification of SR 
proteins. Indeed, SR proteins were identified based on their reactivity to the monoclonal 
antibody mAB104 which reacts with a phosphate-containing peptide sequence (Roth 
1990, 1991; Zahler 1992). Emerging evidence of involvement of protein kinases and 
phosphatases in splicing was accumulating (Mermoud 1992, 1994; Tazi 1992, 1993; 
Woppmann 1993; Gui 1994; Colwill 1996a/b; Rossi 1996). Interestingly, replacement of 
ATP with ATP(yS) stalls the catalytic step of the spliceosome, but not its assembly 
(Mermoud 1992, 1994; Tazi 1992) and a continuous and dynamic cycle of 
phosphorylation/dephosphorylation is proposed to explain these observations (Tazi 
1993). The main impact of phosphorylation on splicing factors is its ability to alter their 
interactions within the spliceosomal complex, leading to changes in the mRNP 
formation, localization, or both; examples are provided below. 
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Changes in pre-mRNA/protein complex formation 
Protein splicing factors interactions with the RNA are dominated by weak 
hydrophobic and electrostatic interactions. Studies of the SR proteins RS domain 
interactions are among the best characterized; they are responsible for determining 
homophylic and heterophylic SR proteins binding. For instance, SF2/ ASF 
phosphorylation enhances its binding to U1-70K (U1 snRNP 70K subunit) but has no 
effect on its binding U2AF35 (Xiao 1997) while it has a negative effect on its binding the 
RNA export factor TAP/NXF1 (Huang 2004), SRp40, hTra2 and itself (Xiao 1997, 1998). 
Not limited to protein-protein interactions, phosphorylation alters SR proteins-RNA 
interactions as well, where phosphorylated RS domains prevent the non-specific RNA 
binding observed under unphosphorylated forms (Xiao 1998) showing that it increases 
specificity of splicing. Phosphorylation events in the process of splicing seem to playa 
regulatory switch, decreasing random interactions and improving specificity. 
HnRNP proteins are also subject to post-translational phosphorylation. SF1 is a 
member of the hnRNP K family and is phosphorylated by cGMP-dependent protein 
kinase-I (PGK-I) at Ser20 blocking its interaction with U2AF65, thereby pre-spliceosome 
assembly (Wang 1999). HnRNP C is phosphorylated by casein kinase II-type activity 
(Fung 1997), which decreases its RNA-binding capacity; however, it increases its target-
specific binding. TIA-1, an apoptosis-activated splicing factor, is also phosphorylated in 
vivo by FAST (Fas-Activated Ser/Thr kinase) in response to Fas ligand binding (Tian 
1995). It is interesting to note that in most cases, an adequate amount of 
phosphorylation is necessary and sufficient for optimal functioning of these splicing 
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factors, as hypo-phosphorylated and hyper-phosphorylated states tend to inhibit 
splicing (Prasad 1999). 
Changes in cellular localization 
An efficient and precise splicing requires specific contribution from each member 
of the spliceosome, therefore spatial distribution of splicing factors is a major 
determinant of the reaction's outcome. Phosphorylation of SR proteins and hnRNPs 
modulates their spatial distribution both between the nucleus and cytoplasm and within 
the nucleus itself, rendering them more or less available to the splicing machinery. 
Members of the importin ~ (imp ~) and transportin (TRN) family, TRN-SR1 and TRN-SR2 
have been shown to .interact with SR proteins for nuclear import both in humans and 
Drosophila (Kataoka 1999, Lai 2000, 2001) and this interaction is dependent on 
phosphorylated RS domains (Lai 2000, 2001). Dephosphorylation of SRp9G8 and 
SF2/ASF decreases their binding to the nuclear export factor TAP/NFX-1 leading to 
cytosolic accumulation (Huang 2004), while phosphorylation of hnRNP A1 by Mnk1/2 
(Guil 2006) in a MKK3/ 6/p38-dependent fashion reduces hnRNP A1 binding to 
transportin-1 under osmotic stress (Allemand 2005) and confines it to the cytosol (van 
der Houven van Oordt 2000). Spatial rearrangement is also observed in the nucleus 
where splicing factors (SR proteins, VB-1), in response to CLK1/2/3/4 and phosphatases 
activities, leave their stronghold Ifnuclear speckles" following phosphorylation, causing 
their nuclear redistribution and change in splice site selection (Hartmann 2001, 
Allemand 2007). 
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Splicing Factor 45 KOa - SPF45 
The pre-mRNA alternative splicing factor 45 KDa, SPF45, was discovered by two 
groups working independently. Neubauer et al. (Neubauer 1998) used an ingenious 
technique to identify components of the spliceosome multi-protein complex. Following 
2D-gel separation of the components of the fully assembled spliceosome, spots were 
excised, analyzed by mass spec and then coupled to EST-databases. A spot with an 
apparent molecular weight of 45 KDa was named SPF45, for splicing factor 45 KDa. 
SPF45 is highly homologous to the DNA damage repair protein DRT111 in A.thaliana. 
Another group was working on identifying novel genes expressed in drug-resistance 
cancer cells; using a suppressive-subtractive polymerase chain reaction, Sampath et al. 
identified SPF45 as a gene expressed in the cyclophosphamide-resistant EMT-6 mouse 
mammary cancer cells {Sampath 2003}. 
SPF45 consists of 401 amino acid residues. It has an N-terminal domain that is 
projected to be largely unstructured (Corsini 2007), a ...... 40-residues G-patch motif 
spanning between residues 235 and 281 (Aravind 1999), and a C-terminal domain 
harboring the RNA Recognition Motif {RRM}. The G-patch domain has 6 highly 
conserved G nucleotides and is predicted to have an unstructured secondary structure 
with possibly two a helices. It also contains repetitive RS and RGG sequences making it a 
candidate for non-specific protein-RNA interactions (Aravind 1999). Directly upstream to 
the G-patch is a ...... 10 residue domain named SPF45-like domain (or SF motif) and is 
common to several proteins with DNA repair function in T.gondii, C.elegans, 
D.melanogaster and A.thaliana (Frenal 2006). The SF domain assumes a helical 
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conformation and is involved in protein oligomerization (Frenal 2006). It has been 
shown that SPF45 interacts with SXL (sex lethal) in Drosophila through their N-termini 
(Lallena 2002) while it interacts with constitutive components of the spliceosome 
through the RRM domain (Corsini 2007). This latter is highly homologous to a group of 
protein-binding RRM domains in nuclear proteins such as PUF60, KIS kinase, HCCl and 
U2AF65 and are thus named UHM, for U2AF-homology motifs (Corsini 2007). The UHMs 
of these proteins interact with tryptophan-containing linear peptide motifs (Kielkopf 
2001, Selenko 2003) and are subsequently named UHM-ligand motifs ULMs. It is 
through the UHM-ULM type of interactions that SPF45-UHM binds the N-terminal ULMs 
of the constitutive spliceosomal proteins U2AF65, SFl and SF3b155 (Corsini 2007) and in 
fact, the C-terminus of SPF45 is capable of mediating the alternative splicing of pre-
mRNA without the need of the G-patch or the N-terminus. 
SPF45 is a ubiquitously expressed protein at low levels in normal tissues. Its 
highest expression is seen in breast, bladder, colon, kidneys and ovaries with main 
distribution to the ductal epithelia (Sampath 2003). SPF45 is a nuclear protein that 
localizes to the nuclear speckles along with other proteins from the spliceosome like 
UlsnRNP and SR proteins (Neubauer 1998, Sampath 2003). In cancer cells, it has the 
highest expression levels in tumors of epithtelial origin such as bladder, breast, colon, 
lung, ovarian, pancreatic and prostate carcinomas (Sampath 2003). 
We currently have very limited understanding of the potential targets for SPF45-
mediated pre-mRNA alternative splicing. So far, only 3 genes are reported to be affected 
by SPF45 expression. In D.melanogaster, SPF45 is responsible for the alternative splicing 
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of the sx/ gene (Lallena 2002). SPF45 activates a cryptic AG dinucleotide upstream of the 
normal 3' AG-dinucleotide responsible for exon 2 definition, leading to expression of 
exon 2 which contains a premature early stop codon and hence preventing its 
expression. However, in the presence of SXL, it binds SPF45 through their N-termini 
preventing the activation of the cryptic AG and leading to exon 2 skipping. The sex-lethal 
protein, SXL, is responsible for female secondary traits maturation (Skripsky 1982). SXL is 
responsible for its own auto-regulation, being expressed only in female but not male 
flies. Similarly to SXL, SPF45 is involved in the development of (3-thalassemia; a single 
point mutation of a guanine to adenine in the first intron of the (3-globin gene generates 
a cryptic AG dinucleotide recognized by SPF45 for activation, leading to expression of 
the (3110 mutation responsible for the thalassemic condition (Lallena 2002). Another 
target for SPF45-mediated alternative splicing is the death receptor FAS (Corsini 2007). 
SPF45 overexpression causes skipping of las exon 6 which encodes the single pass trans-
membrane domain that anchors the receptor to the cell membrane (Cascino 1994). 
Although exon 6 skipping does not inhibit protein expression, the product fails to anchor 
into the cell membrane and is released as a soluble isoform extracellularly. The soluble 
FAS acts as a decoy; it binds the FAS ligand (FASL), however it fails to initiate the 
apoptotic cascade {Cheng 1994}. The FASL signal is then transformed from pro-apoptotic 
to anti-apoptotic by the deletion of the trans-membrane domain. 
Sampath et al. showed SPF45 to be strongly over-expressed in tumors of 
epithelial origins (Sampath 2003). More importantly, when they forced SPF45 
expression in HeLa cells, they induced a drug resistance phenotype, as the cells became 
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resistant to doxorubicin and vincristine. A later study by Perry et al. (Perry 2005) showed 
that SPF45 overexpression in the ovarian cancer cell line A2780 -traditionally used for 
measuring drug sensitivities - caused a multidrug resistant phenotype. SPF45 confered 
drug resistance to the following chemotherapeutic agents: cisplatin, doxorubicin, 
mitoxantrone, etoposide and vincristine. The mechanism of drug resistance is not 
identified, however it was speculated to involve, at least partially, interaction between 
SPF45 and ER~, since co-treatment of the cells with the selective estrogen receptor 
modulator, tamoxifen, partially reversed the drug resistance (Perry 2005). SPF45 has 
been also implicated in the neurodegenerative disease spinocerebellar ataxia type 1 
(SCA1). Polyglutamine expansion of ataxin 1 ATXNl is linked to the development of 
SCAl (Banfi 1994); SPF45 directly interacts with ATXNl through their C-termini (Lim 
2008) and this interaction is necessary for SCAl development. 
SPF45 mechanism of action 
Our understanding of how SPF45 is utilized by the cell for alternative splicing is 
limited. The first target of SPF45 to be studied is the sex lethal (sxl) mRNA in Drosophila 
melanogaster (Lallena 2002) in the lab of Juan Valcarcel. Sxl has a very peculiar property 
that sets it aside from most canonical intron sequences in the fact that intron 2 has two 
potential AG dinucleotide around the 3' splice site that are termed AG p and AG d for 
proximal and distal, respectively. SPF45 is thought to bind directly to the proximal AG 
dinucleotide, priming it as the 3' splice site to be utilized. Later studies from the lab of 
Juan Valcarcel into the binding partners of SPF45 in the alternative splicing of Fas, show 
that the C-terminus of SPF45 harbors a UHM domain that interacts with members of the 
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constitutive splicing machinery, U2AF65, SFl and SF3b155. NMR experiments show 
SPF45 to interact with the aforementioned splicing factors; however, no measurable 
interaction is observed between SPF45 and the pre-mRNA. Whether SPF45 interacts 
with the nascent pre-mRNA or is mainly influenced by interactions with neighboring 
splicing factors remains an important area to unravel the true mechanism of action. 
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Rationale, hypothesis and specific aims 
Identifying MAP kinase(s) targets In their natural tissue specific expression 
pattern is essential for determining the impact of MAP kinases on their function(s). With 
emerging studies on the effects of signaling and phosphorylation, the link between MAP 
kinases and splicing factors, has been at best, very limited. Previous work from our lab 
showed an increase in ERK2 activity in SKOV3 cells upon detachment and growth under 
anchorage-independent conditions. Using an engineered ERK2 enzyme to determine 
MAP kinase-specific substrates in SKOV3 cells, we identify SPF45 as a novel substrate 
under conditions of adherence and suspension. In this dissertation, I investigate SPF45 
expression in ovarian cancer cells, identify the phosphorylation residues and 
characterize this phosphorylation both in vitro and in cells by ERK, JNK and p38 MAP 
kinases. I also examine the effect of the phosphorylation on SPF45 splicing activity, 
determine genetic changes in response to SPF45 overexpression as well as identify novel 
splicing targets and binding partners. Finally, I will address the role of SPF45 on drug 
resistance in cancer. The long term objective of this study is to understand the biological 
role of SPF45 in ovarian cancer and establish a strong link between the MAP kinase 
pathways, pre-mRNA alternative splicing events and the regulation of aberrant genetic 




MAP kinase phosphorylation of SPF45 is responsible for altering SPF45 interactions 
within the spliceosome and modulates SPF45-induced genetic changes and splicing 
activity. 
Specific Aims 
Aim1 Identify SPF45 as a novel MAP kinase substrate. Characterize the 
phosphorylation of SPF45 by ERK, JNK and p38 MAP kinases in vitro and in cells. 
Aim2 Determine the effect of MAP kinase phosphorylation on SPF45 splicing activity. 
Identify novel genetic and splicing events controlled by SPF45 as well as SPF45 
interaction with constitutive splicing factors. Assess the role of SPF45 on drug 
resistance in SKOV3 cells. Determine the impact of modulation of SPF45 functions via 
mutations of the MAP kinase-targeted residues. 
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Chapter 2 Identification of SPF45 as a novel MAP kinase substrate 
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Introduction 
MAP kinases are a ubiquitous family of protein kinases with important regulatory 
functions throughout the cell: they are involved in a diverse array of processes including 
but not restricted to, gene expression, differentiation, proliferation, migration and 
survival (reviewed in Pratilas 2010). Several MAP kinase subfamilies have been identified 
in eukaryotic cells, some of which are common to all eukaryotes while others are 
organism specific. All subfamilies share a common connected topology of activation: 
simplistically, an extracellular stimulus on the cell membrane activates a membrane 
receptor which leads to a sequential activation of a three-tiered cascade starting with 
MAP3K, followed by MAP2K and then the penultimate MAPK. Due to the similarities 
between the subfamilies, substrate promiscuity is not uncommon; hence identification 
of MAP kinase substrates in the cellular contexts and compartments is crucial to 
understand their functions (Eblen 2003). Earlier work from our lab (Eblen 2003, Kumar 
2004, Zheng 2010) led to the generation of an engineered ERK2/MAP kinase capable of 
efficiently identifying specific substrates of ERK2 under physiological and pathological 
cell conditions. 
Interests in MAP kinase pathways stem from their intricate involvements in 
several pathological conditions, especially cancer (McCubrey 2006). In ovarian cancer, 
ERK/MAP kinase pathway is indeed an important player (Thant 2000, Wong 2001, 
Givant-Horwitz 2003 and Ventura 2010). Previous work from our lab identified a novel 
form of sustained ERK activation in several ovarian cancer cell lines upon cellular 
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detachment that we showed to be necessary for anchorage-independent growth (AI-
Ayoubi 2008). Using the engineered ERK2 kinase mentioned above to generate SKOV3-
ERK2Q103 stable ovarian cancer cells, we identified ~Iicing f.actor 45 KD (SPF4S) as a 
novel substrate of ERK2 in ovarian cancer cells under anchorage-dependendent as well 
as -independent conditions. 
SPF45 is an mRNA alternative splicing factor initially identified by mass spec 
analysis to localize and engage with the spliceosome complex (Neubauer 1998). 
Concomitantly, studies of anti-neoplastic agents' resistance identified SPF45 as a gene 
overexpressed in EMT-6 mouse mammary cancer cells selected for cyclophosphamide 
resistance (Perry 2005). Overexpression of SPF45 in HeLa cervical cancer cells confers 
drug resistance against doxorubicin and vincristine (Sampath 2003), while 
overexpression in A2780 ovarian cancer cells confers a multidrug resistance phenotype 
against carboplatin, vinorelbine, etoposide, mitoxantrone, doxorubicin and vincristine 
(Perry 2005). In A2780-SPF45 cells, treatment with the selective estrogen receptors 
modulators tamoxifen and LYll7018 partially reverses mitoxantrone resistance, while 
SPF45 knock-down sensitizes the cells to etoposide (Perry 2005). Structurally, SPF45 has 
a large N-terminus that is unstructured, followed by a lO-residues SF (SPF45-like) motif, 
a G-patch motif of approximately 40 amino acid residues involved in protein-protein and 
protein-nucleic acid interactions and finally a C-terminus containing a modified RNA 
recognition motif (RRM) important for its intrinsic splicing activity (Corsini 2007). 
Crystallographic and NMR studies of the Toxoplasma gondii 55KDa DNA repair protein, 
TgDRE, which shares high homology to SPF45, show the capability of the G-motif to bind 
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small RNA oligonucleotides (as predicted for SPF45 G-domain) and that the RRM domain 
adopts a classical (3a(3J3aJ3 topology necessary for hydrophobic protein-protein 
interactions. Subsequent experiments by Corsini et al. resolved SPF45 RRM domain to 
adopt the same configuration (Corsini 2007). The SF motif is also involved in protein 
oligomerization (Frenal 2006). Besides its function in splicing and drug resistance, SPF45 
interacts with DNA repair proteins RAD201 (Chaouki 2006) and RAD51B (Horikoshi 2009) 
indicating its involvement in DNA repair pathways and specifically through SPF45 N-
terminal Iysines (Horikoshi 2009). Additionally, SPF45 is implicated in the development 
of spinocerebellar ataxia through a protein complex interacting with the polyglutamine 
expanded protein ATXN1 (Lim 2008). 
There is evidence that phosphorylation of splicing factors is implicated in the 
splicing machinery, regulating assembly, splice site selection and localization (Stamm 
2008). Identification of the serine-arginine rich proteins (SR) and the heterogeneous 
nuclear ribonucleic proteins (hnRNPs) as regulators of splicing had a major impact on 
recognizing that splicing factors undergo post-translational phosphorylation important 
for regulation of splicing. SR proteins were initially identified by their immunoreactivity 
to an antibody that detects a phosphorylated epitope (Roth 1991, 1992, Zahler 1992). 
Characterization of SR proteins and hnRNPs regulation led to the identification of SR 
protein kinases (SRPKs), cdc2-like kinases (elK/Sty) and DNA topoisomerase I as the 
main kinases regulating splicing, with a very limited contribution of MAP kinases to pre-
mRNA splicing/alternative splicing. To date, Sam68, (Src-associated in mitosis, 68Kd), 
remains the only pre-mRNA alternative splicing factor to be a direct substrate of 
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ERK/MAP kinase; phosphorylation of Sam68 by ERK/MAP kinase improves its binding to 
an exonic enhancer region leading to increase inclusion of CD44-v5 exon (Matter 2002). 
Of note, MKK3/ 6/p38 MAP kinase is also involved in the regulation of splicing factors, 
through Mnkl activation (Guil 2006), via an inhibitory phosphorylation of the splicing 
repressor hnRNP Ai, causing its cytoplasmic retention (van der Houven van Oordt 
2000). 
In this chapter we show that SPF45 is a novel ERK2/MAP kinase substrate with 
overlapping substrate specificity by JNK and p38 MAP kinase; we identify the targeted 
residues for phosphorylation by MAP kinases and characterize SPF45 phosphorylation 
on these sites in response to oncogenic and extracellular cues. 
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Materials and methods 
eel/lines and cell cultures 
ES-2, CaOV3, and OV2008 cells were a gift from Runzhao Li. SKOV-3 and Cos-1 cells were 
I 
obtained from American Type Culture Collection (ATCC Manassas, VA). OVCAR3 cells 
were a gift from Kristen Atkins, OVCARS and A2780 cells were a gift from Thomas 
Hamilton. lOSE cells were a gift from Nellie Auersperg and were grown in a 50:50 
mixture of media 105 and 199. Cos-1 cells were grown in DMEM (Invitrogen Carlsbad, 
CAl. SKOV-3, and OVCAR5 cells were grown in McCoy's 5A (Invitrogen Carlsbad, CAl. 
ES2, A2780 OVCAR3 and OV2008 cells were grown in RPMI 1640 (Invitrogen Carlsbad, 
CAl. All cell lines were grown in 10% fetal bovine serum (FBS) (ThermoScientific 
Rockford, I L). 
Plasmids and mutagenesis 
SPF45 eDNA was obtained from ATCC in the pOTB7 vector, digested with EcoR1 and 
Xho1 restriction enzymes (New England Bio Ipswitch, MA) and subcloned into the multi-
cloning site of pCMV3-2C vector encoding an N-terminal triple Myc-tag epitope 
downstream of the constitutive CMV promoter. PCR-based site-directed mutagenesis of 
Thr 71 and/or Ser222 was carried out using the following primers: 
Thr71-7 Ala71 (GACCGGCAAA TIGTGGACGCTCCACCGCATGTAGCAG & 
CTGGCCGTTIAACACCTGCGAGGTGGCGTACATCGTC) 
Ser222 -7 Ala222 (GAACAAGACAGACCGAGAGCTCCAACCGGACCTAGC & 
CTTGTTCTGTCTGGCTCTCGAGGTTGGCCTGGATCG) 
Th r71 -7 Asp 71 (GACCGG CAAA TIGTGGACGA TCCACCG CA TGT AGCAG C & 
CTGGCCGTTTAACACCTGCTAGGTGGCGTACATCGTCG) 
Ser222 -7 Asp222 (GAACAAGACAGACCGAGAGATCCAACCGGACCTAGCAAC & 
CTTGTTCTGTCTGG CTCTCT AG GTTGGCCTGGA TCG). 
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Wild type or alanine-mutants SPF45 were subcloned from this vector into pET15b 
encoding a 6-Histidine tag and transformed into BL21 E. coli to generate recombinant 
His-SPF45 proteins that were purified with nickel agarose (Roche Indianapolis, IN). 
Generation of SKOV3-QT8 cells 
Retroviral plasmids (pQCXIP) encoding empty vector/Flag-ERK2/Flag-ERK2-Ql03G were 
transfected into phoenix A cells along with VSV-G and Gag/Pol for virus production and 
packaging. Cellular media containing the viruses were harvested at 36 and 60 hours post 
transfection, filtered with 45 f.!m syringe filters (Corning Lowell, MA) and mixed with 
polybrene (Sigma St Louis, MO) to a final 2 Jlg/m I concentration before infecting the 
SKOV3 target cells. Cells were selected with 1.5 Jlgjml puromycin and several clones 
were generated. Individual clones were harvested and grown in 24 well plates, then 
screened by western blot for Flag-ERK2/or Flag-ERK2-Ql03G expression. 
32P-Labeling of cyclopenty/ ADP (cpADP) 
Nucleoside diphosphate kinase (NDPK, 200 units, Sigma St Louis, MO) and 800 JlCi of [v-
32p]ATP were added in a 100-ml reaction containing HBS (150 mm NaCI, 20 mmHEPES, 
pH 7.4, and 5 mm MgCb). The reaction was allowed to equilibrate at 30°C for 5 min.32p_ 
Labeled NDPK was purified from free [V-32p]ATP by two successive rounds of Microspin 
GSO columns (Amersham Biosciences, Piscataway, NJ). 1000 pmol of cpADP was added 
to the 32P-labeled NDPK in HBS, and the reaction was carried out for 20 min at 30°C. 
After the reaction, contents were transferred to a Microcon-YM30 (Millipore, Bedford, 
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MA} and centrifuged at 13,000 rpm for 15 min. With this procedure we usually obtained 
~ 200 IlCi of purified [y_32p]cyclopentyl-ATP ([V_32p]cpATP). 
Identification of SPF45 as a novel ERK2 substrate 
Four 150-mm dishes of SKOV3-QT8 cells (4x 106 cells/dish) expressing Flag-ERK2-QI03G 
were used. Cells were lysed in M2 buffer (150 mM NaCl, 5 mM KCI, 1 mM CaCI2, 1 mM 
MgCb, 50 mM HEPES, pH 7.4) supplied with protease inhibitors mix (100 JlM Na-o-
vanadate, 50 mM NaF, 40 mM ~-glycerophosphate, 5 mM Na-pyrophosphate, Aprotinin 
and 2 mM PMSF). Immunoprecipitation was performed using M2-Flag antibody (Sigma 
St Louis, MO). Immunoprecipitated ERK2-QG and associated proteins were eluted from 
the M2-agarose beads with FLAG peptide and separated on 8% SOS-PAGE. Labeled 
proteins were excised from the gel and microsequenced using a Finnigan LCQ ion trap 
mass spectrometer with a protana nanospray ion source (W. M. Keck Biomedical Mass 
Spectrometry Laboratory, University of Virginia). 
Generation of antibodies - a-total SPF45~ a-pThr71-SPF45 and a-pSer222-SPF45 
Total SPF45 antibody and phospho-specific antibodies to pThr71-SPF45 and pSer222-
SPF45 were generated in New Zealand White rabbits by Pacific Immunology, who 
assisted in the design and synthesis of immunogenic peptides, as well as generation and 
purification of the antibodies. Peptides used were: SPF45, PYEEDSRPRSQSSKAC; pThr71-
SPF45, SOORQIVD-T( P04)-PPHVAAGC; pSer222-SPF45, YEEQDRPR-S(P04 )-PTG PSNSFC. 
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ERK binding assays 
His-ERK2 or buffer was added to 500 Ilg of nuclear extract from HeLa cells and mixed 
overnight at 4°C. His-ERK2 was isolated with nickel agarose and washed three times with 
wash buffer (20 mM Hepes pH 7.4, 2 mM EDTA and 2 mM EGTA). The pull-downs were 
run on a gel and immunoblotted for SPF45 and ERK2. 
Transfections 
1.5 million Cos-1 cells were plated the night before transfection on 10 cm cell-culture 
dishes (Corning Lowell, MA) and transfected the following day with 6 Ilg total of DNA. 
Briefly, 6 Ilg total DNA and 24 III of Lipofectamine 2000 were suspended in 1.5 ml of 
Opti-MEM (Invitrogen Carlsbad, CA) each for 5 minutes at RT, then mixed together for a 
total of 20 minutes at RT before drop wise addition onto cells. The media and 
transfection mixture were recollected 5-6 hours following transfection, washed once in 
1X PBS and incubated in fresh media supplied with 10% FBS. The cells were collected 24 
hours post-transfection. 
In vitro kinase assay and phosphoamino acid analysis 
0.5 I-lg of recombinant SPF45 was incubated with the kinases of interest (His-ERK2, GST-
p38a and GST-JNK1 (Invitrogen Carlsbad, CAl at an equal activity of 500 nmol/min in 30 
III of kinase buffer (20 mM Hepes pH 7.4, 10 mM Mg acetate, 1 mM dithiothreitol 
(DTT)), lOOIlM ATP and lOIlCi of V 32p_ATP (Perkin Elmer Waltham, MA) at 30°C for 
10minutes. The reaction was quenched by addition of 2X Laemmli sample buffer and the 
phosphorylated protein (His-SPF45) was resolved by SDS-PAGE, transferred by western 
blot into PVDF (Biorad Hercules, CAl membranes and exposed on HyBlot CL films 
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(Denville Scientific South Plainfield, NJ) for autoradiography. Radioactive bands were 
excised, quantified by Cerenkov count and analyzed for phosphorylated residues by 
phosphoamino acid analysis (Boyle 1991). Briefly, radioactive bands were excised, 
hydrolyzed using 6N Hel (Sigma St louis, MO) at 110°C for 1h, washed and lyophilized in 
water than suspended in buffer 1.9 (2.5% v/v 88% Formic acid, 7.8% v/v Acetic acid, 
89.7% v/v H20). 1000 cpm of the final suspension were mixed with standard threonine, 
serine and tyrosine amino acids for detection before spotting and 2-D electrophoresis 
on a TlC plate. The standard amino acids were stained with 0.2% ninhydrin in ethanol 
(Sigma St Louis, MO) and the plate was developed on Hyblot CL films a week after 
exposure. 
Immunoprecipitation 
Cells were lysed in M2 buffer (150 mM NaCI, 5 mM KCI, 1 mM CaCI2, 1 mM MgCI2, 50 
mM HEPES, pH 7.4) supplied with protease inhibitors mix (100 J..lM Na-o-vanadate, 50 
mM NaF, 40 mM l3-glycerophosphate, 5 mM Na-pyrophosphate, Aprotinin and 2 mM 
PMSF). 500 J,lg of lysate were incubated with 2 1-11 of Myc-antibody (Sigma St louis, MO) 
conjugated to protein A agarose with constant mixing for 2 hours at 4°C. The 
precipitates were then washed 3X in M2 buffer followed by suspension in 1X laemmli 
Sample buffer or washed 2X in kinase buffer in preparation for in vitro kinase reaction. 
In vitro kinase reaction of SPF45/alanine mutants 
Empty vector/Myc-SPF45/alanine mutants were transfected into Cos-1 cells, Myc-
immunoprecipitated 24 hours post-transfection then suspended in 30 1-11 of lX 
phosphatase buffer (NEB buffer3: 50mM Tris-HCI, 100 mM NaCl, lOmM MgCb and 1mM 
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Dn) with 2 III of calf intestinal phosphatase CIP (New England Bio) at 37°C for 1 hour 
followed by 2 washes in kinase buffer prior to in vitro kinase phosphorylation as 
described above. 
SPF45 dephosphorylation - Phosphatase Assay 
His-5PF45 (0.5 Ilg) was recollected following the kinase assay (with ERK2) by Ni++-
agarose binding with rocking for 2 hours at 4°C. The 5PF45-conjugated beads were 
washed twice in 1X phosphatase buffer, then re-suspended in 30 III of 1X phosphatase 
buffer supplied with 2 III of Calf Intestinal Phosphatase (New England BioLabs Ipswitch, 
MA) and incubated at 37°C for 1 hour. The reaction was quenched by addition of 10 III 
of 4X Laemmli Sample buffer. Proteins were separated by 5DS-PAGE, transferred onto 
nitrocellulose membrane and visualized using pThr71-5PF45, p5er222-SPF45, total 
SPF45 and ERK2 antibodies by western blotting. 
Immunoblotting 
Cells were lysed and sonicated in M2 buffer with 0.5% SOS and protease inhibitors mix. 
Lysates were normalized using BCA protein assay kit (Pierce Rockford, IL). Each sample 
(100 Ilg) was run on a 10% polyacrylamide gel (50S-PAGE) under denaturing conditions 
and transferred to Protran nitrocellulose membrane (Whatman-GE Healthcare 
Piscataway, NJ). After blocking with 5% milk for 1 hour at room temperature, the 
membranes were incubated with relevant primary antibodies (total-SPF45, pThr71-
5PF45, pSer222-SPF45, Myc, ERK, pERK, p38 MAP kinase, p-p38 MAP kinase, JNK, p-JNK 
and Actin) in 1X PBS with 5% B5A and 0.1% Tween-20, 0.1% sodium azide (Sigma 5t 
Louis, MO) at 4°C overnight. The blots were washed three times in 1X PBS + 0.1% 
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Tween-20 and incubated with the appropriate secondary HRP-conjugated antibody 
(Mouse, Rabbit (Biorad Hercules, CA)) in PBS-O.l%T with 1% milk for 1 hour at room 
temperature. The membranes were then washed 6 times with PBS-O.1%T for a total of 1 
hour at room temperature. The membranes were incubated with femto-ECL (Pierce 
Rockford, IL) for 2 minutes at room temperature and the bands were exposed on Hyblot 
CL films (Denville Scientific South Plainfield, NJ). 
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Results 
Identification of SPF45 as a novel substrate of ERK2 
In previous works, we reported the generation of a mutant ERK2jMAP kinase 
(ERK2-Q103G) capable of identifying specific substrate of the enzyme under the desired 
cellular conditions (Eblen 2003), and show activation of the ERK2jMAP kinase pathway 
in several ovarian cancer cells under anchorage-independent conditions (AI-Ayoubi 
2008). Using SKOV3-QT8, an ovarian cancer cell line stably expressing ERK2-Q103G (Fig 
2.1 A&B), we screened for potential ERK2-associated substrates in ovarian cancer cells. 
SKOV3-QT8 cells were either grown adherent or trypsinized then put in suspension for 3 
hrs. Subsequently, the cells were lysed and Flag-ERK2-Q103G immunoprecipitated 
under mild conditions to preserve protein-protein interactions prior to incubation for 3 
min in kinase buffer containing [32P-y]-N6-cpATP. The kinase reaction was run on a gel 
and we detected radiolabeled bands by autoradiography showing labeling of a 47 kDa 
band under both conditions (Fig 2.1 C left). A parallel immunoprecipitation and kinase 
reaction using more cell lysate from suspended cells and unlabeled cyclopentyl ATP 
displayed a silver-stainable band at the same molecular weight (Fig 2.1 C right). Mass 
spec analysis of the band identifies several proteins including SPF45, a pre-mRNA 
alternative splicing factor. 
SPF45 is phosphorylated by ERK2, JNK and p38 MAP kinases on threonine and serine 
Since MAP kinases are serine/threonine proline-directed kinases that 
phosphorylate the canonical T jSP or PXT jSP sequences, overlapping substrate specificity 
is not uncommon among the different subfamilies. In all that follows, SPF45 cDNA was 
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obtained and subcloned into pCMV3-2C (adds a Myc-tag) and pET1Sb (adds a His- tag) 
for mammalian and bacterial expression, respectively. Accordingly, we tested whether 
phosphorylation of SPF4S by the three MAPK subfamilies occurs, and subjected His-
SPF4S to an in vitro kinase reaction with active recombinant ERK2, p38a and JNK1 in the 
presence of [32p_y]_ATP. Protein fractionation by SDS-PAGE showed a radiolabeled band 
around 50 KDa corresponding to phosphorylated His-SPF45 (Fig 2.1 D&E). The bands 
were excised and processed for phosphoaminoacid analysis (PAA) identifying 
phosphorylated threonine and serine residues on all three bands (Fig 2.1 F). 
Generation of SPF4S antibodies: a-total-SPF4S, a-pThr71-SPF45 and a-pSer222-SPF45 
Among the 401 amino acid residues that make SPF45, only two residues conform 
to the MAPK substrates criterion. Namely, they are Thr71 and Ser222, which - by 
sequence analogy - appear to be highly conserved among mammalian species .. 
suggesting a role for their phosphorylation in regulating the function of this protein (Fig 
2.2 A). As there are no commercially available total and phospho-specific antibodies to 
SPF45 .. we generated polyclonal antibodies in New Zealand White rabbits. To test their 
ability to recognize total-SPF45 as well as pThr71-SPF45 and pSer222-SPF4S by western 
blot .. we subjected SPF45 to three different treatments: no ERK2 phosphorylation, with 
ERK2 phosphorylation and ERK2 followed by phosphatase treatment (Fig 2.2 8). Anti-
total-SPF45 antibody was able to detect His-SPF45 both in the presence and absence of 
ERK2 kinase reaction .. but not the empty SPF45 lane. On the other hand .. anti-pThr71-
SPF4S and anti-pSer222-SPF45 antibodies were weakly able to detect SPF45 before it 
was phosphorylated and their specificity was strongly enhanced following incubation 
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with active ERK2. Phosphatase treatment of the Ni++-purified SPF45 after the kinase 
reaction showed a decrease in phospho-specific antibodies detection of SPF4S but not 
of the total-SPF45 antibody. Altogether, these data support our prediction that Thr71 
and Ser222 are ERK2-targeted residues, at least in vitro. To validate the specificity of the 
phospho-specific antibodies, we generated single and double mutants of Thr71 and 
Ser222 to either alanine (Fig 2.2 C); single and double aspartate mutants were equally 
generated for subsequent experiments. As anti-total-SPF45 was mounted against an 
epitope that does not encompass the phosphorylation residues, it equally detected 
SPF45-mutants (SPF45 T7iA, SPF4SS222A and SPF4SAA) both before and after ERK2-induced 
phosphorylation. Anti-pThr71-SPF4S failed to detect His-SPF4S T7iA and His-SPF4SAA but 
not His_SPF4SS222A, while anti-pSer222-SPF4S detects His-SPF45 T7iA but not His-
SPF4SS222A and His-SPF4SAA following in vitro kinase reaction with ERK2, confirming their 
efficacy in specifically identifying SPF45 and its phosphorylated forms (Fig 2.2 D). It is 
noteworthy to mention that phosphorylation of SPF45 on Thr71 causes a mobility shift 
(Fig 2.20 S222A+ERK2); in a later experiment we show a similar mobility shift for 
SPF45 T71D. Finally, we examined and showed SPF45 phosphorylation on Thr71 and 
Ser222 in response to JNK and p38 MAP kinases (Fig 2.2 E). Unfortunately, the ability of 
these antibodies to immunoprecipitate SPF45 and immunofluorescence cytochemistry is 
not successful (data not shown). ELISA and immunohistochemistry (IHC) were not 
tested. 
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5PF45 and ERK2 are binding partners in vitro and in cells 
5PF45 was initially identified as an ERK2-associated substrate in our search for 
potential ERK2 targets in 5KOV-3 ovarian cancer cells. MAP kinases are known to bind 
their targets in their non-phosphorylated state prior to activation and detachment from 
the protein complex, potentially through interactions with the O-domain in the target 
protein (Cobb 1995). Although not tested, the amino acid sequence of 5PF45 exhibits a 
151 and a potential overlap with a 
nuclear localization signal (N L5) which can possibly explain the nature of interactions 
between ERK2 and 5PF45. To support the hypothesis of binding between ERK2 and 
5PF45, His-ERK2 was incubated overnight at 4°C with nuclear extracts from HeLa cells, 
pulled-down the following day with Ni++-conjugated agarose beads solubilized in 1X 
sample buffer and fractionated by 50S-PAGE. Immunoblotting with anti-total-5PF45 
antibody shows 5PF45 in the ERK2-pull-down, but not with Ni++ beads alone (Fig 2.3 A), 
and the amount of 5PF45 recovered from the nuclear extract was dose-dependent to 
the amount of His-ERK2 in the pull-down assay (Fig 2.3 B), indicating a stoichiometric 
binding of ERK2 to 5PF45. Efforts to show the reciprocal binding of recombinant His-
ERK2 with recombinant 5PF45 were not successful since both proteins are His-tagged 
and efforts to generate GST-SPF45 were futile possibly due to solubility issues (data not 
shown) . Using SKOV3-pQCXIP and SKOV3-pQCSPF45, two cell lines stably expressing 
empty vector and Myc-SPF45 respectively generated in the next chapter, we showed 
that ERK2 co-immunoprecipitates with SPF45 but not the empty vector (Fig 2.3 C). Taken 
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together, we confirmed that ERK2 and SPF45 bind together both in vitro and in cells 
supporting a genuine interaction between ERK2 and its target, SPF45. 
Phosphorylation of SPF45 in Cos-1 cells in the presence of constitutive activation of the 
ERK2/MAP kinase pathway 
To characterize SPF45 phosphorylation in cells in response to continuous 
MEK1/ERK2 activation, we transfected Myc-SPF45/mutants (to alanine and aspartate) 
into Cos-1 cells along with constitutively-active MEK1-S222/2224D (CA-MEK1{DD)) and 
ERK2 (Fig 2.4 A). Twenty four hours hours post-transfection, the cells were lysed and 
Myc-SPF45/mutants were Myc-immunoprecipitated. Immunoblotting against anti-
pThr71-SPF45, anti-pSer222-SPF45 and anti-Myc antibodies showed that SPF45 is 
phosphorylated on both Thr71 and Ser222 in agreement with the in vitro kinase assay. 
Mutations of Thr71 to either alanine or aspartate inhibited its phosphorylation but not 
Ser222. Similarly mutations of Ser222 to either alanine or aspartate prevented its 
phosphorylation but not Thr71. To note, we also observed a shift in SPF45 molecular 
weight with Thr71 phosphorylation that corresponds to the mobility shift displayed by 
SPF45 T71D mutant. Although CA-MEK1(DD) causes a permanent ERK2 activation, no such 
mutation is observed to occur naturally in cells. Hyperactivation of the MAP kinase 
pathways is linked to several mechanisms, including but not limited to: overexpression 
of receptor tyrosine kinases (RTKs), pathophysiological processes such as inflammation 
and stress, and in cancer due to activating mutations in the upstream signaling cascade 
of ERK2 such as K-Ras, H-Ras and B-Raf (see the "Introduction" chapter for more 
details). We transfected Myc-SPF4S into Cos-1 cells along with K-Ras-G12V, B-Raf-V600E 
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or CA-MEK1{DD) with or without ERK2 (Fig 2.4 B). Co-transfection of each member of 
the pathway stimulated SPF45 phosphorylation on both Thr71 and Ser222 above basal 
levels which was further enhanced on Ser222 phosphorylation and greatly induced 
Thr71 phosphorylation by addition of exogenous ERK2. Using Cos-1 cells as a "neutral" 
milieu for studying SPF45 phosphorylation, we showed that hyperactivation of 
ERK2/MAP kinase pathway results in Thr71 and Ser222 phosphorylation indicating that 
SPF45 could be phosphorylated on these two residues in cancer cells that have elevated 
ERK2/MAP kinase expression and activation levels as demonstrated by the assay above. 
We further examined the validity of this hypothesis below in ovarian cancer cell lines. 
Phosphorylation of endogenous SPF45 in ovarian cancer cells following extracellular 
stimulation of MAP kinases pathways 
Phosphorylation of endogenous SPF45 has not been reported. We showed above 
that Thr71 and Ser222 are MAP kinase targets for SPF45 phosphorylation in vitro and by 
forced phosphorylation of exogenous SPF45 in Cos-1 cells. Previously published data 
(Sampath 2003) showed SPF45 to be overexpressed in several solid cancers including 
ovarian cancer. Since SPF45 is an ERK2/MAP kinase substrate in SKOV3 cells, we sought 
to validate Thr71 and Ser222 as genuine MAP kinase targets on endogenous SPF45 and 
to characterize the pattern of SPF45 phosphorylation in cells. Screening for SPF45 
expression levels in several ovarian cancer cells and lOSE cells, a benign immortalized 
ovarian cell line, revealed the following: lOSE expressed little SPF45 and would 
accordingly serve as a negative control while the A2780 cancer cell line showed the 
highest levels of SPF45 expression followed by ES2, OV2008, OVCAR-3 and OVCAR-5 
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cells, in no specific order (Fig 2.5 A). We observed basal levels of Thr71 and Ser222 
phosphorylation in all cell lines tested (Fig 2.5 A). Immunoblotting with anti-phospho 
MAP kinase antibodies revealed variable expression/activation of ERK, p38 and JNK 
kinases, with most exhibiting elevated ERK1/2 activation. Based on these results, we 
speculate that SPF45 maintains a basal phosphorylation level required for its ubiquitous 
functions depending on cellular conditions; additionally, an elevation in Thr71 and/or 
Ser222 phosphorylation levels in response to MAP kinase(s) activation can potentially 
reflect increased cellular requirement of SPF45 functions, which remains to be 
demonstrated. 
We originally identified SPF45 as an ERK2-associated substrate from anoikis-
resistant SKOV-3 cells grown in suspension. Therefore, it was natural to test the 
phosphorylation of endogenous SPF45 in SKOV-3 cells that are either grown adherent or 
detached (Fig 2.5 B). Endogenous SPF45 was phosphorylated detached but not adherent 
cells, suggesting that SPF45 phosphorylation, like ERK2 activation is anchorage-
independent in ovarian cancer cells (AI-Ayoubi 2008). 
In what follows, we describe several experiments performed to identify 
extracellular stimuli that induce SPF45 in ovarian cancer cells and to identify the MAP 
kinase pathway(s) responsible for SPF45 phosphorylation. For these experiments we 
used A2780 (Fig 2.5 C), ES2 (Fig 2.5 D) and SKOV3 (Fig 2.5 E) cells as they had three 
different levels of SPF45 expression: high, medium and modest, respectively. After 
serum starvation overnight the cells were treated with agents that stimulate the various 
MAP kinase pathways, including fetal bovine serum, phorbol myristate acid (PMA), 
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H20 2, anisomycin, EGF, HGF, sorbitol and ultraviolet (UV) light. In A2780 cells, PMA - an 
activator of ERK and p38 - stimulated high Thr71 phosphorylation and moderate Ser222 
phosphorylation. Anisomycin - an activator of JNK - stimulated high Thr71 
phosphorylation, with little to no increase in Ser222 phosphorylation. Similar results 
were observed with UV treatment, which activated both JNK and p38. H20 2, an acute 
stimulator of intracellular ROS and an activator of both p38 and ERK, induced 
phosphorylation of both sites equally. In ES2 cells, no change in Ser222 phosphorylation 
was observed with the different stimuli tested. Thr71 on the other hand exhibited 
elevated phosphorylation levels that were more pronounced an hour following UV, 
anisomycin, sorbitol, H20 2 and EGF stimulation. Finally, in SKOV3 cells, both Thr71 and 
5er222 phosphorylations were observed; Thr71 phosphorylation was more pronounced 
under serum starvation, H20 2 and UV stimulation while Ser222 phosphorylation was 
highest following UV, EGF and HGF stimulation. 
To determine which MAP kinase pathway(s) was responsible for endogenous 
SPF45 phosphorylation in cells, A2780 cells were serum starved, pretreated for 30 min 
with a specific MAP kinase pathway inhibitor and then stimulated as above in the 
presence of the inhibitor (Fig 2.5 F&G). The MAP kinase pathway inhibitors used were 
U0126 for the ERK pathway, 5B203580 for the p38 pathway and 5P600025 for the JNK 
pathway. U0126 inhibited 5PF45 phosphorylation in response to PMA and H20 2; on the 
other hand, SP600025 inhibited 5PF45 phosphorylation in response to UV light, while 
5B203580 inhibited 5er222 only in response to UV, suggesting that ERK, JNK and p38 
MAP kinase are able to phosphorylate endogenous SPF45 in response to extracellular 
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signals in a stimulus-dependent manner. Although we were unable to find a stimulus 
that significantly induced SPF45 phosphorylation on both Thr71 and Ser222 in a p38-
dependent manner, we have observed SPF45 phosphorylation on Thr71 and Ser222 
when SPF45 was co-expressed in Cos-1 cells along with MKK3 and p38 (data not shown). 
Accordingly, SPF45 phosphorylation in a p38-dependent manner, if it were to happen, is 
more likely to be stimulus and cell type-dependent. 
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Fig 2.1 SPF45 is a novel MAP kinase substrate A. FLAG-ERK2-Ql03G or FLAG-ERK2 is stably 
expressed in SKOV-3 cells via retroviral infection. Cell Iysates are used to detect exogenous 
and endogenous ERK2 expression in several clones. B. Immunofluroescence using Flag 
antibody and clone QT8 demonstrates efficient ERK2-Ql03G expression. C. FLAG-ERK-Ql03G 
is immunoprecipitated from SKOV-3 clone QT8 either growing adherent {Adh} or anchorage-
independent (Susp) for 3 hr. Co-immunoprecipitating substrates are labeled in an in vitro 
kinase reaction with [32P-y]-cyclopentyl ATP {left}. A silver-stained scaled-up non-radioactive 
kinase assay is performed in parallel {right} and SPF45 is identified by mass spectrometry 
from this protein band among several other targets. D. In vitro MAPK kinase reaction using 
active recombinant ERK2, JNKl or p38a, and [32P-y]-ATP and His-SPF45 as substrate. The 
reactions are run on a gel and exposed for autoradiography. E. Histogram of counts per 
minutes (cpm) obtained from the phosphorylated SPF45 bands. F. Phosphorylated His-SPF45 
from the reactions in 0 are digested with HCI and processed for 2-dimensional phosphoamino 
acid analysis before exposure for autoradiography. Experiments performed with Scott Eblen. 
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Fig 2.2 SPF45 is phosphorylated on Thr71 and Ser222 A. SPF45 has two potential MAP kinase 
phosphorylation sites well conserved among mammalian species. B. His-SPF45 is 
phosphorylated in vitro with ERK2 followed by CIP treatment. pSer222- & pThr71-specific 
antibodies show SPF45 phosphorylation that is diminished after phosphatase treatment (last 
lane to the right.) C. Cartoon depicting the different combinations of alanine and aspartate 
mutants of SPF45. D. Total-SPF45 antibody detects SPF45 before and after ERK2 
phosphorylation. pThr71- and pSer222-specific antibodies detect SPF45 after ERK2 
phosphorylation but not the corresponding alanine mutants. E. His-SPF45 is phosphorylated in 
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Fig 2.3 ERK2 associates with SPF45 A. Purified His-ERK2 is mixed overnight 
with HeLa cell nuclear extracts. His-ERK2 is pulled down with nickel agarose, 
washed, run on a gel and transferred to nitrocellulose. The membrane is 
immunoblotted with anti-SPF45 and anti-ERK antibodies. B. Increasing 
amounts of His-ERK2 are mixed overnight with HeLa cell nuclear extracts 
and processed as in A. C. ERK2 co-immunoprecipitates with Myc-SPF45 
pulled down from SKOV3-pQCSPF45 with protein A agarose conjugated to 
Myc antibody following 2 hr incubation at 4°C. IP is processed as in A. 
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Fig 2.4 Phosphorylation of SPF45/mutants in Cos-1 cells by ERK2 MAP kinase A. 
Myc-SPF45/mutants are transfected into Cos-1 cells with ERK2 and CA-MEK1{DD}. 
Anti-Myc immunoprecipitates are immunoblotted with anti-phospho-SPF45 and 
anti-Myc antibodies. B. Myc-SPF45 is transfected into Cos-1 cells with mutationally-
activated MEK1, B-Raf or H-Ras -/+ ERK2. Anti-Myc immunoprecipitates are 
immunoblotted with anti-phospho-SPF45 and anti-Myc antibodies. Experiments 






















Fig 2.5 Endogenous SPF45 is primarily phosphorylated by ERK and JNK in cells A. Cell 
Iysates are prepared from ovarian benign immortalized and cancer cell lines. The Iysates are 
run on a gel and endogenous proteins immunoblotted as indicated in the methods. B. SKOV-
3 cells are grown adherent or trypsinized and put in cell suspension for 24 hr. Ceillysates are 
run on a gel and immunoblotted for endogenous SPF45 with anti-SPF45 and anti-phospho-
SPF45 antibodies, along with actin as a loading control. C~ 0 & E. A2780 (C), SKOV3 (0) and 
ES2 (E) cells are serum-deprived overnight and then treated with serum, PMA, H20 2, EGF, 
HGF, sorbitol, anisomycin or UV light for 15 min or 1 hr. Cell Iysates are prepared, run on a 
gel and endogenous proteins immunoblotted with the indicated antibodies. F & G. A2780 
cells are put in serum free media (SF) overnight and then treated with either OMSO (OM), 
the MEKl inhibitor U0126 (UO), the p38 inhibitor SB20358 or the JNK inhibitor SP600025 
(SP) for 30 min prior to stimulation with PMA, H202 or UV for 15 min. The cells are lysed 
and equal amounts of protein run on a gel, transferred to nitrocellulose and immunoblotted 
with the indicated antibodies. Experiments performed with Hui Zheng and Yuying Liu. 
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Fig 2.5 Continued. 
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Discussion 
Identification of MAP kinase substrates in their tissue-specific expressions as well 
as their spatio-temporal regulation is an important task in order to dissect the exact 
roles the different MAP kinases play in controlling cellular functions. Using the approach 
developed by Shokat (Shah 1997) and modified for ERK2 by our group (Eblen, 2003), we 
report the detection of SPF45, a pre-mRNA alternative splicing factor, as a novel 
substrate of ERK2 in SKOV3 cells, an ovarian cancer cell line that we previously showed 
to strongly activate ERK2 pathway under anchorage-independent conditions (AI-Ayoubi 
2008). Radio-labeling of ERK2-associated substrates with a 32p isotope under anchorage-
dependent and -independent conditions revealed a phosphorylated band at 47Kda 
corresponding to SPF45, which was detected by mass spec analysis of a silver-stained 
equivalent band. We further showed, using phospho-amino acid and mutational 
analyses, that Thr71 and Ser222 are the MAP kinase-target residues. We also confirmed 
that SPF45 is similarly phosphorylated by JNK and p38 MAP kinases, in vitro, on Thr71 
and Ser222. We generated polyclonal and phospho-specific antibodies against the total 
protein as well the phosphorylated epitopes, and used them to determine the 
phosphorylation of transfected SPF45 in Cos-1 cells in response to co-expressing 
activators of the ERK2/MAP kinase pathway which had the highest response upon co-
expression of activated MEKl and ERK2, simulating a continuous upstream signaling to 
ERK2. We also explored the phosphorylation of endogenous SPF45 in several ovarian 
cancer cell lines in response to stimulation with known activators of the different MAP 
kinase pathways. In A2780, ES2 and SKOV3 cells, SPF45 phosphorylation was mainly 
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induced following ERK (serum, PMA, EGF and HGF) and JNK (anisomycin and UV 
irradiation) activation but weakly in response to p38 (sorbitol and H20 2). While p38 MAP 
kinase strongly phosphorylated SPF45 in vitro, the response is, at best, modest in these 
cells in response to the stimuli tested. Additionally, using chemical inhibitors of the 
different kinase pathways supported our observation that ERK and JNK were more 
involved in SPF45 phosphorylation, at least in response to the stimuli we used, even 
stimulation by H20 2 - a strong p38 activator - was rather mediated by ERK. While it 
does not rule out the possibility that p38 MAPK has the potential of regulating SPF45 
phosphorylation (such as Ser222 phosphorylation in response to UV light), it clearly 
indicated the specificity of the different kinases in controlling SPF45 functions. In fact, 
both Thr71 and Ser222 were phosphorylated upon ERK activation while JNK had a more 
pronounced effect on the phosphorylation of Thr71 compared to Ser222. Taken 
together, we predict that the phosphorylation pattern of SPF45 coupled with the spatio-
temporal activation of the responsible kinase to dictate the function of the protein in a 
stimulus-dependent fashion. 
SPF45 is a highly conserved protein among vertebrates, exceeding 80% 
homology. Interestingly, peptide sequences surrounding Thr71 and Ser222 are 
conserved as well, suggesting an old and preserved role of the phosphorylation in 
regulating the functions of SPF45. In Xenopus, the homolog of Thr71 is however 
replaced by a serine followed by a proline, which actually retains the ability to be 
phosphorylated by MAP kinases and therefore potentially preserves its function. As 
Thr71 lies in the N-terminal domain whose structure has not been resolved yet, it is hard 
99 
to speculate on the role that the phosphorylation may impart on the protein. Ser222 lies 
in the SPF45-like (SF) motif, in the vicinity of the G-patch domain. It is unclear what a 
phosphorylation in the vicinity of a G-patch motif or within the SF-domain will do to the 
protein's functions as there are no accounts linking these domains and phosphorylation. 
The SF motif is involved in protein oligomerization (although no oligomerization of 
SPF45 has been described yet) and the G-patch is linked to protein and ribonucleic acid 
interactions. Accordingly, we suspect that the phosphorylation on Ser222 to play an 
important role, possibly more so than Thr71, in modulating SPF45's interactions within 
the spliceosome, as well as any other protein complex it can be involved with. Previous 
studies linked SPF45 to DNA repair pathways, multidrug resistance, apoptosis 
regulation, spinocerebellar ataxia as well as ~-thalassemia. As diverse as these functions 
may be, determining SPF45 targets and the effect that the phosphorylation plays is 
needed to better understand how it can be mediating some or all of these effects. 
Similar to the MAP kinase-targeted splicing factor Sam68, these functions can be 
mediated by the impact of more than one kinase, while the same phosphorylation may 
have different outcomes based on several factors - including but not limited to - the 
cellular distribution of SPF45 and its interaction with spliceosomal protein complexes. In 
fact, regulation of splicing factors by MAP kinase pathways is a rare event. Evidence of 
involvement of signaling pathways in regulating splicing factors are accruing; however, 
Sam68 remains the only splicing factor which is known to be under direct regulation of 
ERK/MAP kinase pathway to date (Matter 2002). Forced expression of Sam68 leads to 
an increase in inclusion of C044 variable exon vS in an ERK-dependent fashion. Fyn, a 
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src-tyrosine kinase, also phosphorylates Sam68, causing an increase in the pro-apoptotic 
Bcl-x(s) isoform (Paronetto 2007), but it does not have any effect on CD44 v5 inclusion, 
indicating the specificity of the different phosphorylations in modulating the splicing 
activity. HnRNP Al, a general repressor of splicing, is phosphorylated by Mnkl in 
response to MKK3/6/p38 activation following osmotic response, inducing its detainment 
in the cytosol lifting the ban on splicing (Guil 2006). Although not directly 
phosphorylated by p38, this is another example of the implication of MAP kinases in 
splicing, a function that is mainly performed by splicing factors specific kinases, such as 
SRPKs, ClKs/STY and Topol. In a similar analogy, SPF45 phosphorylation in a MAP 
kinase-dependent manner is expected to be involved in the regulation of many 
downstream targets, the identification of which and determining the role of the splicing 
in modulating their expression patterns are crucial to understand the effect that SPF45 
induces in the biology of the cells in general and cancer cells more specifically. 
Incessant and aberrant proliferations as well as altered genomic profiles are 
among the hallmarks of cancer cells (Hanahan 2000). An interesting question that arises 
in this context is the meaning of increase in splicing factors levels and activities. For 
example, is SPF45 over-expression in ovarian cancer cells a cellular necessity imposed by 
the new status of the cells or is it a mere bystander that evolved in the middle of the 
genomic chaos of cancer? The fact that the levels of SPF45 are increased in many types 
of cancer compared to their normal counterparts (Sampath 2003), as well as our 
observation that - although not consistent in all tested cell lines -, there is an obvious 
increase in SPF45 expression in ovarian cancer cells compared to the benign 
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immortalized lOSE, suggests that SPF45 is a necessary component of what one might call 
IIcancerome". Additionally, the different potential combinations of splicing factors which 
in part depend on the balance of their expression levels can possibly outweigh the 
number of transcription factors; as such, an increase in a specific splicing factor such as 
SPF45 must have its tremendous effects on the cellular biology. Hence, identifying the 
downstream targets of SPF45, as well as SPF45 interacting partners and their post-
translational modifications, becomes necessary to determine its role and to develop 
successful chemotherapeutic strategies. In the next chapter, we discuss the effect of 
SPF45 phosphorylation on its splicing activity, identify genetic changes induced by SPF45 
overexpression, novel SPF45-splicing targets and address their impact on ovarian cancer 
biology. 
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Chapter 3: Regulation of SPF45 splicing activity by MAP kinase phosphorylation. Role 
of Thr71 and Ser222 in modulating SPF45 functions. 
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Introduction 
In analogy with electronic circuits, post-translational modifications serve as 
molecular switches that regulate proteins' functions, turning them "on/off" or even 
changing their function radically. In that sense, protein phosphorylation is regarded as 
one of the main regulatory molecular switches, and splicing factors are no exception. 
Phosphorylation of SR proteins and hnRNPs has been extensively studied and shown to 
regulate the formation of the mRNP-spliceosome complex -the major structure that 
determines the outcome of the splicing reaction. It also controls the spatial localization 
of the splicing factors in the nucleus and the cytosol (Stamm 2008). Phosphorylation of 
SR proteins is central for homophilic and heterophilic interactions; for example, 
phosphorylation of SR proteins is important in determining the outcome of alternative 
splicing. Tripathi et al. show that a long nuclear noncoding RNA, MAlAT-l, regulates 
alternative splicing through modulating the phosphorylation of SR proteins, influencing 
their subnuclear localization (Tripathi 2010). Phosphorylation of SF2/ ASF splicing factor 
has a wide array of effects on its interactions: no effect is seen on binding to U2AF3s, but 
it positively reinforces the interactions with Ul-70K (Xiao 1997) while it negatively 
affects its interactions with TAP/NXF1, SRp40, hTra2 and itself (Xiao 1997, 1998). 
PI3K/Akt, elKs and Topo I phosphorylation of SRp75, SRp55 and SF2/ASF enhance 
human tissue factor (HTF) mRNA splicing {Eisen reich 2009 alb}. Phosphorylation of 
SRp38 on the other hand, changes its function from a repressor to activator of splicing 
(Feng 2008). 
104 
Another class of alternative splicing factors, hnRNPs, commonly identified as 
repressors of splicing, can also be under the control of phosphorylation. SF1, a member 
of the hnRNP K family, is phosphorylated by PGK-I which inhibits its interactions with 
U2AF65 preventing spliceosome assembly {Wang 1999}. Casein kinase II-type activity is 
responsible for hnRNP C phosphorylation, affecting the RNA binding capacity {Fung 
1997}. Fas-activated Ser/Thr kinase {FAST} phosphorylates the hnRNP protein TIA-1, 
strengthening its interactions in the spliceosome and enhancing its pro-apoptotic effects 
{Tian 1995}. Phosphorylation of hnRNP A1 by Mnk1 in a p38 MAP kinase-dependent 
manner in response to osmotic stress causes its localization to the cytoplasm {van der 
Houven van Oordt 2000}, and induces senescence in normal human fibroblast cells 
{Shimada 2009}. Changes in localization are also observed with SR protein 
phosphorylation, such as the changes in associations between SRi and importin and 
transportin families {Kataoka 1999, Lai 2000, 2001}. 
The mechanism by which SPF45 concerts its effects is still under investigation. 
Although initially found to be recruited by the polypyrimidine-tract binding protein 
(PTB) to the cryptic 3' AG-dinucleotide of the Drosophila Sxl pre-mRNA {Lallena 2002}, 
SPF45 exerts more complicated interactions in the splicing of Fas exon 6. Since neither 
the G-patch nor RRM domains are able to bind a RNA oligonucleotide, SPF45 
interactions with the pre-mRNA are expected to occur through binding to other factors 
within the spliceosome in a UHM-ULM fashion (UHM: U2AF Homology Motif; ULM: 
UHM !:igand Motif) (Corsini 2007). UHM-ULM interactions are not uncommon among 
proteins within the spliceosome. Indeed, the SPF45 RRM domain coincidently matches a 
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UHM domain and interacts with ULMs of the constitutive splicing factors U2AF65, SFl 
and SF3bl55: isolated SPF45 UHM domain co-immunoprecipitates with GST-tagged 
isolated ULM domains of the aforementioned factors (Corsini 2007). By the same 
authors, they show using ULM-selective SPF4s mutants that these interactions are 
necessary for SPF45 splicing activity in HeLa cells, while mutations that do not disrupt 
the interaction perform equally to the wild type in splicing. Interestingly, they suggest 
that phosphorylation events on SF1 and SF3blss to be important in regulating a 
potential sequential mode of binding and interactions. 
Our interest in SPF4s stems from its involvement in cancer, and ovarian cancer in 
particular, where it was shown to confer a multi-drug resistance phenotype in an 
ovarian cancer cell line (Perry 2005). Additionally, it is implicated in DNA repair (Chaouki 
2006) and alteration of splicing (Lallena 2002, Corsini 2007), yet very little is known 
about the mechanism(s) of its actions. Although some splicing factors, such as NOVA, 
work in a tissue specific manner (Buckanovich 1993), the majority of these proteins have 
universal tissue-independent functions. The balance of the splicing factors expressed in 
cells dictates the general pattern of genetic and, consequently, proteomic events 
(Mayeda 1993). Accordingly, identifying the targets of SPF45 in ovarian cancer cells is a 
crucial step in unveiling its involvement in the pathobiology of the disease. In this 
chapter, we determine the effect of phosphorylation of SPF45 by ERK2 and p38MAP 
Kinase on Thr71 and Ser222 on its splicing function using a minigene reporter construct. 
We also generate stable SKOV3 cell lines expressing ectopic wild type SPF45 or mutants 
(SPF4sAA and SPF4sDD) and investigate their drug resistance profile. Using the stable 
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cells, we perform a gene and exon-array to identify novel downstream genetic and 
splicing targets of SPF45 that are dysregulated by SPF45 expression and assess the 
impact of the mutation on Thr71 and Ser222 on these targets. Molecular changes 
associated with these genetic changes are investigated as well. Finally, we use the stable 
cells to determine the role of the phosphorylation sites in SPF45 binding to constitutive 
splicing factors, in an effort to understand the mechanism of regulating the interactions 
which are believed to dictate SPF45 outcomes. 
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Materials and Methods 
Plasmids and minigene system 
Genomic DNA was isolated from lOSE cells by phenol/chloroform extraction followed by 
ethanol precipitation. Fas genomic DNA spanning exon 5 through 44 base pairs into 
exon 7 were amplified by PCR using the following primers: FasS_primer 
AGATGTGAACATGGAATCATCAAGGA & Fas3_primer TTICCTTTCTGTGCTITCTGCATGTI. 
The amplicon was subcloned into Topo 2.1 vector (Invitrogen Carlsbad, CAl and the 
following primers: FaslnRe5_primer GTAAGAATGAGGCAAATCTTIGTGA-3' and FaslnRe3-
_primer s'-CCTICTTATATITCTCTTAGTGTGAAAGTA-3' were used to amplify the whole 
plasmid leaving out 1105 bp spanning nucleotides 53 through 1183 from the 5' -end of 
intron 6 and the resulting amplicon was incubated with T4 DNA ligase (New England 
BioLabs Ipswitch, MA) overnight at 16°C for blunt ligation. Fas DNA was cut using EcoRI 
(New England BioLabs Ipswitch, MA) and ligated into the multi-cloning sequence of 
pCDNA3 downstream of a CMV promoter to generate the !:lfas minigene. 
Generation of SKOV3 stable eel/lines 
Retroviral plasmids (pQCXIP) encoding empty vector/SPF45/SPF4sAA/SPF45DD were 
transfected into 293T cells along with pAMPHO, VSV-G and Gag/Pol for virus production 
and packaging. Cellular media containing the viruses were harvested at 36 and 60 hours 
post transfection, filtered with 45 ~m syringe filters (Corning Lowell, MA) and mixed 
with polybrene (Sigma St Louis, MO) to a final 2llg/ml concentration before infecting the 
SKOV3 target cells. Cellular populations expressing the genes of interest were pooled 
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and selected with 1.5 Ilgjml puromycin for 2 weeks. Following the 2 weeks period, 
puromycin is added at half strength as a maintenance dose. 
SPF45 binding assays 
SKOV3-Vecj-SPF45j-SPF45AAj-SPF4SDD cells were grown to confluence in a 10 cm cell 
culture dish (Corning Lowell, MA) at 37°C, 5% C02 and harvested with M2 lysis buffer 
(150 mM NaCl, 5 mM KCI, 1 mM CaCI2, 1 mM MgCI2, 50 mM HEPES, pH 7.4) on ice. 
Homogenized Iysates were incubated on ice with occasional vortexing followed by 
centrifugation for 15 min at 15000 rpm 4°C to separate the debris from the soluble 
phase. Standard BCA (Pierce Rockford, IL) assay was used to quantify protein 
concentrations. 1000 Ilg of protein Iysates were incubated with protein agarose beads 
pre-conjugated to Myc antibody for 24 hours at 4°C. The beads were spun down quickly 
and washed three times with gentle vortexing three times using M2 buffer before 
adding 1X Laemmli sample buffer and boiling for 3 minutes. The proteins were 
separated on a 10% 50S-PAGE gel (Biorad Hercules, CAl and transferred onto 
nitrocellulose membrane. 
!Jfas alternative splicing assay 
A- Transfections 
2.5x105 Cos-1 cells were plated the night before transfection on 6-well plates (Corning 
Lowell, MA) and transfected the following day with 1.2 Ilg total of DNA. Briefly, 1.2 Ilg 
total DNA and 4.8 III of Lipofectamine 2000 (Invitrogen Carlsbad, CAl were suspended in 
0.25 ml of Optimem (Invitrogen, Carlsbad) each for 5 minutes at RT, then mixed 
together for a total of 20 minutes at RT before drop wise addition onto cells. The media 
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and transfection mixture were recollected 5-6 hours following transfection, washed 
once in PBS and incubated in fresh media supplied with 10% FBS. The cells were 
harvested in TRlzol (Invitrogen Carlsbad, CAl 24 hours post-transfection. 
8- RNA isolation 
RNA was isolated from cells by phase separation using TRlzol (Invitrogen Carlsbad, CAl 
followed by chloroform (Sigma St Louis, MO) extraction and isopropanol (Sigma, St 
Louis) precipitation. The RNA was washed twice in 75% ethanol and re-suspended in 25 
III of DEPC (Fisher Pittsburgh, PAl-treated water. Total RNA purity and concentration 
were assessed by UV-spectrophotometry. 
C- RT-PCR and gel-electrophoresis 
2.0 Ilg of total isolated RNA were reverse-transcribed in a 20.0 111 reaction using the High 
Capacity cDNA Reverse Transcription Kit {Applied Biosyst Carlsbad, MA} according to the 
manufacturer's protocol. Cycling parameters were the following: 25°C for 10 min, 37°C 
for 120 min, 85°C for 5 min then hold at 4°C. Randomly-primed cDNA was used for 
subsequent amplification. 1.0 111 cDNA was mixed with 200nM of each of the forward 
and reverse primers and 23.5 111 PCR supermix (Invitrogen Carlsbad, CAl. Cycling 
parameters were the following: 94°C for 5 min, followed by 22 cycles of 94°C, 58°C and 
72°C for 30 sec each, followed by 10 min extension at 72°C then hold at 4°C. PCR 
products were separated and quantified on an ethidium bromide-stained 2% agarose 
gel. 
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Real time qRT-PCR 
Total cellular RNA for use in quantitative RT-PCR assay was extracted from confluent 
SKOV3 cells stably expressing empty vector/SPF4S/SPF4SAA/SPF4S DD using TRlzol 
(Invitrogen Carslbad, CAl lysis followed by chloroform/isopropanol extraction and 
precipitation and ethanol washes. RNA samples purity was assessed by an A26o/A28o ratio 
between 1.9 and 2.1 and total RNA was quantified by UV-spectrophotometry by 
absorbance at 260nm wavelength. Total RNA (2.0 Ilg) was transcribed to random-
primed cDNA using High Capacity cDNA Reverse Transcription Kit (Applied Biosyst 
Carlsbad, CAl according to manufacturer's protocol in a 20.0 III reaction. The resulting 
cDNA was subjected to real-time PCR using RT2SYBR Green dye (Qiagen Valencia, CAl 
and pre-validated primers for the following genes: erbB2, FN1, TGF-f3 and periostin 
(Qiagen Valencia, CAl while 18s rRNA (Qiagen Valencia, CAl was used as an internal 
control. 1.0 III of the first-strand eDNA product was mixed with 12.5 III of RT2SYBR Green 
qPCR Master Mix (Qiagen Valencia, CAl, 10.5 III of H20 and 1.0 III of gene-specific 10uM 
PCR primer pair stock in a 25.0 III reaction. Each sample was run in duplicate and a total 
of 3 independent repeats were performed. Cycling parameters were 50°C for 2 min and 
95°C for 10 min followed by 40 cycles of 95°C and 60°C for 15 and 60 seconds, 
respectively. A single band for each of the PCR products was observed on an ethidium 
bromide-stained 2% agarose gel electrophoresis assessing products integrity. Threshold 
cycle (CT) values were determined for each gene and the corresponding 18srRNA. Fold 
change in gene expression was calculated by the l:!l:!CT method. 
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Cell proliferation rate 
SKOV3 stable cell lines (lxl0s) were plated on 6 well plates on day 1 and counted at 24 
hr intervals. Briefly, the cells were gently washed with PBS, trypsinized in 100 Ill, and 
collected with 100 III McCoy's supplemented with 50% FBS. Cells were homogenously 
suspended and manually counted using a hemocytometer. 
Cellular adhesion assay 
96-well tissue culture dishes were coated with fibronectin (20 Ilg/ml), laminin-l (10 
J,.lg/ml), poly-L-Lysine (10 Ilg/ml) or nothing overnight at 4°C. Plates were washed twice 
with washing buffer (0.1% BSA in PBS) and blocked with blocking buffer (0.5% BSA in 
PBS) at 37°C for 60 min, followed by washing buffer and chilled on ice. Stable SKOV3 
cells were suspended at 4x10s celts/ml and 50 III of the suspension were aliquoted into 
the wells. Plates were incubated at 37°C, 5% C02 for 30 min, then placed on a plate 
shaker at 2000 rpm for 15 sec. Unattached cells were removed by aspiration and the 
wells were gently washed with washing buffer, stained with crystal violet (5 mg/I in 2% 
ethanol) for 10 min, washed gently three times and dried at room temperature. Crystal 
violet stain was solubilized in 2% SDS and plates were read at 550 nm. 
MTS cytotoxicity/proliferation assay 
SKOV3-pQCSPF45 or control were seeded on 96 well-plates (3.0xl03 celis/1001l1/well) 
and treated the following day with increasing concentrations of the following 
chemotherapeutic agents: cisplatin, doxorubicin, etoposide, mitoxantrone, paclitaxel 
and vincristine (Sigma, St Louis). 72 hours later, cell viability/proliferation was measured 
in a colorimetric assay using the tetrazolium salt 3-(4,5-dimethylthiazole-2-yl)-2,5-
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diphenyltetrazolium bromide MTS kit (Promega Madison, WI) as described by 
manufacturer and analyzed on a bioard 96-well plate spectrophotometer. All assays 
were performed in triplicate with three independent experiments. 
Immunoblotting 
Cells were lysed and sonicated in M2 buffer with 0.5% SDS and protease inhibitors mix 
(100 11M Na-o-vanadate, 50 mM NaF, 40 mM J3-glycerophosphate, 5 mM Na-
pyrophosphate, Aprotinin and 2 mM PMSF). Lysates were normalized using BCA protein 
assay kit (Pierce Rockford, IL). Each sample (100 Ilg) was run on a 10% polyacrylamide 
gel (SDS-PAGE) under denaturing conditions and transferred to a Protran nitrocellulose 
membrane (Whatman-GE Healthcare, Piscataway, NJ). After blocking with 5% milk for 1 
hour at room temperature, the membranes were incubated with relevant primary 
antibodies {Myc, erbB2, SFI, SF3b155 and Actin} in PBS with 5% BSA and 0.1% Tween-
20, 0.1% sodium azide at 4°C overnight. The blots were washed three times in 1X PBS + 
0.1% Tween-20 and incubated with the appropriate secondary HRP-conjugated antibody 
(Mouse, Rabbit (Biorad Hercules, CA)) in IX PBS-O.I%T with 1% milk for 1 hour at room 
temperature. The membranes were then washed 6 times with PBS-O.I%T for a total of 1 
hour at room temperature. The membranes were incubated with femto-ECL (Pierce 
Rockford, IL) for 2 minutes at room temperature and the bands were exposed on Hyblot 
CL films (Denville Scientific South Plainfield, NJ). 
Immunofluorescence 
7.5x104 SKOV-3 stable cells were plated on glass cover slips pre-coated with fibronectin 
(10ug/ml) and incubated at 37°C, 5% CO2. 24 hours later, the cells were washed 1X with 
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PBS and fixed with 4% formaldehyde for 30 min at room temp. The cells were then 
permeabilized with ice cold 1% Triton-X on ice for 5 min followed by blocking with 5% 
BSA (Fisher Pittsburgh, PAl for 30 min at room temp. The glass cover slips were 
incubated with Myc-antibody (1:1000 dilution) for 1 hour at room temperature in the 
dark, followed by another hour of incubation with secondary anti-rabbit antibody 
conjugated to FITC. The cover slips were washed in lX PBS then ddH20 and mounted on 
microscope glass slides. Nuclei were stained with DAPI. Slides were visualized using epi-
fluorescence on a Nikon microscope. 
Gene- and exon-array analysis 
Total RNA was amplified using the NuGEN™ Applause™ WT-Amp Plus ST Amplification 
System. First-strand synthesis of cDNA was performed using a unique first-strand 
DNA/RNA chimeric primer mix, resulting in cDNA/mRNA hybrid molecules. Following 
fragmentation of the mRNA component of the cDNA/mRNA molecules, second-strand 
synthesis was performed and double-stranded cDNA was formed with a unique 
DNA/RNA heteroduplex at one end. In the final amplification step, RNA within the 
heteroduplex was degraded using RNaseH, and replication of the resultant single-
stranded cDNA was achieved through DNA/RNA chimeric primer binding and DNA 
polymerase enzymatic activity. A modification step targeting the amplified single-
stranded cDNA resulted in the generation of sense-strand cDNA product compatible 
with the Affymetrix GeneChip® Exon arrays. The ST-cDNA was purified for accurate 
quantitation of the cDNA and to ensure optimal performance during the fragmentation 
and labeling process. The ST - cDNA was assessed using spectrophotometric methods in 
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combination with the Agilent Bioanalyzer. The appropriate amount of amplified 5T-
cDNA was fragmented and labeled using the Encore™ cDNA Biotin Module. The 
enzymatically and chemically fragmented product (50-100 nt) was labeled via the 
attachment of biotinylated nucleotides onto the 31-end of the fragmented 5T-cDNA. The 
resultant fragmented and labelled 5T-cDNA was added to the hybridization cocktail in 
accordance with the NuGEN™ guidelines for hybridization onto Affymetrix GeneChip® 
arrays. Following the hybridization for 16-18 hours at 45°C in an Affymetrix GeneChip® 
Hybridization Oven 640, the array was washed and stained on the GeneChip® Fluidics 
Station 450 using the appropriate fluidics script, before being inserted into the 
Affymetrix autoloader carousel and scanned using the GeneChip® Scanner 3000. 
Statistical Analysis 
Statistical analysis was performed at p< 0.05 level of significance and determined using 
one-way ANOVA with Tukey's post-hoc test. 
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Results 
SPF45 causes increase in ~fas splicing in a dose-dependent manner 
Regulation of alternative splicing of Fas cassette exon 6 is influenced by the 
increase in SPF45 expression based on a screen of SPF45 splicing targets in HeLa cells 
(Corsini 2007). Although the splicing activity has been shown to be confined to its C-
terminal RNA recognition motif (RRM) (Corsini 2007), it remains necessary to identify 
the factors that influence SPF45-alternative splicing function. The in vivo model of 
alternative splicing using a Fas minigene represents an ideal approach to study the 
effect of trans factors on regulation of splicing, as it preserves the cellular splicing 
machinery in its optimal milieu. Genomic Jas DNA purified from lOSE cells was used to 
create a minigene labeled llJas (Fig 3.1 A) (Cascino 1995), spanning exon 5 through 44 
base pairs of exon 7 and including introns 5 and 6 with a 1105 bp deletion in intron 6, 
previously shown not to hinder the ability of Fas to undergo alternative splicing (Cascino 
1997). To determine the appropriate dose of SPF45 to be transfected into the cells along 
with llfas, increments of SPF45 DNA were transfected into Cos-1 cells with a fixed ~fas 
amount (0.3 (..lg): 0.4, 0.8, 1.2 and 1.6 (..lg of SPF45 DNA were co-transfected with ~fas; 
the total DNA mix was kept at a constant amount of 2.0 (..lg by adding the appropriate 
amount of empty pCMV3-2c vector (Fig 3.1 a). RT-PCR analysis of the resulting splicing 
reaction showed a dose-dependent increase in exon 6 exclusion, reaching around 50% 
between 0.4 and 0.8 ~g of transfected SPF45. Accordingly, we considered 0.6 (..lg of 
SPF45 as the optimum dose in our splicing model to study the influence of 
phosphorylation of SPF45 on its alternative splicing function. 
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ERK phosphorylation of SPF45 reduces its alternative splicing activity towards ~fas 
Post-translational modifications (PTMs) of proteins play an important role in 
determining their functional outcomes and phosphorylation is one of the most studied 
and investigated PTMs on proteins, as it mediates the effect of the majority of kinase 
signaling cascades. Phosphorylation of spliceosomal proteins and their associated 
proteins has been extensively studied and remains mostly carried out by spliceosomal 
protein-specific kinases such as SRPKs, ClKs and topoisomerase I. Besides Sam68, no 
other splicing factor protein has been identified as a direct target for phosphorylation by 
a MAP kinase. As we showed in the previous Aim, SPF45 is a target for phosphorylation 
by ERK2/MAP kinase as well as JNK and p38 MAP kinases. We also showed that co-
expressing constitutively active MEK1, CA-MEK1-{DD) and ERK2 along with SPF45 caused 
phosphorylation of SPF45 on both Thr71 and Ser222 residues. To investigate the role of 
ERK2/MAP kinase phosphorylation of SPF45 on its splicing activity, we made use of the 
in vivo minigene system described above using the ratio of short/long ~fas isoforms as a 
measure of splicing function. CA-MEK1-(DD) and ERK2 were transfected into Cos-1 cells 
along with SPF45 and ~fas, and total RNA was isolated 24 hours post-transfection. We 
also used the MEK inhibitor U0126 to potentially reverse the role of phosphorylation. 
RT-PCR analysis of the spliced ~fas showed an average of 40% decrease in the ratio of 
short/long ~fas isoforms in the presence of constitutive ERK2/MAP kinase pathway 
activation as compared to vector control (Fig 3.1 C&O). This effect was partially reversed 
using U0126 showing only 17% decrease in splicing. Altogether, this experiment 
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demonstrated that a continuously n:-aintained phosphorylation of 5PF45 is responsible 
for decreasing its alternative splicing activity (Fig 3.1 C&D). 
P38MAP Kinase phosphorylation of 5PF45 strongly reduces its alternative splicing 
activity towards ~fas 
In a similar attempt to determine the impact of p38MAP kinase phosphorylation 
on SPF45 splicing function, we transfected Cos-1 with MKK3(E) and p38a MAP kinase 
along with 5PF45 and ~fasJ and total RNA was isolated 24 hours post-transfection for 
analysis. In this assay, we used the p38MAP kinase inhibitor 5B203580 to determine the 
role of p38 inhibition on splicing. RT-PCR analysis of analysis of the spliced ~fas showed 
a 65% decrease in the ratio of short/long ~fas isoforms compared to 5PF45 alone. 
Inhibition of p38 with 5B203580 completely returned 5PF45 splicing function to basal 
level (Fig 3.1 E&F). While p38MAP Kinase phosphorylation caused a more prominent 
effect on 5PF45 function, the impact of this finding is still unclear. Experiments 
performed in our lab have determined stronger binding to and phosphorylation of 
SPF45 by p38 MAP kinase compared to ERK in co-immunoprecipitation and co-
transfection assays to assess 5PF45 phosphorylation (data not shown), which can 
potentially explain the results of the splicing assay. 
While we showed in the previous chapter that JNK1 phosphorylates 5PF45 in 
vitro, our efforts to replicate the splicing assay with activated MKK4 and JNK1 
expression along with SPF45 and ~fas were unsuccessful. JNK1 and MKK4 displayed 
poor expression in Cos-1 cells upon transfection and were not usable to study the effect 
of JNK phosphorylation of 5PF45 on its splicing function (data not shown.) We believe 
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that MKK4/JNKl transfection in Cos-1 cells induces an apoptotic effect. Further 
experiments are required to determine the role of JNK phosphorylation on SPF45 
splicing functions. 
Mutation of SPF45 phosphorylation enhances its alternative splicing activity and 
provides rescue from the decrease induced by MAP Kinase phosphorylation 
As continuous phosphorylation of SPF45 caused a decrease in its alternative 
splicing activity, we speculated that mutation of both Thr71 and Ser222 into either 
alanine or aspartate would mimic a non-phosphorylated and a continuously 
phosphorylated state, respectively. Vector control, wild-type SPF4S, SPF4SAA and 
SPF45DD were transfected separately into Cos-1 cells along with !lfas; the cells were 
harvested 24 hours post-transfection to assess the extent of alternative splicing (Fig 3.1 
G&H). Compared to wild-type SPF4S,. SPF4SAA showed a 16% increase in the ratio of 
short/long !:lIas isoforms (p<O.OS) while SPF4S DD showed a significant 37% increase 
(p<O.Ol) in its alternative splicing activity. Despite that SPF4SAA has a relatively modest 
increase in splicing activity,. it is consistent with our previous finding that continuous 
phosphorylation of SPF4S causes a decrease in alternative splicing; hence, inhibiting the 
phosphorylation by mutation to alanine shows the predicted positive effect on splicing. 
We expected SPF4SDD - by virtue of the negative charges on the aspartate residues - to 
mimic a continuously phosphorylated state of the protein; surprisingly, it displayed a 
more robust increase in alternative splicing. Unlike the native SPF4S protein, which is 
subjected to dynamic and continuous upstream phosphorylation by MAP kinases and 
downstream de-phosphorylation by cellular phosphatases, SPF4SDD is locked in a 
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"pseudo-phosphorylated" state. In fact, it has been proposed that a "balancedJJ 
reversible phosphorylation of splicing factors is crucial for their adequate function and is 
almost entirely disrupted under "hypo-JJ or "hyper-II phosphorylated states (Cao 1997, 
Xiao 1998, Dieker 2008, Chen 2009). Based on these experiments, SPF45DD failed to 
mimic the dynamic phosphorylation/dephosphorylation cycles required by SPF45 to 
carry its functions properly. Therefore, when we compared the splicing activity of wild-
type SPF45 to that of SPF45AA in the presence of CA-MEK1(DD)/ERK2, SPF45AA (Fig 3.1 
I&JL it showed a 32% increase in activity compared to wild-type SPF45, which is an 
apparent increase due to the attenuating effect of phosphorylation on the native SPF45 
but not SPF45AA • 
SPF45 slows cellular proliferation in a phosphorylation-dependent manner 
To further understand the role of SPF45 overexpression in ovarian cancer cells 
pathobiology, we generated stable populations of SKOV3 ovarian cancer cells expressing 
Myc-SPF45/mutants/empty vector. We used the SKOV3 cell lines for the following two 
reasons: i. SPF45 was identified in a screen of ERK2 associated substrates in SKOV3 cells 
and ii. SPF45 was expressed at lower endogenous levels in SKOV3 cells compared to the 
ovarian cancer cell lines examined. Pooled populations of SKOV3 cells expressing native 
SPF45 or mutants were generated by retroviral infection and puromycin selection to 
avoid clonal variation. Immunofluorescence microscopy of the different generated 
stable cell lines showed populations of cells with a quasi-equal expression levels (Fig 3.2 
A). Western blot using Myc antibody showed close expression levels among the 
different cell lines (Fig 3.2 B). Comparing the levels of exogenous SPF45 to endogenous 
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levels with a western blot using total-SPF4S antibody revealed a 2:1 ratio of exogenous: 
endogenous SPF45 (Fig 3.2 C). Cell proliferation rates of the stable cells were 
determined by manual count at 24 hours interval, with an initial number of lO,OOO cells 
plated per well per cell line. SKOV3-pQCXIP displayed an accelerated proliferation rate 
compared to SKOV3-pQCSPF4S which followed an indolent course. Interestingly, we 
observed a divergence in the behavior of SPF45 mutants on cellular phenotype in this 
assay. SKOV3-pQCSPF4SAA proliferation was similar to the control group while SKOV3-
pQCSPF4SDD behaved like SKOV3-SPF4S (Fig 3.2 0). Although both SPF4SAA and SPF4SDD 
cause an increase in !:lfas splicing, the discordance in their effect on cellular proliferation 
suggests that SPF4SDD retains a selective phospho-mimetic phenotype depending on the 
choice of function involved. We show in a subsequent section of this chapter the 
molecular events that regulate SPF4S-mediated cellular proliferation. 
SPF4S overexpression in SKOV3 cells does not increase drug resistance 
Since SPF4S overexpression in A2780 ovarian cancer cells and HeLa cervical 
cancer cells confers a multidrug resistance phenotype, we sought to determine the drug 
sensitivity/resistance of SPF45 in SKOV3 cells. SKOV3-pQCSPF45 vs SKOV3-pQCXIP 
against cisplatin .. doxorubicin .. etoposide, mitoxantrone, paclitaxel and vincristine .. and 
then assess the role of SPF45 phosphorylation in drug resistance, if any. We examined 
the drug sensitivity/resistance in an MTS colorimetric assay using cellular proliferation in 
a 96 well plate exposed to stepwise lO-fold increasing doses of chemotherapeutic 
agents as a measure of survival (Fig 3.3). No difference between SPF45 overexpressing 
cells and control cells was observed. While these results were un-expected, it is 
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imperative to realize that developing resistance could be cell-type specific based on the 
genetic and proteomic makeup. Further experiments investigating the role of SPF45 
drug resistance in different cell lines might be required to explain this discrepancy. 
Gene- and exon-array analysis 
To identify novel SPF45 targets that can explain the implications of this splicing 
factor in the pathobiology of ovarian cancer, we performed an exon- and gene-array to 
using the stable cell lines generated above. Changes in gene expressions and exon 
splicing were compared between SKOV3-pQCXIP and SKOV3-pQCSPF45 on an Affymetrix 
Human Exon 1.0 ST gene chip. Differential gene expression analysis revealed thousands 
of transcripts to be altered between SKOV3-pQCXIP and SKOV3-pQCSPF45; we divided 
the results into two groups based on the stringency (low and high) of the statistical 
analysis. We identified 524 transcripts in the low stringency group (136 upregulated, 
388 downregulated SPF45 vs. vector) and 158 transcripts in the high stringency group 
(39 upregulated, 119 downregulated). We also divided changes in exon expression into 
low and high stringency groups based on statistical analysis with 396 potential 
alternative splicing events in the low and 138 in high stringency groups. 
Based on intensity signals, fold changes and statistical analysis, we concentrated 
our efforts in this work on four genes for further validation: ErbB2; FN1; TGF-[3; and 
POSTN. We also explored their role in SPF45-mediated cellular phenotypes and their 
implication in ovarian cancer. The results are presented in a subsequent section of this 
chapter. Below we provide a summary of the top genetic and exonic changes we 
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identified in our analysis and then discuss in further detail the roles of the 4 genes 
mentioned above. 
Clustering of the gene transcripts in the microarray 
The low stringency list of differentially-expressed genes provided a richer 
content in the amount of transcripts included; therefore we used it to determine the 
functional clustering of these genes into specific pathways. Functional analysis was 
performed by Almac Diagnostics against a GeneGo annotated Pathway using MetaCore 
software system from GeneGo, Inc. The most enriched pathways from the list of 
differentially expressed genes are ranked based on the enrichment p-value, which 
corresponds to the probability of observing the number of genes in the differentially-
expressed genes annotated to a particular pathway by randomly picking genes from the 
whole array. Furthermore, we divided the list into 2 groups of up- and down-regulated 
genes in SKOV3-pQCSPF45 compared to SKOV3-pQCXIP. 
Up-regulated gene pathways clusters 
Gene pathways with upregulated differentially-expressed genes components 
were grouped and ranked based on the multi-testing corrected - using the false 
discovery method - enrichment p-value. Twenty two pathways were found to be 
significant at an adjusted p<O.OS. Of the 22 pathways, 7 are involved in G-protein 
coupled receptor signaling while another 7 are involved in immune response. 
Interestingly, SPF45-overexpressing cells upregulated genes in the AP-l transcription 
pathway genetic cluster. Since AP-l transcription factor is involved in a diverse group of 
functions such as proliferation, differentiation, migration, wound healing, inflammation 
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and apoptosis, affecting its regulation could potentially present as a key modulator of 
several cellular functions. Cytoskeletal remodeling, neuronal migration and cell cycle 
pathways were also upregulated as well as genes of mucin production associated with 
cystic fibrosis. Results are summarized in table 3.1. 
Down-regulated gene pathways clusters 
Similarly, gene pathways with downregulated differentially-expressed gene 
components were grouped and ranked based on FDR-adjusted p<0.05 identifying 20 
pathways. We determined 6 pathways to be involved in nucleoside metabolism, 3 cell 
cycle regulation pathways and 4 pathways of the cystic fibrosis. One apoptosis related 
pathway was also among the top 20 downregulated clusters pointing out to the 
potential role of SPF45 in decreased cell death. Interestingly, since CFTR-related genetic 
pathways appear to be dysregulated both up and down suggests a potentially important 
implication for SPF45 in regulating cystic fibrosis; however, investigating this disease is 
beyond the purpose of this work. Oxidative phosphorylation, regulation of translation 
initiation, alternative complement clusters and antigen presentation by MHC class I 
were also downregulated. Results are summarized in table 3.2. 
Genetic pathways with altered splicing events 
Affymetrix Human Exon 1.0 ST gene chip is designed to handle individual exons 
or parts of exons as independent objects, allowing the detection of alternatively spliced 
events (inclusion or skipping of exons), and overcoming the limitations of classical 
expression arrays which concentrate on transcription events at the 3' end of a gene. 
Exon 1.0 ST employs empirical annotations, curated mRNA sequences and ab-initio 
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prediction computations of 5.4 million probes annotating 1 million exon clusters for 
detection of alternative splicing events at the exon levels. Despite the advanced 
technology of the array, it is amenable for a high rate of false positives and the rationale 
is summarized in the following points: i. alternative splicing is not an all-or-none 
phenomenon; subtle changes carry the potential of significant biological events ii. 
alternative splicing is a very common phenomenon, predictably accounting for 90% of 
genetic events iii. the exon array does not detect specific transcripts, but rather 
assembles several transcripts (defined by Probe Set Regions-PSR) to associated loci 
raising the possibility of linking unrelated transcripts and iv. differential gene expression 
needs to be accounted for in determining differential alternative splicing events. 
Although the rate of false positive might be substantial, the exon array provides a 
starting point for the identification of true changes in splicing events; therefore, further 
validation by physical and bioinformatics analyses is required. In comparing SKOV3-
pQCSPF45 to SKOV3-pQCXIP, gene pathways with changes in exon expressions were 
clustered and ranked based on adjusted p<0.05. We identified thirty seven (37) 
pathways and the top 25 pathways are provided in table 3.3. Of the 25 top pathways, 8 
are involved in cell adhesion, 3 in each of cytoskeletal remodeling and immune 
response, one pathway is involved in regulation of CFTR activity and one in DNA damage 
nucleotide excision repair. These results predict an association between SPF45 
overexpression and cellular adhesion (attachment, spreading and migration) as well as 
cellular morphology and/or size. The identification of a cluster involving CFTR regulation 
was not surprising since CFTR-implicated pathways were shown to be dysregulated up 
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or down in the gene-array. As for DNA damage repair, SPF45 is evolutionarily linked 
(DRT111: SPF45 homolog in A. thaliana) as well as experimentally to DNA repair 
enzymes such as RAD 201 (Chaouki 2006) and RAD 51B (Horikoshi 2010) of the RAD51 
family; additionally, mutations in the C-terminus of SPF45 cause a decrease in DNA 
repair in drosophila (Chaouki 2006). Hence, it was no surprise to identify DNA repair 
pathways affected by SPF45 overexpression. Further investigation of the role of SPF45 in 
these pathways, as well as possible interactions, are necessary to determine the impact 
of SPF4S in DNA repair, apoptosis and possibly drug resistance. 
Validation of target genes expression levels 
Based on the results obtained from the gene microarray we performed, we 
focused on four different genes: ErbB2, FN1, TGF-J3 and POSTN. The choice of the genes 
was based on several factors: i. fold change in the array ii. intensity signal iii. statistical 
analysis and iv. relationship to cancer progression and migration. Using pre-validated 
gene-specific primers and RT2SYBR Green chemistry, we determined below the fold 
changes of each of the aforementioned genes in wild-type SPF45-overexpressing cells 
compared to vector group. Also, we determined the fold changes in SPF4SAA and 
SPF4SDD SKOV-3 stable cells. Total RNA was isolated from each of these cells grown in 6-
well plates to 90% confluence. Gene-changes validation was performed on three-
independent passages for each of the cell lines. 
ErbB2 
ErbB2 levels were decreased by 69% in SKOV3-pQCSPF45 and by 80% in SKOV3-
pQCSPF4SDD compared to vector control, while it was decreased only by 36% in SKOV3-
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pQCSPF45AA • We further validated ErbB2 expression by western blot (Fig 3.4 A&B). 
While ErbB2 protein expression was slighlthy decreased in SKOV3-pQCSPF45AA celis, it 
was dramatically decreased in SKOV3-pQCSPF45 and SKOV3-pQCSPF4SDD• Accordingly, 
ErbB2 expression represents an example of a SPF45-mediated event that is responsive 
to the phosphorylation of Thr71 and Ser222. We further determined that ErbB2 
expression in these cells is regulated by Elf3, an Ets-family transcription factor, but not 
Elf! or PEA3. Decreased ErbB2 expression correlated with decreased Elf3 expression but 
not Elf1 and PEA3 which maintained a relatively constant expression among the 
different cell lines (Fig 3.4 C). Interestingly, the decrease in Elf3 expression was 
translated by similar effects on ErbB2 expression and cellular proliferation, which 
actually paralleled SPF45 expression and phosphorylation pattern. Further experiments 
will be required to identify the link between MAP kinase activation, SPF45 
expression/phosphorylation, and Elf3. 
Fibronectin FNl 
Fibronectin levels were roughly 5 folds higher in SKOV3-pQCSPF45 compared to 
vector control. Unlike with ErbB2 expression, mutation of Thr71 and Ser222 had no 
effect on SPF45-induced increase in fibronectin levels, as evidenced by near-equal fold 
change in FNl levels in both SKOV3-pQCSPF45AA and SKOV3-pQCSPF45DD• We further 
validated the qRT-PCR results with a northern blot and a western blot for protein levels 
(Fig 3.4 D,E&F). FN expression correlated with SPF45 gene expression and was not 
affected by the phosphorylation sites mutations, indicating a non-phosphorylation-
dependent SPF45 function and adding to the versatility of this protein. 
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TGF-8 
TGF-J3 levels showed a trend towards decrease in SKOV3-pQCSPF4S compared to 
vector control while they were significantly doubled in the SKOV3-pQCSPF4SAA and 
SKOV3-pQCSPF4SDD groups. No further investigation of TGF- J3 was pursued (Fig 3.4 G). 
Periostin 
Based on the microarray data, we expected periostin - a protein involved in bone 
and teeth formation, but also has been shown to be overexpressed in several cancers 
and to be linked to migratory effects of some cancer cells (Tischler 2010, Michaylira 
2010) -, to have the highest fold increase in wild-type SPF45 group compared to vector 
control. Validation by real-time peR failed to show such a difference (Fig 3.4 H); 
additionally, we could not obtain consistent fold change levels in the four groups tested 
(large standard deviation). This is very likely due to the very low abundance of the 
mRNA and the lowest threshold cycle of detection is the 28th cycle. Accordingly, slight 
changes in the mRNA levels would translate as high fold changes and this is where the 
microarray technology fails. Although periostin seemed a luring candidate because of its 
predicted fold increase and its function in cancer cells, this case provided a clear 
example regarding the limitations of the microarray results and the necessity for further 
validation. 
Validation of FN-EOA as a splicing target for SPF45 
Three regions in the fibronectin mRNA are subject to alternative splicing: extra 
domain 3 A (EDIIIA), extra domain 3 B (EOIIIB) and the variable region (V or IIICS) (Fig 3.5 
A). EOA and EOB are cassette-exons while the variable region spans two exons over 120 
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nucleotides in length. The variable region can generate up to 5 different splice forms 
that are very close in length (0 to 120 nucleotides). The combination of 
inclusion/exclusion of these different regions potentially generates up to 20 different 
isoforms of fibronectin (Schwarzbauer 1983). We showed above, using real-time PCR 
and northern blot, that fibronectin levels are increased in SKOV3-pQCSPF45 (and the 
mutants cell lines) compared to SKOV3-pQCXIP. Based on the results of the exon array, 
we also expected fibronectin to undergo alternative splicing in SKOV3-pQCSPF45. We 
employed two approaches to determine changes in EDA and EDB fibronectin splicing 
patterns in SKOV3-pQCSPF4S (as well as SPF4SAA and SPF45DD mutant cell lines) vs. 
SKOV3-pQCXIP: end-point PCR and real-time PCR. 
End-point peR fails to validate FN alternative splicing 
SKOV3-pQCXIP, SKOV3-pQCSPF4S, SKOV3-pQCSPF4SAA and SKOV3-pQCSPF4SDD 
cells were grown to 90% confluence in 6-well plates prior to harvest for RNA extraction 
and synthesis of cDNA. Since EDA and EDB are spliced in/out in a cassette-exon splicing 
pattern, we used primer sets outside of the corresponding exonic sequences to detect 
both the (+) and (-) isoforms of fibronectin. As total fibronectin levels are higher in the 
SPF45-overexpressing cells, we used the ratio of EDA (+)jEDA (-) isoforms as well as EDB 
(+)/EDB (-), as a measure of change in FN splicing. PCR was first performed with 28 
cycles of amplification and the bands were visualized on a 2% agarose gels (Fig 3.5 B 
bottom). EDA (+) bands (upper band) were observed in WT-SPF4S, SPF4SAA and SPF4SDD 
lanes but not the vector lane, while EDA (-) was present in all lanes; with respect to EDB-
FN splicing, EDB (-) and (+) isoforms were detected in wild-type SPF4S, SPF4SAA and 
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SPF45DD lanes but not the vector lane. Decreasing the amplification cycle number to 22, 
neither EDA (-) nor (+) bands were detected in the vector lane, while both were present 
in the wild-type SPF45 lane (Fig 3.5 B middle). Raising the cycle number to 35, both EDA 
(-) and (+) isoforms were detected in the vector and the wild-type SPF45 lanes (Fig 3.5 B 
top). Since the end-point PCR is not quantitative, no decisions could be made concerning 
a change in splicing of either EDA or EDB regions and further experiments were needed. 
Real-time peR validates FN alternative splicing 
To overcome the hurdles of end-point peR technique in validating a change in 
splicing, we employed real-time peR to determine the fold inclusion of EDA(+) and 
EDB(+) isoforms (Fig 3.5 C). We isolated total RNA from SKOV3-pQCXIP, SKOV3-
pQCSPF45, SKOV3-pQCSPF45AA and SKOV3-pQCSPF45DD cells grown to 90% confluence 
in 6-well plates and reverse-transcribed to synthesize cDNA. Three separate passages 
were harvested and ran on a real-time PCR plate in duplicate. Using RT2SYBR Green 
chemistry, total fibronectin primer set and exon-specific primers to EDA and EDB 
regions were used to determine the fold inclusion of EDA(+) and EDB(+) isoforms. We 
used 18sRNA as a housekeeping gene control. The fibronectin primers were designed to 
detect a region common to all FN isoforms while EDA and EDB primers were specific to 
FN isoforms that contain their corresponding regions. As the fold increase of EDA(+) 
mRNA in the Wild-type SPF45 ('" 2.8 folds) group compared to vector exceeds the fold 
increase of total FN in wild-type SPF45 compared to vector ('" 2.1 fold), we concluded 
that there is an increase in EDA exon inclusion concomitant with an increase in SPF45 
expression levels. Fold increase in EDA(+) isoform in SPF45AA and SPF45DD groups 
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compared to vector was similar to that of total fibronectin, indicating that intact Thr71 
and Ser222 were necessary for EDA inclusion. Fold increase in EDB exon in wild-type 
SPF45, SPF45AA and SPF45DD cell lines compared to vector control were similar to those 
of total fibronectin in their corresponding groups. As a result, no change in EDB exon 
splicing levels could be deduced. Based on these data, we conclude that fibronectin EDA 
exon is subject to alternative splicing regulated by SPF45. Although we showed that 
mutation of the MAP kinase target sites reversed the increase in EDA splicing, further 
experiments are needed to support the role of phosphorylation on these sites in 
controlling EDA splicing. Currently, minigene splicing assays are the standard of choice 
to study the effect of trans factors and their modification on splicing; using minigene 
plasm ids of fibronectin EDA or EDB along with SPF45 plasmid in Cos-1 cells will likely 
support our findings on the effect of SPF45 on fibronectin splicing as well as determine 
further impacts of SPF45 phosphorylation. 
To determine a potential role for the increase in EDA(+) inclusion in FN1, we 
investigated the effect of SPF45 and the phosphorylation mutants on cellular adhesion. 
The stable cell lines were plated onto the following matrices for 30 min: tissue culture 
plastic, laminin, poly-l-lysine and fibronectin; followed by cell fixation, staining with 
cry tal violet and measurement at 550 nm. While all cells displayed an equal and non-
specific attachment to plastic, laminin and poly-l-Lysine, there was an overall increase in 
attachment to fibronectin. Furthermore, SKOV3-pQCXIP had the highest attachment 
with SKOV3-pQCSPF45, -pQCSPF4SAA and -pQCSPF45DD having 29.6%, 15.8% and 19.5% 
decrease compared to SKOV3-pQCXIP, respectively. Of note, the stable cell lines 
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adhesion to fibronectin parallels EDA(+) FN expression suggesting a possible implication 
for changes in FN isoform and cellular attachment to extracellular matrix. 
Mutations on Thr71 and Ser222 does not decrease SPF45 binding to SF1 and SF3b155 
In order to understand the role of the phosphorylation sites in the mechanism of 
alternative splicing, we investigated the role of the phosphorylation sites and their 
mutants on SPF45 binding to two proteins in the spliceosome, SF1 and SF3b155, which 
are known SPF45 binding partners (Corsini 2007). Immunoprecipitation of Myc-SPF4S, 
Myc-SPF45AA or Myc-SPF45DD after transient transfection did not show a difference in 
binding to SF1 or SF3b155 (Fig 3.6). While we did not observe an effect of the 
phosphorylation mutants on interaction with these splicesomal proteins} further 
experiments with protein-RNA assays might be warranted to better address this 
question. 
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Fig 3.1 MAPK phosphorylation of SPF45 decreases its splicing function towards ~Fas A. Schematic of 
the llFas minigene system. B. 0, 0.4, 0.8 and 1.6 Ilg SPF45 were added to 0.3 Ilg of ~Fas and 
transfected to Cos-l cells followed by Fas RT-PCR. C&O. ERK2 activation decreased SPF45 splicing 
activity and was partially reversed with MEK inhibtor U0126. A representative gel is shown above. 
Ratios were determined by densitometry; p values as indicated, n=3. E&F. p38MAP kinase activation 
strongly decreased SPF45 splicing function towards ~Fas and was completely reversed using p38 
inhibitor 58203580. A representative gel is shown above. Ratios were determined by densitometry; p 
values as indicated, n=3. G&H. SPF45AA splicing function compared to SPF45 with active ERK 
expression; p values as indicated on the histogram in H, (n=4) . 
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Fig 3.2 Generation of SKOV3 stable cells overexpressing SPF45 or mutants A. Immunofluorescent staining 
using myc-antibody of SKOV3-pQCXIP, -pQCSPF4S, -pQCSPF4SAA and -pQCSPF4SDD. Nuclei were stained 
with DAPI. Stable cell lines were generated with retroviral infection and puromycin selection. B. Cell 
Iysates of SKOV3 stable cells resolved by 10% 50S-PAGE and immunoblotted with anti-Myc antibody; ~­
actin was used as a loading control. C. Relative expression levels of exogenous to endogenous SPF4S in 
SKOV3 stable cells. D. Cell proliferation assay of the four stable cell lines was performed using cell counting 
at 24 hours interval; NS, non-significant (n=3, triplicates). 
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Gene pathway cluster 
1. f3-adrenerglc receptor transactivation of EGFR 
2. Angiotensin signaling via Pyk2 
3. Cytoskeleton remodeling via Activin A 
4. Immune response 
s. Gastrin in cell growth and proliferation " 
6. EphB receptor in dentritic spine morphogenesis and 
syna ptogenesis 
7. Mucin expression in cystic fibrosis via IL-G and IL-7 
8. Immune response 
9. Immune response 
10. Olfactory transduction 
11. VEGF family signaling 
12. ESRl regulation of G1/S transition 
13. Regulation of GnRH 
14. Gastrin in inflammation - immune response 
15. Immune response 
16. ligand-dependent activation of ESR1/ AP-1 pathway 
17. Transcription role of AP-l in regulation of cell 
metabolism t 
" 
18. Histamine - immune response 
19. a2-adrenergic activation of ERK 
20. Metabolic pathway 
21. Mucin expression in cystic fibrosis via TLRs 
22. Muscle contraction-regulation of eNOS activity in 
endothelial cells 
Table 3.1 Up-regulated genetic pathways induced by SPF45 overexpression in SKOV3 
cells 
Gene pathway cluster 
1. GTP-XTP metabolism .:" 'J 
2. RXR transcription 
3. CTP-UTP metabolism . 
4. Chromosome condensation in metaphase 
5. ATP/ITP metabolism ~ , " 
6. Oxidative phosphorylation 
7. Apoptosis and survival - Granzyme A 
8. CFTR translational fidelity 
9. APe 
10. Spindle and chromosomes assembly 
11. ATP metabolism 
12. Normal CFTR trafficking 
13. 4508 eFTR trafficking 
" 
14. Amino acid metabolism 
15. Alternative pathway 
16. Regulation of translation/initiation 
17. Ubiquitin metabolism 
18. Antigen presentation by MHC I 
19. Regulation of eFTR activity 
r' 
;, 
20. G-protein signaling - RACl in cellular processes 




Gene pathways with altered splicing events 
1. Alternative complement pathway 
I :' 
, 
2. Role of tetraspanins in the integrin-mediated cell adhesion 
3. Endothelial cell contact by non-junctional mechanisms , 
4. Nucleotide excision repair 
I, 
5. Endothelial cell contacts by junctional mechanisms 
6. Histamine Hl receptor signaling in the interruption of cell barrier integrity 
7. Regulation of CFTR activity (normal and cystic fibrosis) 
8. ECM remodeling 
9. Role of PKA in cytoskeleton reorganization 
, 
. 
10. Ligand-dependent transcription of retinoid-target genes 
11. Calcium signaling t 
12. lectin induced complement pathway 
13. Integrin-mediated cell adhesion and migration ; 
14. Classical complement pathway 
15. Angiotensin signaling via STATs " 
16. Cadherin-mediated cell adhesion 
17. Netrin-l in regulation of axon guidance ,1' 
18. Cytoskeletion remodeling 
19. Dopamine 02 receptor activation of POGFR in CNS 
20. Vitamin K metabolism 
21. EPO-induced MAPK pathway 
" 
22. PDGF activation of prostacyclin synthesis 
23. Vitamin 86 metabolism 
24. Spindle assembly and chromosome metabolism 
25. Chemokines and adhesion 
Table 3.3 Genetic pathways with identified changes in splicing events accompanying 
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Fig 3.3 SPF45 does not confer drug resistance to SKOV3 cells MTS cytotoxicity assay in 96 wells 
plates of SKOV3-pQCXIP, -pQCSPF45 using cisplation, doxorubicin, etoposide, mitoxantrone, 
paclitaxel and vincristine. 3.0e+3 cells/well were plated onto separate wells and treated the 
following day with 10 fold increasing doses from 1.0e-4 JIM to 1.0e+2 JIM. 72 hrs post-
treatment, MTS reagent was added and the cells were incubated for 2 hrs at 37°C and analyzed 
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Fig 3.4 SPF45 induces genetic and transcriptional changes in SKOV3-SPF45 and mutants A. qRT-
PCR of ErbB2 in in the four stable cell lines. ErbB2 level was set to 1 in SKOV3-pQCXIP and 
expressed relative to vector in the rest of the cell lines (p<O.Ol n=3, duplicates) . B. Western blot 
of erbB2 in cell Iysates of the corresponding cell lines. C. We?tern blot of Elfl, Elf3 and PEA3 
transcription factors in the corresponding cell lines (n=3) . D. qRT-PCR of FNl in the four stable 
cell lines. FN 1 level was set to 1 in SKOV3-pQCXIP as in (A) (p<O.Ol n=3, duplicates) . E. Northern 
blot of FN 1 using a 32P-labeled single-stranded DNA probe produced by asymmetric PCR to FN 
exons 6&7. 28s and 18s rRNA were used as loading control. F. Western blot of FNl in the 
corresponding cell lines using total cell Iysates. G&F. qRT-PCR of TGF-~ and Periostin in the 































































Fig 3.5 SPF45 regulates fibronectin splicing, increases EDA inclusion and decreases adhesion to 
fibronectin matrix A. Schematic diagram of fibronectin domains consisting of three different 
repeats. Regions B, A and V correspond to the alternatively spliced domains. B. 28 cycles RT-PCR 
{bottom} of FN-EDA and FN-EDB regions using RNA isolated from the corresponding cell lines. 
EDA RT-PCR is repeated at 22 cycles {middle} and 35 cycles {top} . C. qRT-PCR of FN, FN-EDA and 
FN-EDB with exon-specific primers, using RNA isolated from the corresponding cell lines. FN-EDA 
is 30% increased in SKOV3-pQCSPF45 compared to FN {p<O.Ol} and EDB {p<0.05} {n=3, in 
duplicate}. D. Cell adhesion assay. Stable cells were plated in 96-well plates onto the matrices as 
per histogram, fixed at 30 min after plating and absorbance measured at 550 nm; p values as per 
graph, NS non-significant {n=3, octuplets}. 
140 








SF1 .- , ~ .~ "~-
..c, >" ......... .~ ~. " 
.,' 
Fig 3.6 Mutations on Thr71 and Ser222 do not disrupt SPF45 binding to SFl and SF3b155 
SPF45 or mutants were myc-immunoprecipitated from the corresponding SKOV3 stable cells 
overnight at 4°C and resolved by SDS-PAGE. Immunoprecipitates were western blotted with SF1, 
SF3b155 and Myc antibodies. 
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Discussion 
We showed in the previous aim that SPF45 is phosphorylated by MAP kinases on 
Thr71 and Ser222, in vitro and in cells. In this chapter, we determined the role of the 
phosphorylation on the alternative splicing activity of SPF45 in vivo using a minigene 
system of the death receptor Fas, transfected into Cos-1 cells. We first showed that 
SPF45 causes a dose-dependent increase in las alternative splicing then used a dose that 
generates a 1:1 ratio of the long and short Fas mRNA isoforms in the ensuing 
experiments. Co-expressing SPF45 and activated ERK2/MAP kinase (using 
constitutionally-active MEK1(DD), we showed a decrease in Fas splicing compared to 
SPF45 alone, which was partially reversed when the cells were treated with MEK 
inhibitor U0126, reflecting a decrease in SPF4S alternative splicing activity towards Fas 
pre-mRNA, upon SPF45 phosphorylation. We also showed a similar and more 
pronounced effect of p38 MAP kinase phosphorylation of SPF45 on the alternative 
splicing acitivity. To support these findings, we impaired the ability of ERK2 to 
phosphorylate SPF45 using SPF45-alanine-mutant of Thr71 and Ser222 MAPK-
phosphorylation targeted residues (SPF4SAA ). We also generated a phospho-mimetic 
protein as well using SPF4S-aspartate-mutant of the same residues (SPF4S DD). SPF4SAA 
showed a modest increase in SPF45 alternative splicing activity compared to Wild-type 
SPF45, while SPF45DD remarkably caused a strong increase in SPF45 alternative splicing 
activity towards Fas. Comparing wild-type SPF4S and SPF45AA in the presence of CA-
MEK1(DD) and ERK2, demonstrated an increase of SPF45-alanine-mutant alternative 
splicing activity vs wild-type SPF4S, and we attributed this observation to the 
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attenuating effect of the phosphorylation on wild-type SPF4S function, an effect that is 
not applicable to SPF4SAA • While SPF4SDD was expected to behave similarly to 
SPF4SPT71PS222, it may not be necessarily true with respect to splicing. In fact, inducing 
phosphorylation of wild-type SPF4S by upstream signal activation is more likely to 
represent the true effect of phosphorylation on the protein's alternative splicing 
activity, as phosphorylated splicing factors are under a dynamic control of upstream 
phosphorylation and downstream de-phosphorylation (Cao 1997, Xiao 1998). A 
plausible explanation is that aspartate mutations of Thr71 and Ser222 influence SPF4S 
interaction(s} with other components of the spliceosome (eg SF1, SF3b15S, U2AF) .. and 
the inability to get dephosphorylated causes the discrepancy observed between SPF4S DD 
and MAPK-phosphorylated SPF4S. Additionally, using SPF4SAA to inhibit ERK2-mediated 
phosphorylation had the opposite effect of wild-type SPF45, reinforcing the role of 
Thr71 and Ser222 in regulating SPF4S function and supporting the observation of 
decreased Fas splicing upon SPF4S phosphorylation. 
As we are interested in the biological role of SPF45 in ovarian cancer, our aim 
was and remains to identify novel targets of genetic and splicing modulation. Of the 
large list of potential substrates that were detected by gene and exon array, we focused 
on fibronectin and ErbB2 for the purposes of this dissertation. Fibronectin is involved in 
a wide array of cellular functions including adhesion, migration, growth and 
differentiation. In cancer, fibronectin is implicated in cellular mobility, metastasis and 
chemoresistance (Kaspar 2006). In development fibronectin occupies a central role, as 
FN-/- mice are embryonic lethal (George 1993, Watt 1994). Although complex in 
143 
function, this molecule's amino acid sequence is reduced to three types of repeating 
domains (also called FN repeats) totaling 29 to 31: 12 type I, 2 type II and 15-17 type III 
(Hynes 1990). Although sequence homology of each of the different repeats does not 
exceed 50%, structural homology is conserved. For instance, the different type III 
repeats are only 20-40% identical, but they all share similar ~-sandwich structural 
topology (Main 1992, Leahy 1992). Two quasi-identical monomers of these different 
repeats are linked by disulfide bonds to create a more complex molecule. Fibronectin is 
encoded by a single gene but has varied expression and sequence patterns due to 
intense regulation by alternative splicing, which is tissue and species-dependent 
{Schwarzbauer 1983, Tamkun 1984, Gutman 1987}. In humans, three fibronectin regions 
are known to undergo alternative splicing: EDA, EDB and the variable region V. EDA and 
EDB are included by the simplest form of splicing - ie exon-cassette inclusion. The 
variable region presents a more challenging splicing pattern, as it spans around 120 
amino acids that are potentially spliced into 5 different sequences. Accordingly, four 
different forms of fibronectin could be formed by the inclusion/exclusion of EDA and 
EDB (EDA+/EDB+, EDA+/EDB-, EDA-/EDB+ and EDA-/EDB) and another five could be 
formed by the splicing arrangements of the variable region V leading to a total of twenty 
different potential isoforms (4xS = 20). Both EDA and EDB are type III repeats known to 
influence their surrounding topology unveiling "cryptic" sites in the FN molecule (Muro 
1999). The exact roles of these two domains remain elusive: they are both expressed in 
several solid cancers such as thyroid, lung, liver and breast (Muro 1999), although the 
impact of each domain alone on tumor progression remains unclear. EDB is associated 
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with angiogenesis (Khan 2005) and is expressed in the stroma and blood vessels of 
tumors. EDA is implicated in rheumatoid arthritis (Shiozawa 2001), tumor spreading 
(Manabe 1997) and invasions (Liu 1998) as well as proliferation of the blood vessel 
intima (Spargo 1994). While they differ in their spatiotemporal expressions in normal 
adult tissues, concomitant EDA and EDB expression is linked to fetal tissues and 
neoplastic masses, suggesting an active role of each of these two domains. FN-/- is 
embryologically lethal in mice (George 1993), but EDA-/- mice and EDB-/- mice are 
viable and fertile (Muro 2003, Fukuda 2002). In recent years, conditional knock-out mice 
of both EDA and EDB domains were generated and shown to be embryologically lethal 
(Astrof 2007), indicating the necessity of both domains in development. While 
fibronectin is known to be overexpressed in ovarian cancers and to be associated with a 
poorer prognosis (Ricciardelli 2006), nothing is known about EDA and EDB expression 
levels in ovarian cancer. In our experiments, we have observed an increase in 
fibronectin expression in SKOV3 cells overexpressing SPF45. Furthermore, we showed 
that expression of both the EDA and EDB domains was elevated in the presence of 
increased SPF45 expression independent of the mutations of Thr71 and Ser222. Also we 
showed that the inclusion of EDA domain in SKOV3-pQCSPF45 cells compared to SKOV3-
pQCXIP is higher than that of total fibronectin in the same respective cell lines, 
suggesting that SPF45 enhances inclusion of EDA domain dependent on intact Thr71 and 
Ser222 residues. Additionally, we determined the adhesion profile of the different 
stable cells and showed that they adhere to plastic, laminin and poly-L-Iysine non-
specifically after a short 30 min time point. Adhesion to fibronectin was however 
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increased around 3 fold compared to the other surface coatings, with SKOV3-pQCSPF45 
demonstrating the weakest attachment compared to SKOV3-pQCXIP, -pQCSPF45AA and -
pQCSPF4SDD, which can be explained by the increase in EDA-FN expression in SKOV3-
pQCSPF45. The fact that SPF45 increases fibronectin expression and affects EDA splicing 
in SKOV3 cells raises several questions: does SPF45 increase fibronectin expression in a 
different cell line? What is the role of EDA and EDB inclusions in fibronectin in the 
context of ovarian cancer? Does it affect cellular growth, spreading, invasion and/or 
chemoresistance? While the answers to these different questions remain unanswered, 
it is appropriate to speculate that altered fibronectin levels in cells would be responsible 
of adhesive, proliferative and potentially invasive properties. 
While FN expression levels were independent of SPF45 phosphorylation status, 
we demonstrated a decrease in ErbB2 in SPF4S expressing cells in a phosphorylation-
dependent manner. A member of the EGFR family and lacking a physiological ligand, 
ErbB2 heterodimerizes with other EGFR members (Her1, Her3 and Her4) in order to 
activate its protein tyrosine kinase activity (Graus-Porta 1995, 1997; Karunagaran 1996) 
leading to activation of several transduction pathways including PI3K/Akt and MAPK 
(Campiglio 1999). ErbB2 is overexpressed in several solid cancers including colon 
(D'Emilia 1989), primary lung cancer (Shi 1992), breast cancer (Seshadri 1989) and 
ovarian cancer (Lichtenstein 1990). In ovarian cancer, ErbB2 has been found to be 
overexpressed up to 50% (Kury 1990). Unfortunately, this elevated expression of ErbB2 
in advanced ovarian cancer is associated with a poorer prognosis for survival (Cirisano 
1996). Several cellular and physiological disturbances are associated with ErbB2 
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overexpression. For instance, it modulates cellular adhesion through interaction with 
CD44s, thereby enhancing binding to hyaluronan (Bourguignon 1997). Not limited to the 
standard form of CD44, ErbB2 is recruited to another complex containing a variant CD44 
(CD44-v3) and Vav2 in response to hyaluronan binding inducing Rac1 and Ras signaling 
in SKOV3-ipl ovarian cancer cells inducing cell migration and growth (Bourguignon 
2001). In response to heregulin (an EGFR ligand), ErbB2 interacts with PAK1 and actin 
stimulating PAK1 activity in a PI3K/ Akt manner, causing cytoskeletal reorganization and 
cellular migration of ErbB2-transfected MCF-7 breast cancer cells (Adam 1998). 
Heregulin and ErbB2 signaling induce an activating phosphorylation of c-Src in MCF-7 
cells influencing their metastasis (Vadlamudi 2003). Also, overexpression of ErbB2 in 
another breast cancer cell line MCF-10A enhances cellular proliferation, migration and 
invasion (Seton-Rogers 2004). ErbB2 effects on cellular proliferation are not limited to 
ovarian and breast cancer cells, as it induces proliferation of head and neck squamous 
cell carcinoma in response to LPA (Gschwind 2002) and in prostate cancer cells in 
response to CXCL12/CXCR4 chemokine signaling (Chinni 2008). Beyond tumor growth 
and cellular migration, ErbB2 has been also been linked to decreased apoptotic 
response in MCF-7 cells by upregulating survivin and Bcl-2 through activation of 
ERK/MAPK and PI3K/Akt pathways (Siddiqa 2008). In clinical trials of platinum therapy of 
ErbB2 positive ovarian cancer cells, it has also been shown to decrease clinical outcome 
and enhance tumor resistance (Meden 1998, Verri 2005). Currently, several trials with 
ErbB2 monoclonal antibodies are being investigated for adjuvant therapy of advanced 
and chemotherapeutic resistant breast cancer (Romond 2005, Siamon 2006) and solid 
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tumors (Kaumaya 2009), as targeting ErbB2 harboring cells in athymic nude mice or in 
mouse model of tet-controlled ErbB2 cells leads to decreased tumor growth, enhanced 
apoptosis and tumor remission (Harwerth 1993, Schiffer 2003). Given the importance of 
ErbB2 in mitogenically modifying tumors, it was interesting to see it upregulated in 
response to SPF45 overexpression. Our results indicate that elevated SPF45 levels 
decreased ErbB2 expression in a phosophorylation-dependent manner: 69% decrease in 
SKOV3-pQCSPF45 and 80 % decrease in SKOV3-pQCSPF45DD• As it caused an increase in 
cellular proliferation, ErbB2 expression levels parallel the proliferation rates of the 
corresponding stable SKOV3 cell lines, suggesting that SPF45 alters SKOV3 proliferation 
in an ErbB2-dependent manner. Furthermore, we showed that ErbB2 expression is 
regulated by SPF45 possibly in response to Elf3 but not Elf1 or PEA3 Ets transcription 
factors. Several questions arise to address the specific role of Erb2 in response to SPF45-
mediated overexpression such as investigating the adhesive, proliferative and drug 
resistance phenotypes of these cells. While SKOV3 cells are ErbB2 positive irrespective 
of SPF45 overexpression, the role of added ErbB2 might be elusive. Interestingly, 
development of resistance to cisplatin is associated with decreased expression of ErbB2 
(Langton-Webster 1994), which can partially explain the mechanism of SPF45-mediated 
drug resistance or alternatively, that the decrease in proliferation could result in the 
drug resistance. It will be necessary to determine ErbB2 changes with SPF45 
overexpression in different cell lines to test this hypothesis. We are currently generating 
stable SPF45-expressing cells in HeLa (human cervical cancer cells) and MCF-7 (human 
breast cancer cells) both of which are ErbB2-negative, as well as several ovarian cancer 
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cell lines with both ErbB2-negative and -positive genotypes. Generation of these stable 
cells in tissues different than ovarian cancer cells will also help establish the role of 
SPF45 in cancer biology as well as address the role of ErbB2 in mediating SPF45 effects 
on cellular proliferation and drug resistance. If SPF45 does induce genetic changes in 
other cell lines similar to the ones observed in SKOV3 cells, it will reinforce our 
prediction of the Ifuniversal" role of SPF45; in other words, since splicing factors are not 
as ubiquitous as transcription factors, if it happens that they are overexpressed in cells 
they will probably induce similar changes. Biological systems tend to be more complex 
however, and the "universal" response might not be accurate. It will be interesting 
though to determine the percentage of agreement in genetic changes in these different 
systems. 
Several clones of drug-resistant SKOV3 have been generated with introduction of 
increasing doses of chemotherapeutic agents such as cisplatin, taxol, doxorubicin and 
etoposide. The different mechanisms of resistance included decreased drug retention 
(Mistry 1992), increased BRCA1 and DNA damage repair (Husain 1998), P-glycoprotein 
expression (Bradley 1989, Yang 1995), Bcl-xL expression (Liu 1998), MRP-1 (Sharp 1998), 
decreased topoisomerase II activity (Kubota 1994), ErbB2 levels (Langton-Webster 1994) 
and more recently decreased RICTOR, RAPTOR and mTOR activities (Foster 2010). 
Unfortunately, we did not observe any of these changes with the gene array performed. 
While one or more of these genetic changes might have evaded detection, we also did 
not observe a change in cellular resistance. Generating different cancer cell lines, 
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ovarian and non-ovarian, overexpressing SPF45 will be necessary to better address the 
role of SPF45 overexpression on drug resistance. 
Aside from the genetic changes induced by SPF45 and the effect of 
phosphorylation on its splicing activity, we sought to determine how the 
phosphorylation affects SPF45 splicing mechanism. For this end we focused on two 
splicing factors, SF1 and SF3b155, which are important for their role in constitutive 
splicing of pre-mRNA. SF1 consists of a single polypeptide of 75KDa and is necessary for 
the formation of the first ATP-dependent step in spliceosome assembly (Arning 1996). 
SF3b155 is a 155 KDa protein that exists in a complex structure of several ~pliceosome­
Associated Proteins (SAPs) and therefore is also known as SAP155 (the other proteins 
are known as SAP49, SAP130 and SAP145) (Oas 1999). SF1 contains two [KH] RNA-
binding domains and binds the adenine branch point; subsequent to ATP-hydrolysis, SF1 
is replaced by SF3b155 (Thickman 2006). SF3b155 would then bind the pre-mRNA in the 
BPS recruiting U2sNRP forming the A complex (Gozani 1998). Recently, SF3bl55 has 
been shown to regulate the selection of the 5' splice site of Bcl-x pre-mRNA inducing 
higher expression levels of Bcl-x(s) with its subsequent effect on potentiating the role of 
chemotherapeutic agents (Massiello 2006). Besides their role in directing the steps of 
splicing, little is known about SFl and SF3bl55. Manceau et al identified 
phosphorylations by KIS on a SPSP motif in SF1 and showed that phosphorylated SF1 has 
higher binding to U2AF65 (Manceau 2006). SF3b155 is known to be phosphorylated by 
NIPP-1 (nuclear inhibitor of protein phosphatase 1) which recruits PPl to SF3b155 and 
subsequently inhibits splicing (Tanuma 2008), although the kinase(s) responsible 
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remain(s) elusive. In cancer} SFl deficiency is associated with a decreased incidence of 
testicular germ cell tumors in 129-Ter and M19 mice (two strains with high incidence of 
spontaneous TGCT): while SF1-/- are embryologically lethal} SFl+/- mice show marked 
reduction} indicating a potential role of SF1 in cancer initiation (Zhu 2010). Interestingly} 
SF1 levels are inversely correlated with the tumorigenic potential of intestinal epithelial 
cells (Shitashige 2007). In our experiments, we investigated the binding of SF1 and 
SF3b155 to SPF45 in co-immunopreicipation experiments and the effect of mutating 
Thr71 and Ser222 on these interactions. While the SPF45 UHM domain interacts with 
ULMs in SFl and SF3b155 (Corsini 2007), we provided the first proof of a total protein 
interaction between these proteins. However, we have not observed a change in 
binding with SPF4SAA or SPF4SDD• While these findings show that SPF45 interaction with 
SF1 and SF3b155 is not dependent on intact phosphorylation sites} further experiments 
need to be performed to confirm it} such as isothermal calorimetric dissociation and 
NMR-based binding assays. The mechanism that explains how phosphorylation of SPF45 
alters splicing remains unfortunately elusive. Whether it affects binding SF1 or SF3b155 
or maybe RNA sequences remains to be investigated. 
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Chapter 4: Summary, limitations, contribution and future directions 
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Summary 
The purpose of this dissertation is to examine the role of MAP kinase 
phosphorylation of SPF45 in modulating its function{s} in ovarian cancer cells. Our 
experimental approach is as follows: 1} to show that SPF45 is a substrate of MAP kinase 
in vitro and in vivo as well as identifying the targeted residues; 2} to determine the 
phosphorylation patterns of SPF45 in ovarian cancer cells in response to exogenous 
stimulation of MAP kinase pathways; 3} to determine the effect of the phosphorylation 
on regulating SPF45 alternative splicing activity towards ~Fas reporter system; 4) to 
identify genetic changes in SKOV3 ovarian cancer cells overexpressing SPF45 and the 
effect of phosphosite-mutants on these changes; 5) to identify novel pre-mRNA splicing 
targets of SPF45 and 6} to examine the role of SPF45 and the phospho-sites mutants in 
multi-drug resistance in ovarian cancer cells. 
SPF45 is a novel substrate of ERK/MAP kinase 
Previous work performed in our lab showed the generation of a mutant ERK2 
kinase capable of identifying specific kinase targets under the desired cellular conditions 
{Eblen 2003}. We have also published (Appendix I) a report showing increase in ERK2 
phosphorylation in SKOV3 cells upon cellular detachment and anchorage-independent 
growth. Using these same conditions, we have identified SPF45 as a potential novel 
ERK2 substrate. To demonstrate SPF45 as a genuine MAP kinase substrate, we 
expressed and isolated SPF45 from C05-1 cells as well as generated the recombinant 
protein and subjected both mammalian and bacterially expressed SPF45 to in vitro 
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kinase assays using not only ERK, but also JNK and p38 MAP kinase, as they can possibly 
share substrates. We showed SPF45 to be phosphorylated by the three MAP kinase 
subfamilies and phosphoamino acid analysis detected serine and threonine 
phosphorylations. As there are only two residues in SPF45 that satisfy the MAP kinase 
targets consensus sequence, namely Thr71 and Ser222, we generated alanine mutants 
of these two residues and repeated the kinase assays using active ERK2, which showed 
no phosphorylation on SPF4SAA , indicating that Thr71 and Ser222 are the unique MAP 
kinase target residues. Although not universally applicable, ERK/MAP kinase binds to its 
substrates prior to phosphorylation. We used three approaches to show that ERK2 and 
SPF4S exist in a binding complex. First, we identified SPF45 as an ERK2-binding protein 
in a co-immunoprecipitation of ERK2 from SKOV3 cells. Second, nuclear extracts from 
HeLa cells mixed with His-ERK2 showed SPF45 binding to ERK in a dose-dependent 
manner. Finally, using SKOV3 cells stably expressing Myc-SPF45, we showed ERK2 to co-
immunoprecipitate with Myc-SPF45, but not empty-vector control. Altogether, we are 
confident that SPF45 is a genuine ERK2/MAP kinase substrate and we aimed to 
determine its phosphorylation pattern when exogenously expressed in cells, but more 
importantly the phosphorylation profile of endogenous SPF4S in ovarian cancer cells. 
SPF45 is preferentially phosphorylated in ovarian cancer cells by ERK/MAP kinase and 
JNK in response to exogenous stimulation 
Identification of the phosphorylation sites in vitro provided an important clue to 
generate total SPF45 antibody as well as anti-pThr71-SPF45 and anti-pSer222-SPF45, 
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since until the time of writing this dissertation these reagents remain commercially 
unavailable. These antibodies were crucial for the subsequent experiments as they 
reduced the demand for large amounts of radioactivity to study SPF45 phosphorylation 
in response to MAP kinase stimulation, as well as reduced the labor required to reach 
the same conclusions (such as using phosphoamino acid analysis and tryptic peptide 
mapping). In determining SPF45 phosphorylation in celts, we expressed Myc-SPF45 in 
Cos-1 cells along with activated upstream activators of ERK, namely KRas G12V, BRaf 
V600E or CA-MEK1(DD) in the presence or absence of exogenous ERK2. Our data 
showed phosphorylation of Thr71 and Ser222 under all conditions, however, co-
expression of ERK2 increased their phosphorylation, especially Thr71. These results 
suggested that SPF45 is phosphorylated in cells similarly to in vitro, and we confirmed 
that SPF45 is phosphorylated on both Thr71 and Ser222 when CA-MEK1(DD) and ERK2 
are co-expressed in Cos-1 cells, while the phosphorylation of these two residues is lost 
when they are replaced by either alanine or aspartate. It is interesting to note that 
aspartate mutants displayed an upward mobility shift; phosphorylated wild-type SPF45 
equally displayed an upward shift. Prior to examining SPF45 phosphorylation in ovarian 
cancer cells, we screened SPF45 expression levels in several ovarian cancer cells and a 
benign transformed epithelial ovarian cancer cell line, to determine approrpriate cell 
lines for studying SPF45 phosphorylation in response to exogenous stimuli. Compared to 
malignant cell lines, lOSE, a benign transformed epithelial ovarian cell line, showed a 
low level of SPF45 expression. Of the different ovarian cancer cell line tested, A2780 had 
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the highest level; SPF45 expression in ES2 was moderate and SKOV3 had the lowest 
expression. All three cell lines were used to determine endogenous SPF45 
phosphorylation patterns in response to stimulation of the MAP kinase pathways using 
known activators. Under the conditions of stimuli tested l SPF45 was phosphorylated 
primarily in response to ERK and JNK and weakly to p38 MAP kinase. While it does not 
rule out the possible involvement of p38 in regulating SPF45 phosphorylation, these 
results suggest that ERK and JNK to be more likely involved in SPF45 regulation. The fact 
that SPF45 is phosphorylated by ERK and JNK suggests that SPF45 phosphorylation 
occurs in response to both mitogenic and stress stimuli, which translates as a potential 
involvement of SPF45 in a wide array of functions. More importantly, it would be 
interesting to determine the interplay between different signaling cascades in regulating 
SPF45 activity. Additionally, it should not come as a surprise that SPF45 may be 
phosphorylated by other kinases; SPF45 amino acid sequence predicts several 
phosphorylation sites including, but not limited to, Akt and PKA kinases. 
MAP kinase phosphorylation of SPF45 decreases its alternative splicing activity towards 
~Fas 
To examine the implication of SPF45 phosphorylation by ERK/MAP kinase on its 
alternative splicing activitYI we utilized a ~Fas minigene reporter system. We optimized 
the transfection conditions to obtain, in the presence of SPF451 equal splicing of ~Fas 
into short and long isoforms; a 1:1 ratio of short:long isoform is used as the basal level 
of splicing. We showed that co-transfection of CA-MEK1(DD) and ERK2 with SPF45 
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causes 40% reduction in the ratio of the short/long ~Fas isoforms compared to SPF45 
expression alone, and we partially reversed this decrease by using the MEK inhibitor 
U0126. Equally, we showed a similar effect by phosphorylating SPF4S using 
MKK3(E)/p38MAP kinase, while our efforts were unsuccessful in determining the impact 
of JNK overexpression on SPF45 alternative splicing function. To further support that 
inhibition of phosphorylation would produce the opposite effect, i.e. an increase in 
short/long ~Fas isoforms ratio, we compared the splicing activity patterns of wild type 
SPF4S, SPF4SAA and SPF45DD• While SPF4SAA induced a modest increase in short/long 
~Fas ratio around 16% on average, SPF4SDD unexpectedly displayed the strongest 
increase, an average of 37%. Nevertheless, the splicing activities of wild-type SPF4S and 
SPF4SAA in the presence of CA-MEK1(DD) and ERK2 showed an average of 32% increase 
in SPF4SAA activity. SPF4SDD was generated in the scope of mimicking a continuously 
phosphorylated form of SPF4S; however, our experimental data in splicing assays did 
not support it and SPF4SDD failed to act as a phospho-mimetic of SPF4S toward fas 
splicing. A possible hypothesis that could explain this result is the dynamic nature of 
splicing factors regulation. Since alternating cycles of phosphorylation and 
dephosphorylation are thought to direct the function of splicing factors in the regulation 
of their activities {Prasad 1999, Shin 2004}, SPF45 mutants cannot participate in these 
"regulatory" cycles; wild-type SPF4S on the other hand, is freely available for a 
continuous upstream phosphorylation by CA-MEK1{DD}/ERK2 or MKK3{E)/p38MAPK 
and downstream dephosphorylation by cellular phosphatases (yet to be determined), 
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hence subjected to "phospho-regulation". A potential alternative explanation could lie 
in the effect of the phosphorylation and/or the mutations in controlling SPF45 
subcellular localization either within the nucleus or through altered nuclear-cytoplasmic 
shuttling. Unfortunately, subcellular localization experiments were not successful in our 
hands, and they remain potential unanswered questions to be investigated. 
SPF45 induces genetic changes in SKOV3 ovarian cancer cells in both phosphorylation-
dependent and -independent manners 
As there are few known targets for alternative splicing by SPF45 and no reports 
describing the genetic changes imposed by its overexpression l we addressed these 
questions by performing an exon-array and a gene-array on SKOV3 cells stably 
overexpressing exogenous wild-type SPF45; SKOV3-pQCXIP (empty vector control cell 
line) was used as a control. We identified 158 potentially altered genes levels (high 
stringency criteria) and 139 potential novel splicing targets of SPF45. However, array 
data require physical confirmation and we focused on four different genes selected for 
their expression level changes in the array and their known involvement in cancer 
biology; they are: ErbB2, fibronectin, transforming growth factor-(3 and periostin. We 
also investigated their expression levels in SKOV3-SPF4SAA and SKOV3-SPF45DD to assess 
the effect of Thr71 and Ser222 residues/mutations on SPF45 functions. ErbB2 was 
roughly 70% decreased in SKOV3-SPF45 compared to vector, while in SKOV3-SPF54AA it 
was 36% decreased and SKOV3-SPF45DD 80% decreased. ErbB2 mRNA levels were 
equally translated on the protein level in their corresponding cell lines. Fibronectin 
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expression was roughly 5 folds increased in wild-type SPF4S, SPF4SAA and SPF4S DD 
compared to vector control. Real-time RT-PCR data were supported by northern blot of 
fibronectin and the mRNA levels were equally translated on a protein level (data not 
shown.) It is interesting to note that Thr71 and Ser222 mutations do not affect 
fibronectin levels compared to wild-type SPF4S. Taken together, the role of mutations of 
Thr71 and Ser222 on ErbB2 and FN expression suggests the existence of phospho-
SPF4S-dependent and -independent effects. Two more genes were tested for their 
relative abundance in the generated stable cells: TGF-(3 and perisotin. No statistical 
difference was observed in TGF-(3 between SKOV3-pQCXIP and SKOV3-pQCSPF4S while 
both SKOV3-pQCSPF4SAA and SKOV3-pQCSPF4SDD showed 2 fold increase. Finally, 
periostin, which - based on the array results - was expected to show the strongest fold 
increase with SPF4S overexpression, failed to have any statistical difference among the 
four groups tested. Simply, the levels of periostin were so low, that any change in its 
concentration from one group to the other would show an lIapparent" difference in the 
array analysis that may not necessarily materializes by physical approaches. In fact, the 
example of periostin represents one of the crucial reasons to address the results of 
gene-arrays cautiously and validate these observations with further experiments. 
EDA-Fibronectin but not EDB-Fibronectin is a novel splicing target for SPF4S 
In addition to the genetic changes in fibronectin expression, exon-array analysis 
predicted several regions within FN to undergo alternative splicing in response to SPF4S 
overexpression. A caveat of the exon-array we used is its inability to point out to the 
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specific exons undergoing alternative splicing. Using literature search to check for 
reported alternative splicing regions of fibronectin, we identified three FN domains, 
extra domain III A (EDA), extra domain III B (EDB) and a variable (V) region that have 
been reported to undergo alternative splicing under different disease conditions and in 
a tissue specific manner. We directed our attention to EDA and EDB and designed 
primers to check for inclusion/exclusion of these regions in SKOV3-pQCXIP, -pQCSPF4S, -
pQCSPF4SAA and -pQCSPF4SDD using semi-quantitative reverse-transcriptase PCR. This 
method failed to show differences in inclusion/exclusion of these regions as RT-PCR 
lacks the ability to calculate with precision the ratios of the different bands when it is 
difficult to determine the reactions outcomes in a linear phase. To overcome this 
problem, we designed exon-specific primers to EDA and EDB and studied their relative 
abundance in the four different groups using real-time quantitative RT-PCR. Similar to 
our previous results, fibronectin was equally increased in SPF4S overexpressing cells 
(wild type and mutants) and the difference between the three groups was non-
significant. Also, EDB-FN was equally elevated in the same groups compared to vector 
control, and showed a similar fold increase to total fibronectin. However, EDA inclusion 
was 37% increased in wild-type SPF4S compared to SPF4SAA and SPF4SDD as well as total 
fibronectin in wild-type SPF45 stable cells. These data showed that SPF4S is implicated 
in fibronectin alternative splicing, that mutations of the phosphorylation sites abrogate 
its effect on EDA inclusion, and that exon-array data, coupled with biophysical 
techniques, bioinformatics and literature search can be used as a tool to identify the 
160 
regulation of alternative splicing of specific genes. Although real-time RT-PCR is not the 
standard technique to address alternative splicing, it proved to be a useful approach to 
answer this question for the speed of the experiment as well as its high sensitivity and 
ability to render a quantifiable measurement. Generation of fibronectin-EDA minigene 
and/or a fibronectin-EDA pre-mRNA oligomer could be used to address the alternative 
splicing of this region in response to SPF45 overexpression in vivo and in vitro, 
respectively. Although these experiments are the gold standard techniques in studying 
alternative splicing, they both lack the specificity of studying the splicing in a biological 
tissue, as we did in the SKOV3 ovarian cancer cells. 
Mutation of Thr71 and Ser222 does not affect SPF45 binding to constitutive splicing 
factors 
SPF4S-mediated alternative splicing has been explained, in vitro, through 
hydrophobic interactions with constitutive splicing factors in the initial steps of the 
spliceosome assembly, namely SFl and SF3blS5, via the RNA recognition motif in SPF4S 
C-terminus domain. To assess possible interactions of SPF4S with these proteins in vivo, 
we performed a co-immunoprecipitation of Myc-tagged SPF45 or mutants using the 
stable cell lines generated. Indeed, we show that both SFl and SF3b15S co-
immunoprecipitate with Wild-type Myc-SPF45, demonstrating in cells a physical 
interaction between SPF45 and constitutive factors of the splicing machinery. While we 
expected that SPF4SAA and/or SPF4SDD to have different binding to SFl and SF3b155, no 
difference was observed. Assays that address this process in a dynamic manner, looking 
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at spliceosome complex in its development and assembly might provide a better clue 
whether the phosphorylation of Thr71 and/or Ser222 is involved in these interactions. 
SPF45 overexpression in SKOV3 ovarian cancer cells does not alter their cytotoxic 
response to chemotherapy 
Although forced SPF45 expression in ovarian and cervical cancer cells is linked to 
drug resistance, we did not observe such a phenotype in SKOV3 cells. While it is unlikely 
that a single factor, such as the overexpression of a single protein, is responsible for the 
multidrug resistance phenotype, SPF45 is a splicing factor that has the potential to 
affect a large number of downstream targets, many of which could lead in a combined 
effort to the drug resistance phenotype. The only pathway that we identified in the 
genetic array to be related to drug resistance in SKOV3 cells involves ErbB2. In fact, 
ErbB2 levels were shown to decrease in a cisplatin resistant SKOV3 clone (Langston-
Webster 1994). The decrease in ErbB2 level in response to SPF45 overexpression, might 
therefore account for the elevated drug resistance profile of SKOV3 cells. While Perry et. 
al (Perry 2005) showed that SPF45 induces a drug resistance phenotype in A2780 and 
HeLa cells, these studies were performed using few highly-resistant clones selected 
among multiple clones generated, not all of which display resistance; the stable cells we 
generated represent a heterogeneous population of cells pooled to overexpress SPF45 
and hence might not display the similar outcome of individually selected colonies. 
Investigating the drug resistance phenotype of SPF45 in multiple cancer cell lines} 
ovarian and non-ovarian, is therefore necessary to address this question. Furthermore, 
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it would provide a platform to determine the common genetic and splicing events 
regulated by SPF45 both in a tissue-specific and -nonspecific manner. 
Limitations of the study 
This study is based in a large extent on the assumption that MAP Kinases 
phosphorylate SPF45 solely on Thr71 and Ser222. While it is typical to identify a priori 
phosphorylation sites using in vitro analysis of kinase-subjected proteins, in vivo 
determination of phosphorylation remains the gold standard for adequate functional 
analysis and for unraveling the impact the phosphorylation imparts on the substrate. 
Further experiments using in cells radioactive phosphate labeling of SPF45 for phospho-
peptide mapping or alternatively mass spec analysis of SPF45 may possibly reveal 
phosphorylation sites not previously suspected or identified. In fact, mass spec analysis 
offers a powerful tool to determine multiple simultaneous post-translational 
modifications on SPF45 and has a strong potential for a wider insight onto 
phosphorylated SPF45 regulation. With this technique, the role of other kinases can be 
further investigated and SPF45 response to kinase activation under different 
extracellular cues, be assessed. A great advantage of mass spec analysis is its ability to 
analyze a large number of treatment in a fast and accurate way, generating a large 
amount of information in a timely and effective manner. 
From another perspective, while we determined the phosphorylation of SPF45 in 
several ovarian cancer cells stimulated with known ERK, JNK and p38 MAPK activators, 
SPF45 phosphorylation under physiological and pathophysiological conditions was not 
163 
addressed. Given that the scope from this set of experiments was to show SPF45's 
phosphorylation in vivo, the question was answered appropriately. However, the study 
fails to investigate the functional significance of SPF45 phosphorylation under these 
conditions. It equally fails to address SPF45 phosphorylation under treatment with 
chemotherapeutic agents. Although drug resistance experiments are non-contributory 
in this work, investigating SPF45 response to anti-neoplastics adds additional 
information regarding SPF45 phosphorylation status in response to cellular treatment 
with chemotherapeutic agents. Unfortunately, the experiments performed in this thesis 
are limited to evaluating Thr71 and Ser222 solely and do not anticipate phosphorylation 
of SPF45 on different residues in response to activation of MAP kinase enzymes. 
Coupling these experiments with mass spec analysis will likely avoid the problem of 
unspecific bands due to the reactivity of the phospho-specific antibodies and will 
provide a wider view on the different possible post-translational modifications that 
occur on SPF45 in response to the different treatments employed. 
The data we presented in this thesis showed a role for SPF45 phosphorylation by 
MAPKs in altering the splicing pattern of Fas. While we proposed in a previous section 
an explanation for the failure of SPF45DD to demonstrate a similar response to 
phosphorylated SPF45, we cannot exclude the possibility that increased MAPK activity in 
the cell can lead to increased Fas alternative splicing in a non-SPF45 mediated 
mechanism. Under this scenario, SPF45 overexpression facilitates Fas splicing in 
response to a yet-to-be-determined MAPK-dependent mechanism. Additionally, failure 
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of SPF4SDD mutant to behave similarly to phosphorylated SPF45 raises the suspicion that 
SPF4S DD might have a different impact on the cells than SPF4SPT71pS222. Also, since 
SPF45AA and SPF4SDD display similar response in terms of the genetic changes on FN and 
TGF-~} which supports the importance of Thr71 and Ser222 residues in regulating the 
functions of SPF4S, it may potentially indicate that SPF4SDD is not a true phospho-
mimetic analog of SPF4SPT71PS222 or that it selectively functions as a phosphomimetic. If 
this were to be true, caution is required when using SPF4SDD as a mimetic for 
SP F4SPT71pS222. 
In this work, we showed that phosphorylation of SPF4S impacts its alternative 
splicing activity towards Fas. Due to the paucity of known pre-mRNA sequences 
influenced by SPF45 activity, the study is limited to fas gene spanning exons 5 through 7. 
While in vitro alternative splicing has fallen in favor compared to in vivo techniques 
using minigene systems and peR approach, partly due to the convenience and simplicity 
of the minigene approach} and partly because splicing is studied in its quasi-native 
environment} using in vitro techniques offers control over the contents of splicing 
complex used, and can potentially substantiate the results of the minigene approach. 
Additionally, it can provide further information about the nucleic-proteomic interactions 
between SPF45 and the splicing complex, as well as SPF45 interactions with other 
splicing factors within the spliceosome. Given the large number of potential splicing 
events subjected to SPF45 regulation, as determined by the exon array analysis, 
generating minigenes of the predicted sequences will be necessary to further 
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understand the relationship between phosphorylation of SPF45 and alternative splicing. 
Alternatively, uSing the qRT-PCR approach that we use in this thesis to show the 
alternative splicing of the EDA region of FN, can be applied on a larger scale with 
specifically designed primers to determine the splicing changes of suspected alternative 
splicing events. Unfortunately, the array results do not point directly to the alternatively 
spliced sequences, and further bioinformatics analysis coupled with literature search 
will be necessary to determine these splicing events. 
We have discussed previously the importance of the gene- and exon-array in 
determining novel genetic and splicing events regulated by SPF45; we equally discussed 
the limitation of this technique in terms of high rate for false positive results as well as 
the need for support using biochemical approaches. While we focused our efforts on 
four distinct genes from the gene array, the list of targets to be investigated is quite 
large and requires substantial dedication to sift through the data and validate the 
outcomes. Hence, bioinformatics tools will prove to be essential in speeding up the 
process. Functional map analysis is an example of linking different genes in a logical and 
biochemically acceptable pattern and has the potential to identify strong candidates for 
major molecular changes in the cells. DNA repair, regulation of apoptosis and cellular 
adhesion and migration are interesting areas for investigation, specifically in the context 
of cancer biology. 
One of the major drawbacks of this study is its inability to reproduce the drug 
resistance phenotype imparted by SPF45 overexpression in ovarian cancer cells, as 
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published by Perry et al. (Perry 2005) and hence whether phosphorylation of SPF45 by 
MAP kinases has any effect on drug resistance. Several caveats can be accounted for to 
explain this failure. Our study is based on two publications by the same group, where 
the authors claim a link between SPF45 overexpression and multidrug resistance in 
A2780 and HeLa cells. Accordingly, the data on which the second aim of our hypothesis 
is based are weak, given the paucity of supporting evidence. While the rewards of this 
project can be remarkable, the lack of cumulative supporting data places this study in a 
high-risk category for failure upon addressing the possible link between phosphorylation 
of overexpressed SPF45 and drug resistance. Although we expect SPF45 to induce the 
drug resistance phenotype observed by Perry et al. (Perry 2005) in A2780 cells, it is 
possible to conclude that the choice of a different cell line, such as SKOV3 cells in this 
study, might not exhibit a similar behavior. Unfortunately, multiple efforts to generate 
A2780 cells that stably express SPF45 or its mutants were unsuccessful to test this 
hypothesis. Additionally, a major difference exists between our approach and that of 
the other group. Perry and his colleagues proposed a relationship between SPF45 and 
drug resistance based on few A2780 and HeLa clones - selected from a larger number of 
SPF45 expressing clones - because of their enhanced drug response profile, while we 
based our approach on generating pooled populations of cells stably expressing SPF45. 
As such, it may not come as a surprise the failure of our approach. If that turns out to be 
the true explanation for this disparity, it would likely be safe to assume that SPF45 does 
not have a role in drug resistance. However, until stable populations of cells in A2780 
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and Hela overexpressing SPF45 are generated, this question remains unanswered. Using 
a lentiviral system for expression of SPF45 and its phosphorylation-sites mutants and/or 
an inducible expression system in the aforementioned cells may overcome the 
difficulties of infection using a retroviral plasmid and re-evaluation of drug resistance. If 
SPF45 is genuinely responsible for such a phenotype, investigating the mechanism(s) will 
be crucial. While glutathionylation, overexpression of MRP, PgP and MDR 1 are possible 
mechanisms for drug resistance, the data by Perry et al (Perry 2005) refute their 
involvement in SPF45 mechanism of resistance. Enhanced DNA repair and altered 
expression of apoptotic genes are common pathways to impart drug resistance to 
cisplatin, doxorubicin, etoposide and vincristine. If efforts to express SPF45 in different 
cell lines were to be successful and SPF45 does induce a drug resistance phenotype, 
investigating genetic changes of DNA repair pathways and altered apoptotic genes, 
presents a plausible starting point to understand its mechanism. Using the results of the 
gene array in SKOV3 and possibly repeating the gene array analysis among different cell 
lines may identify common pathways altered in response to SPF45. An interesting aspect 
of these experiments is the richness of information that can be construed regarding 
SPF45 roles and functions, regardless of its impact on drug resistance. As mentioned 
earlier, DNA repair pathways, altered apoptotic genes, cellular adhesion, spreading and 
migration are important venues in cancer biology and drug discovery worth to be 
investigated in their own regards. 
Contribution and future directions 
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The importance of this study was identifying a novel mechanism of regulation of 
splicing through the MAP kinase signaling cascade. As mentioned earlier, there are few 
accounts of MAP kinase involvement in splicing regulation linking splicing mechanisms 
to extracellular cues. This fact can have dramatic results in the context of cancer. 
We have determined SPF45 splicing activity towards !lfas upon phosphorylation 
by ERK2 and p38 MAP kinase. It would be interesting to identify SPF45's splicing activity 
upon phosphorylation by JNK. Similar experiments with activated JNK will unveil the role 
of JNK on SPF45. Our findings that genetic changes and splicing events are affected by 
mutations of the MAP kinase target sites suggest a potential role of the different MAP 
kinase families in controlling SPF45 functions. In fact, such a response is very plausible 
especially that MAP kinases are activated in specific response patterns depending on the 
external and internal cellular conditions. Obviously, we are still at the beginnings of 
identifying the significance of this regulation, especially that SPF45 is overexpressed in, 
besides ovarian cancer, a broad range of solid tumors including breast, bladder, colon, 
lung and pancreatic cancer all of which display elevated expression and/or activation of 
one or more of the different MAP kinase subfamilies as well as several other signaling 
cascades secondary to oncogenic activation, environmental conditions of cancerous 
behavior or even chemotherapeutic agents. We show a change in the SKOV3-pQCSPF45 
attachment to fibronectin coated wells compared to SKOV3-pQCXIP. Cellular adhesion is 
a complex process governed by multiple molecules and interactions between the 
extracellular matrix and intracellular/transmembrane proteins. Additionally, cellular 
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adhesion is of prime importance for cancer cells: migration, invasion and cellular 
proliferation are all affected by changes in cellular adhesive properties. Would the 
observed decrease in SKOV3-pQCSPF45 attachment within the first hour of seeding have 
any significance for cancer progression such as increased migration or invasion, remains 
to be determined. Alternatively, the observed increase in TGF{3 together with 
fibronectin expression may enhance cellular compactness, increasing multicellular 
spheroid formation and invasive phenotypes (Sodek 2009). One approach to identify 
possible changes in adhesion is to perform a real-time gene array of adhesion pathways. 
In fact, we have recently obtained a pre-validated 96 well array (Qiagen) capable of 
detecting changes at the mRNA level of more than 80 different genes involved in cellular 
attachment to extracellular matrix; any changes identified will have a great impact in 
determining the role of SPF45 on cellular adhesion. Although not a comprehensive 
approach, it can provide an important lead into the molecules involved in this 
phenotype. Besides, attachment (a measure of bound cells) and spreading (a measure of 
the flattening of adherent cells) assays could be performed to better characterize this 
phenotype as well as determine the biochemical and structural regulation of the points 
of attachments also known as focal adhesions. 
In understanding the functions and roles of SPF45, an important question always 
arises: are SPF45 effects universal? Would it confer similar genetic changes and 
phenotypes in different cell lines? It is actually quite difficult to answer this question. 
The fact that splicing factors are not as diverse as transcription factors suggest that they 
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tend to rely on the ratios of the different combinations of splicing factors as well as the 
strength of interactions with the cis sequences in the introns/exons of the pre-mRNA 
(Mayeda 1993, Faustino 2003, Shin 2004). Accordingly, it is almost impossible to predict 
the phenotypic outcome because of the heterogeneity of the different cell lines. For 
example, SPF45 confers drug resistance in HeLa and A2780 cells (Sampath 2003, Perry 
2005); however we do not observe a similar phenotype in SKOV3 cells. If we 
simplistically assume that SPF45 induces similar genetic changes in SKOV3 cells that it 
induces in HeLa and A2780, then there must be other factors in these cells but not 
SKOV3 that causes the drug resistance. To answer this question, it would be imperative 
to investigate SPF45 effects when overexpressed in several cell lines. In fact, we are 
currently generating stable cell lines in several ovarian cancer cell lines as well as HeLa 
and MCF-7, a breast cancer cell line, of SPF45 and phospho-sites mutants to test this 
hypothesis. The importance of our approach is that we generate pooled population of 
heterogeneous cells that overexpress SPF45 to circumvent the problem of clonal 
variation. As such, if we fail to identify drug resistance changes in these cells, it will 
increase our confidence to assume that SPF45-mediated drug resistance is more likely 
an isolated event of individually selected clones rather than a true SPF45 effect. If on the 
other hand, drug resistance is enhanced in more than one of these cells, identifying the 
common genetic/proteomic changes will probably determine the mechanism of this 
resistance. Additionally, the cell lines generated in HeLa and MCF-7 will help answer 
several other questions; for instance, it will be interesting to compare the common 
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genetic changes induced by SPF45 overexpression. It will serve as a direct answer to the 
role of splicing factors as universal regulators of genetic outcomes. The higher the 
number of common changes observed, the stronger is the support for this hypothesis. 
Additionally, common genetic changes determined by gene and exon arrays in different 
cell lines are likely to be true events due to their overlap as well as decreased bias; it 
would generate higher likelihood of true genetic and splicing changes induced by SPF45. 
Testing the adhesive, migratory and invasive properties of the different stable cell lines 
would also assess the role of SPF45 in cancer. 
As the role of SPF45 in cancer is still to be determined and studied, it would be 
necessary to generate knock-out mice of SPF45 to evaluate the role that it plays in 
cancer: initiation, progression, maintenance or suppression. Knockout mice of proteins 
of interest are an invaluable tool in singling out the properties of a protein. It would 
determine the role of SPF45 in development as well as the different phenotypic changes 
that could be imparted by lack of its expression. If the deletion turns to be embryonic 
lethal, conditional knockouts can be generated to study SPF45 functions in a tissue-
specific pattern. 
We have already mentioned that SPF45 is expressed in several solid tumors, 
which display varying levels of oncogenic signals and activate a multitude of signaling 
cascades. The amino acid sequence of SPF45 shows potential phosphorylation sites of 
several other kinases, many of which, such as PKC and Akt are of prime importance in 
cancer signaling. Determining the potential regulation of SPF45 phosphorylation by 
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these different cascades, as well as putative cross-talks with MAP kinase signaling will be 
exciting as well as important to better understand the link between signaling cascades 
and splicing machinery in regulating cancer cells and in generating efficient therapeutic 
interventions. 
In conclusion, this dissertation investigated and confirmed the involvement of 
MAP kinase signaling in the functions of the splicing factor SPF45, regulating its splicing 
activity and potentially modulating its downstream genetic and splicing targets. SPF45 is 
but one player among a vast group of cellular factors that widely contribute to the 
aberrant nature of cancer cells. As our understanding of the molecular mechanisms that 
govern SPF45 interactions, as well as upstream events that modify its activities, we will 
get one step closer into developing sound strategies and efficient therapeutic 
interventions to overcome drug resistance or even cure cancer. 
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ABSTRACT 
Ovarian cancer metastasis involves the sloughing of epithelial cells from the 
ovary into the peritoneal cavity, where the cells can survive and proliferate in peritoneal 
ascites under anchorage-independent conditions. For normal epithelial cells and 
fibroblasts, cell adhesion to the extracellular matrix is required to prevent apoptosis and 
for proper activation and nuclear signaling of the ERK MAP kinase. The mechanisms of 
ERK regulation by adhesion have been determined by our lab and others. In this report, 
we elucidate a novel means of ERK regulation by cellular adhesion in ovarian cancer 
cells. We demonstrate that ERK and its activator MEK are robustly stimulated after cell 
detachment from a substratum in several ovarian cancer cell lines, but not a benign 
ovarian cell line, independent of serum and FAK or PAK activity. MEK and ERK activation 
was sustained for 48 hr after detachment, while activation by serum or growth factors in 
adherent cells was transient. Re-attachment of suspended ovarian cells to fibronectin 
restored basal levels of MEK and ERK activation. ERK activation in suspended cells was 
dynamically controlled through an autocrine stimulatory pathway and prevalent 
phosphatase activity. Suspended cells demonstrated higher levels of ERK nuclear 
signaling to Elkl compared to adherent cells. Inhibition of ERK activation with the MEK 
inhibitor U0126 had minor effects on adherent cell growth, but greatly decreased soft 
agar colony growth. These data demonstrate a unique regulation of ERK by cellular 
adhesion and suggest a mechanism by which ERK may regulate anchorage independent 
growth of metastatic ovarian cancer cells. 
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Extracellular Regulated Kinases (ERKs) are members of the MAP Kinase family of 
protein kinases that regulate many aspects of cell biology including, proliferation, 
differentiation, migration, survival, and gene expression [Pearson et al.I 2001]. Inactive 
ERKs reside in the cytoplasm, but following activation translocate to various cellular 
locations including the nucleus [Chen et aL, 1993; Lenormand et aI., 1993] where they 
phosphorylate a variety of substrates to affect gene transcription. ERK activation and 
nuclear translocation is required for cell proliferation [Brunet et aL, 1999] and cell 
adhesion has been reported to be a requirement for ERK nuclear tranlocation and 
activation of the Elk1 transcription factor [Aplin et aI., 2002]. Cell adhesion is also 
required for ERK activation by mitogens, as cells in suspension fail to activate ERK in 
response to growth factors [Lin et aL, 1997; Renshaw et aI., 1997]. Overexpression of an 
activated mutant of Focal Adhesion Kinase (FAK) [Renshaw et aI., 1999] or p21 Activated 
Kinase (PAK) [Howe and Juliano, 2000] can stimulate anchorage independent activation 
of ERK, demonstrating that these proteins act as adhesion-dependent sensors for ERK 
activation. FAK is activated in adherent cells through autophosphorylation of Tyr397, 
which forms a binding site for Src [Calalb et aI., 1996; Lipfert et aI., 1992]. Activation of 
Raf, MEK and ERK and functional coupling between Raf and MEK and MEK and ERK upon 
cell attachment to fibronectin is dependent upon activation of PAK [Eblen et aI., 2002; 
Edin and Juliano, 2005; Slack-Davis et aI., 2003] through a FAK and Src dependent 
pathway [Slack-Davis et al., 2003]. This mechanism occurs in part through PAK 
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phosphorylation of MEK1 on S29B} which is required for MEKl activation and stimulates 
MEK1/ERK complex formation in newly-adherent cells [Eblen et al.} 2002; Slack-Davis et 
al.} 2003]. 
Ovarian cancer is the fifth leading cause of cancer deaths in women and the 
deadliest form of gynecological cancer. In humans most ovarian cancers originate from 
the ovarian surface epithelium (OSE), which is a poorly differentiated mesothelium with 
a tenuous attachment to the underlying basement membrane [Dietl and Marzusch, 
1993]. Dissemination of ovarian cancer cells to the peritoneal cavity involves the loss of 
attachment of the OSE from the underlying basement membrane or their extravasation 
from inclusion cysts that form within the ovary [Auersperg et aL, 1998]. Ovarian cancer 
patients often develop peritoneal ascites fluid containing metastatic cells growing 
individually or as multicellular spheroids, in addition to factors that promote tumor cell 
growth [Mills et al., 1990; Westermann et al., 1997; Westermann et al., 1998]. Ascitic 
cells survive and proliferate under anchorage-independent conditions until they attach 
to the mesothelium of the peritoneal cavity via fibronectin and hyaluronan produced by 
peritoneal mesothelial cells [Burleson et aL, 2004; Casey et al., 2001; Lessan et aI., 
1999]. 
Mouse models have identified ras as a causative agent in the development of 
ovarian cancer [Uu et aI., 2004; Orsulic et aL, 2002]. Indeed, in humans two-thirds of 
low-grade ovarian tumors have mutations in the k-ras or b-raf oncogenes I while 16% of 
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high grade tumors carry k-ras mutations [Ho et aI., 2004; Singer et aI., 2003a; Singer et 
aI., 2003b]. However, activation ERK is observed in 80% of low grade tumors, 40% of 
high grade ovarian tumors [Hsu et aI., 2004], and 91% of pleural and peritoneal 
effusions from patients with metastatic disease [Davidson et aI., 2003], suggesting that 
other factors also contribute to ERK activation in metastatic ovarian cancer. 
Downregulation of MAP Kinase Phosphatase-1, a negative regulator of ERK, has been 
observed in ovarian tumor samples [Denkert et aI., 2002]. Overexpression of growth 
factor receptors that stimulate ERK activation, such as ErbB-2 and c-Met, is observed in 
ovarian tumors [Berchuck et aI., 1990; Di Renzo et aI., 1994]. In addition, ascites fluid is a 
complex milieu rich in mitogens such as lysophosphatidic acid (LPA) and Platelet Derived 
Growth Factor (PDGF) [Matei et aI., 2006], among others, but the cellular origins of most 
of these factors are unknown. 
We examined the regulation of ERK activation by loss of cellular adhesion, an 
early step in cancer metastasis, in several ovarian cancer cell lines. We demonstrate a 
strong, sustained activation of M EK and ERK in response to loss of cell/matrix adhesion. 
Re-attachment of cells restored basal levels of active ERK. Conditioned media from 
suspended cells could stimulate ERK activation in serum-starved adherent cells, 
suggesting an autocrine mechanism for ERK activation in suspended cells. ERK signaling 
to the nucleus was enhanced in suspended cells and inhibition of ERK signaling had 
profound effects on soft agar growth. These studies demonstrate a novel means of ERK 
regulation by cellular adhesion and suggest that upregulation of ERK activation through 
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an autocrine mechanism promotes the ability of ovarian cancer cells to grow anchorage-
independent. 
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MATERIALS AND METHODS 
Cells and Reagents. SKOV-3 cells were purchased from American Type Culture 
Collection (Manassas, VA) and grown in McCoy's SA media supplemented with 10 % 
fetal calf serum. lOSE cells were a generously provided by Dr. Nellie Auersperg. CAOV3, 
ES2, TOV21G, and OV2008 cells were a kind gift from Dr. Runzhao Li. OVCAR3 cells were 
a kind gift from Dr. Kristen Atkins. ERK2 antibody was kindly provided by Dr. Michael J. 
Weber. Phospho-ERK antibody was purchased from Sigma (St Louis, MO). FAK and 
phospho-Y397 FAK antibodies were purchased from Cell Signaling (Danvers, MA). 
Phospho-MEK, MEK, phospho-AKT, AKT, tubulin and MKP-l antibodies were purchased 
from Invitrogen (Carlsbad, CAl. 
Suspension assay. Six-well dishes coated with 1% agarose were prepared by melting 4% 
agarose into phosphate buffered saline (PBS). This solution was then mixed with 3 parts 
serum-free McCoy's SA media and used to coat 6 well dishes. Adherent cells growing in 
media containing 10 % fetal calf serum were washed once with PBS and detached with 
trypsin-EDTA. The trypsin was inhibited with 1 mg/ml soybean trypsin inhibitor (Sigma) 
in PBS. The cells were collected, counted, pelleted by centrifugation, and resuspended in 
serum-free media at a concentration of 1 X106 cells / ml for all experiments. Two 
milliliters of cells were added to each well. The cells were then incubated for the 
indicated time at 37 DC and S % C02 before harvest by gentle pipetting into 15 ml 
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conical tubes containing 10 ml of cold PBS on ice. Centrifuged cells were snap frozen and 
stored at -70°C until lysis. For replating experiments, fibronectin was coated onto dishes 
overnight at 4 °c at a concentration of 10 I11g/ml. Replated cells were put onto these 
dishes in the same serum-free media that they were suspended in and incubated at 37 
°c and 5 % CO2 until harvest. Citric saline experiments were performed in a similar 
manner, except that cells were washed, incubated with citric saline for 15 min and 
collected by gentle pipetting. The cells were centrifuged, washed in PBS, and 
resuspended in serum free media. 
Western blotting. Cells were lysed in M2 lysis buffer [Eblen et aI., 2001] and protein 
concentrations determined using the BeA kit (Pierce, Rockford, IL). Typically, 20 I1lg of 
protein was run on an SDS PAGE gel and transferred to nitrocellulose. The membranes 
were blocked in 5 % milk and incubated with antibodies from 1 hr to overnight. 
Secondary antibodies conjugated to horseradish peroxidase were followed by enhanced 
chemiluminescence (Pierce) to visualize proteins. 
MTT assay. SKOV-3 or lOSE cells were plated in triplicate into 12 well dishes at a 
concentration of 1 X 103 cells / well. The following day (day 0) the cells were treated in 
duplicate with either 10 111M U0126 or DMSO vehicle control. On each of the next 4 
days, triplicate wells of cells were washed and incubated in MTT reagent for 2 hrs before 
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harvest in DMSO. MIT activity was measured by reading the absorbance at 570 nm and 
reference wavelength of 630 nm. These experiments were performed 3 times. 
Luciferase assays. SKOV-3 cells were transfected using UpofectAMINE (Invitrogen) with 
1 [1]g of 5X Gal4 Luciferase, 50 ng of Ga14-Elk1 [Roberson et aI., 1995], 100 ng of TK 
Renilla luciferase, and either 100 ng of empty vector or 100 ng of mutationally-activated 
MEK1 (MEK1 S218/222D) per 6 cm dish. After a 5 hr transfection in serum-free McCoy's 
SA medium, the medium was removed, the cells were washed once with PBS and 
allowed to recover overnight in 10 % serum containing media. The day after transfection 
the cells were washed twice in PBS and either incubated in serum-free media or 
trypsinized and suspended in serum-free media, as described above. After 24 hr, both 
adherent and suspended cells were harvested, lysed and luciferase activity (Renilla and 
firefly) measured. The ratio of firefly:Renilia luciferase was determined for each sample. 
Activity in the adherent cells in the absence of activated MEK1 was set to 1 for each 
experiment. The results are a combination of 5 separate experiments all performed in 
triplicate. Statistical analysis was performed using the Student's t-test and significance 
determined as p < 0.05. 
Soft agar assay. SKOV-3 cells were mixed at a density of 5 X 103 cells / ml in 0.4 % bacto 
agar, 10 % serum, and either 10 [liM U0126 or DMSO control. One milliliter of this 
mixture was overlayed onto 3S mm dishes containing a 0.6 % agar plug. Assays were 
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performed in triplicate. The cells were incubated at 37 DC and 5 % CO2 for 5 weeks. 
U0126 or DMSO was administered to the cells every 3 days by dissolving 11111 DMSO or 1 
[1]1 of a 10 mM stock solution of U0126 into 100 ilIl of serum-free media and overlaying it 
onto the 1 ml of cells in agar, allowing for drug absorption at a final concentration of 10 
[liM. After 5 weeks, four random fields of cells from each plate were photographed 
under a 2.SX objective. Distance on the plate was determined using a known standard. 
The images were analyzed using Image J software {website: http://rsb.info.nih.gov/ij/} in 
order to quantitate colony number and individual colony size. Colonies above 400 111m2 
in 4 fields from each triplicate dish were counted. Results from each triplicate were 
averaged and the standard deviation determined. A Student's t-test was performed 
between DMSO control and U0126 treated dishes and significance determined as p < 
0.05. The experiment was performed a total of 3 times with similar results. An identical 
experiment performed with lOSE cells did not yield any soft agar colony growth. 
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RESULTS 
Loss of Cell Anchorage Activates ERK in Ovarian Cancer Cells 
Cellular adhesion is required for efficient activation of ERK by mitogens in most 
epithelial cells and fibroblasts [Lin et aI., 1997; Meredith et aI., 1996; Renshaw et aI., 
1997]. To determine if serum could stimulate ERK activation in suspended ovarian 
cancer cells, adherent SKOV-3 cells were detached with trypsin followed by treatment 
with soybean trypsin inhibitor. The cells were then put in suspension culture for 3 hr in 
the presence or absence of serum. Cells under these suspended conditions remain 
rounded, do not attach to the agarose, and are easily collected by gentle pipetting (data 
not shown). Adherent SKOV-3 cells in serum had modest ERK activation, whereas cells 
suspended for 3 hr in serum had robust activation of ERK and MEK (Fig. lA). Surprisingly, 
suspended cells incubated in serum-free media had a similar level of MEK and ERK 
activation as those suspended in serum. Release of cells by both typsin and citric saline 
and trypsin resulted in a loss of FAK phosphorylation, but an increase in ERK activation 
(Fig. 1B). In addition, we performed a short time course to look at ERK activation 
between 0-3 hr after trypsinization or citric sailine treatment. Activation of ERK did not 
occur until 1-2 hr after cells were in suspension culture under either condition (Figs. Ie 
and 10). 
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To determine if activation of ERK also occurred in benign ovarian epithelial cells 
in suspension culture, we compared the level of ERK activation in detached SKOV-3 cells 
to lOSE cells, a benign cell line derived by SV40 large T antigen immortalization of 
normal ovarian surface epithelium [Auersperg et aI., 1994]. After 3 hrs in suspension in 
serum free media, the basal level of ERK activation in adherent lOSE cells was lost, while 
ERK activation was strongly induced in SKOV-3 cells (Fig. lE). To determine if activation 
of ERK upon detachment occurred in other ovarian cancer cell lines, we screened five 
other ovarian cancer cell lines for ERK activation in serum free media in response to 
cellular detachment. We observed an induction of ERK1 and ERK2 activation at 1 and 3 
hr after detachment in four of the six cell lines tested (Figure IF). ERK activation upon 
detachment was strongest in SKOV-3 cells, which have wild-type ras and b-raf genes 
[Yang et aI., 2003] , but was also observed in OVCAR3, TOV21G, and CAOV3 cells. Like 
lOSE cells, ERK activation in adherent OV2008 cells was lost upon cell detachment, as 
has been reported in many benign and cancerous cell lines [Eblen et aI., 2002; Fukazawa 
et aI., 2002; Honma et aI., 2006; Howe et aI., 2002; Howe and Juliano, 2000; Kraus et aI., 
2002; Lin et aI., 1997; Renshaw et aI., 1997; Slack-Davis et aI., 2003; Zhang et aI., 2006] 
while ERK activation in adherent ES2 cells remained unchanged after cell detachment. 
Activation of ERK in suspension was also observed in cells incubated for 3 hr in the 
presence of 1 % bovine serum albumin, 4 mM EGTA, or a combination of the two, 
suggesting that ERK stimulation was not due to cell / cell contact or changes in 
osmolarity (Figure IG). 
185 
Prolonged ERK Activation is FAK and PAK Independent 
Growth factor stimulation of ERK in adherent cells is transient, often returning to 
basal levels within hours of stimulation. SKOV-3 cells are resistant to anoikis and can 
survive prolonged times in suspension culture [Frankel et aI., 2001]. To determine the 
duration of ERK activation in suspended SKOV-3 cells, we performed a longer time 
course to determine the activation of ERK and its activator MEK in cells kept in 
suspension for a 2-day period. Activation of both M EK and ERK in suspended cells was 
sustained for the entire 48 hr time course (Figure 2A). Microscopic observation (data not 
shown) as well as immunoblotting for the phosphorylated, active form of focal adhesion 
kinase {FAK} demonstrated that the cells were not attached to the agar (Figure 2A), as 
Y397 phosphorylation of FAK only occurs in adherent cells [Calalb et aI., 1996]. We have 
previously reported that MEKI and ERK activation by cellular adhesion to the 
extracellular matrix requires phosphorylation of MEKI on Ser 298 by PAK [Eblen et aI., 
2002; Slack-Davis et aI., 2003L is negatively regulated by ERK feedback phosphorylation 
of MEKI on T292 [Eblen et aI., 2004] and that both were cell adhesion-dependent [Eblen 
et aI., 2004; Slack-Davis et aI., 2003]. To investigate whether activation of MEKl and ERK 
in suspended ovarian cancer cells was controlled by enhanced phosphorylation of MEKl 
S298 in the absence of T292 phosphorylation, we immunoblotted for both of these 
phosphorylation sites on endogenous MEKl using phospho-specific antibodies. The 
results demonstrate that the prolonged activation of MEK and ERK in suspended SKOV-3 
cells was independent of PAK signaling, due to the absence of Ser 298 phosphorylation 
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in suspended cells. Interestingly, Thr 292 phosphorylation of MEKl had become 
anchorage independent due to the enhanced activation of ERK in suspended cells. These 
data demonstrate that MEK and ERK activation in suspended ovarian cells is 
independent of signaling from FAK and PAK and occurs even in the presence of a 
negative feedback loop. We next compared the duration of MEK and ERK activation in 
suspended cells in the presence or absence of serum. MEK and ERK activation were 
equally robust in suspended cells under both conditions at 3, 24, or 48 hr (Figure 2B). 
Phosphorylation of AKT, which was present in adherent cells, was not significantly 
enhanced upon cell suspension, while FAK activation was greatly reduced. 
Acute Mitogen Treatment of Adherent Cells Stimulates Transient ERK Activation 
Mitogen stimulation of cells typically results in robust ERK activation within 
minutes, returning to basal levels after several hours. To determine if the prolonged 
activation of ERK in suspension under serum and serum free conditions also occurred in 
adherent cells stimulated with mitogens, we first determined the ability of serum, 
epidermal growth factor {EGF}, and hepatocyte growth factor {HGF} to stimulate ERK in 
adherent SKOV-3 cells. SKOV-3 cells overexpress both ErbB-2 [Wiechen et aI., 1999] and 
c-Met [Corps et al.I 1997], the HGF receptor, and both EGF and HGF have been shown to 
be important in ovarian cancer biology [Berchuck et aI., 1990; Huntsman et aI., 1999; 
Meden et aI., 1998]. Cells were serum-starved overnight and then stimulated with 
increasing amounts of each mitogen for 10 min. (Figure 3A). Serum was a poor 
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stimulator of ERK activity at this time point, while EGF induced robust ERK activation at 
all concentrations. HGF was a moderate activator of ERK at the highest concentration 
tested. To determine the duration of ERK activation by each mitogen, a time course was 
performed after stimulation with 1 ng/ml EGF, 10 ng/ml HGF (Figure 38) or 10% serum 
(Figure 3C). ERK activation with each mitogen was transient, returning to basal levels 
within several hours. These data demonstrate a fundamental difference in the duration 
of ERK activation stimulated by growth factor addition in adherent cells versus 
activation due to loss of cell attachment. 
Cell / Matrix Re-attachment Restores Basal MEK and ERK Activation 
To directly test the effects of extracellular matrix attachment on ERK activation, 
SKOV-3 cells were detached and put into suspension for 3 hr. The cells were then either 
left in suspension for additional time or allowed to re-attach to fibronectin-coated 
dishes (Fig. 4A). Fibronectin is one of the main extracellular matrix proteins that is 
produced by mesothelial cells of the peritoneal cavity and is important for attachment 
and migration of ovarian cancer cells to the mesothelium [Casey et aI., 2001; Lessan et 
aI., 1999]. Replating suspended SKOV-3 cells onto fibronectin resulted in a restoration of 
basal MEK and ERK activity within 2 hr, while both proteins remained active in parallel 
cultures of cells that were kept in suspension. Phosphorylation of MEK1 on Ser298 and 
FAK on Tyr397 were both restored upon cell adhesion. To compare the response of 
benign versus malignant ovarian cancer cells in this assay, lOSE and SKOV-3 cultures 
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were detached and suspended in parallel. The cells were then either kept in suspension 
or replated onto fibronectin-coated dishes, as in Figure 4A. MEK and ERK activation was 
enhanced in detached SKOV-3 cells (Fig. 48), as above. Upon reattachment of the cells 
to fibronectin coated dishes, basal levels of MEK and ERK activation were restored 
within hours. Conversely, the level of activation of ERK and MEK in adherent lOSE cells 
was lost in detached cells, but restored upon adhesion of the cells to fibronectin. 
Phosphorylation of FAK and 5298 of MEKl were adhesion dependent in both cell lines. 
Protein levels of MKP-l, a nuclear MAP Kinase phosphatase, are down-regulated in 
ovarian cancer [Denkert et aI., 2002], were much lower in 5KOV-3 cells compared to 
rOSE cells, but did not significantly vary with the attachment state of the cells. 
Collectively, these data directly demonstrate that cellular adhesion to extracellular 
matrix and/or cell spreading acts to down-regulate ERK in malignant, but not benign, 
ovarian cells. 
Dynamic Regulation of ERK Activation by an Autocrine Mechanism 
We reasoned that if the activation of MAP Kinase in suspended ovarian cancer 
cells is due to low expression/ activity of ERK-specific phosphatases, such as MKP-l, 
suspended cells should have low MEK activity and there should be a slow turnover of 
ERK phosphorylation. Therefore, inhibition of upstream signaling with the MEK inhibitor 
U0126 should only decrease MAP Kinase phosphorylation after a prolonged treatment. 
We put 5KOV-3 cells in suspension for 3 hr and treated them with U0126 for the last 2 
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min, S min, 10 min, 15 min, 30 min or the entire 3 hr before harvest (Fig. SA). 
Interestingly, inhibition of MEK activity with U0126 for as little as 2 minutes before 
harvest caused the complete dephosphorylation of active ERK within the cell. Similar 
results were seen with 2 minutes of U0126 addition over a 48 hr time course in 
suspension (Fig. 5B). Therefore, even in the presence of reduced MKP-1 expression, the 
enhanced activation of ERK in suspended cells is not due to loss of phosphatase activity 
towards ERK, but is instead a very dynamic process involving activation by MEK followed 
by a rapid inactivation of ERK by phosphatases. 
Since activation and inactivation of ERK in suspended cells was dynamic, we 
sought to determine if this activation was due to an autocrine stimulatory pathway. We 
collected conditioned media from serum starved cells suspended for either 3 hr or 24 hr 
(Fig. 6A). Activation of MAP Kinase in SKOV-3 cells was evident at both 3 and 24 hr in 
suspension, with greater activation at 24 hr. Either fresh serum-free media or the 
conditioned media from the suspended cells was then added to adherent, serum-
starved SKOV-3 cells. Addition of conditioned media from suspended cells, but not fresh 
serum-free media, to adherent SKOV-3 cells resulted in a rapid activation of MEK and 
ERK in the adherent cells. A strong activation, equal to the level in suspended cells, was 
observed at S min after addition. Activation was reduced at 15 and 60 min after addition 
but was much higher than basal levels. Performing a longer time course of ERK 
activation using conditioned media from 24 hr suspended cells demonstrated that basal 
levels of ERK activation were restored between 3 and 6 hr after addition (Fig. 68). These 
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data demonstrate that suspended cells produce a soluble factor that acts in an 
autocrine fashion to stimulate intracellular signaling to MEK and ERK. 
Enhanced ERK Nuclear Signaling in Suspended Cells 
Upon activation of adherent cells with a mitogen, ERK translocates to the 
nucleus [Chen et aI., 1993; Lenormand et aI., 1993], which is required for cellular 
proliferation [Brunet et aI., 1999]. It has been reported that ERK cannot signal to its 
nuclear substrate Elk1 in the absence of cellular adhesion [Aplin et aI., 2001). We used 
an Elk1-responsive luciferase reporter system [Roberson et aI., 1995] to test for the 
ability of ERKs to signal to the nucleus in suspended SKOV-3 cells. Cells were transfected 
with plasmids encoding a GAL4-Elk1 fusion protein, 5X GAL4 luciferase [Roberson et aI., 
1995], and TK Renilla luciferase. The following day the cells were either serum starved 
or put in suspension in serum free media. Adherent and suspended cells were harvested 
24 hr later and luciferase activity determined (Figure 7). The TK Renilla reporter 
demonstrated an overall reduction in transcription in suspended cells (data not shown). 
Normalizing to Renilla luciferase, ERK-responsive firefly luciferase activity was 2.5 fold 
higher in suspended SKOV-3 cells compared to adherent cells (Fig. 7). Co-transfection of 
a mutationally activated MEKl enhanced ERK nuclear signaling in both adherent and 
suspended cells, demonstrating that enhanced ERK activation in adherent cell lines 
could stimulate luciferase production and that the difference in endogenous signaling 
was due to the enhanced ERK activation in suspended cells. These results demonstrate 
191 
that cellular detachment in SKOV-3 cells enhances MAP Kinase signaling to the nucleus 
and regulation of gene transcription. 
Enhanced Role of ERK in Suspended Cells 
ERK activation has a known role in cell proliferation. To determine the effect of 
ERK activation on anchorage dependent versus anchorage independent cell growth, we 
first performed cell proliferation assays on adherent SKOV-3 and lOSE cells. Cells were 
plated and treated the following day with either 10 [z]M U0126 or DMSO control. Cells 
were treated with MTT reagent 2 hr before harvest over the next 4 days (Fig. BA). After 
4 days of treatment, cell proliferation in U0126 treated cells was decreased 22 % in lOSE 
cells and only 12% in SKOV-3 cells, both of which, while small differences, were 
statistically significant. These results suggest that SKOV-3 cells have a reduced 
requirement for ERK activity in regards to adherent proliferation compared to lOSE cells. 
Since we have observed an enhanced activation of ERK in detached SKOV-3 cells, we 
hypothesized that ERK inhibition may have a greater effect on anchorage independent 
growth. Therefore, we determined the ability of lOSE and SKOV-3 cells to grow in soft 
agar in the presence of DMSO or the MEK inhibitor U0126. Cells were treated with 
DMSO or U0126 at the time of plating and every 3 days afterwards. lOSE cells 
demonstrated no growth in soft agar (data not shown), as expected. Conversely, SKOV-3 
cells produced colonies in soft agar, as reported [Pegues et aI., 1999; Popadiuk et aI., 
2006]. We observed an overall reduction in colony number and size in the presence of 
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U0126 (Figs. 88 and 8e). U0126 treatment decreased colony growth by 69% compared 
to DMSO treated cells, demonstrating that inhibition of ERK activation has profound 
affects on anchorage independent growth of ovarian cancer cells. 
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DISCUSSION 
We present the novel finding of strong and sustained activation of MEK and ERK 
in ovarian cancer cell lines in response to loss of cell adhesion. To our knowledge, this is 
the first report of loss of cell adhesion stimulating an induction of ERK activity. ERK 
activation in suspension was dynamically regulated by autocrine activation and robust 
phosphatase activity. Re-attachment of suspended cells restored basal ERK activity. ERK 
signaling to the Elk1 transcription factor was enhanced in suspended cells and MEK 
activity was required for soft agar growth. These results demonstrate a unique mode of 
ERK regulation by cell attachment and demonstrate a novel mechanism of ERK 
activation that occurs specifically during loss of cell adhesion, which has implications for 
anchorage independent growth of ovarian cancer cells. 
In benign epithelial cells and fibroblasts, ERK activation by growth factors 
requires cell adhesion to the extracellular matrix [Lin et aL, 1997; Renshaw et aL, 1997] 
Loss of cell attachment inactivates the ERK pathway due to inhibition of PAK by PKA 
[Howe and Juliano, 2000] and uncoupling of MEK and ERK [Eblen et aI., 2002]. ERK 
inactivation in suspended cells has also been noted in several cancer cell lines, including 
breast cancer [Fukazawa et al., 2002], small cell lung cancer [Kraus et aL, 2002], and in 
highly metastatic melanoma [Zhang et al., 2006] and hepatocellular carcinoma [Honma 
et aI., 2006] cell lines. This suggests that loss of ERK activation in suspension does not 
just occur in benign cells, but also in cancer cells as well. 
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ERK activation in newly-adhering cells requires activation of the Rac / PAK 
pathway, which acts to enhance activation of the ERK pathway through PAK 
phosphorylation of Raf on Ser338, leading to Raf activation [Edin and Juliano, 2005]. We 
have shown that PAK phosphorylation of MEKl on Ser 298 is required for MEK1 
activation upon cell adhesion [Slack-Davis et aI., 2003] and functional coupling between 
MEKl and ERK, which are dissociated in suspended cells [Eblen et al., 2002]. Expression 
of mutationally-activated FAK [Renshaw et aI., 1999] or PAK [Howe and Juliano, 2000] in 
suspended cells has been shown to result in ERK activation. However, we demonstrate 
that MEK and ERK activation in suspended ovarian cancer cells does not occur through a 
mechanism involving aberrant PAK activity leading to anchorage-independent 
phosphorylation of MEKl on Ser298. These results suggest that signaling to MEK and 
ERK in suspended SKOV-3 cells is through a mechanism that does not require pathways 
that crosstalk for ERK activation in adherent cells. Indeed, inactivation of FAK was 
observed in suspended SKOV-3 cells and we have previously shown that PAK activation 
in newly-adherent cells requires FAK activity [Slack-Davis et aI., 2003]. Interestingly, we 
observe that feedback phosphorylation of MEK1 on Ser292 [Mansour et aI., 1994], 
which is normally adhesion dependent and acts as a negative regulatory mechanism for 
MEK1 activation during cell adhesion [Eblen et aI., 2004], is not diminished in suspended 
SKOV-3 cells due to sustained activation of ERK. We currently show that it does not play 
an inhibitory feedback role in the context of loss of cell adhesion. 
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ERK activation in response to EGF stimulation in adherent SKOV-3 cells was 
robust and returned to basal levels within hours, as has been reported extensively in the 
literature for other cell types. However, ERK activation in newly-detached cells in the 
absence of any external mitogen stimulation occurred with slow kinetics accompanied 
by sustained activity. One possibility for this slow but sustained activation of ERK is the 
loss of ERK-directed phosphatase activity, through a mechanism in which basal 
activation of MEK slowly phosphorylates ERK and there is insufficient phosphatase 
activity to restore basal levels of ERK activity. Indeed, reduced expression of MKP-l 
occurs in ovarian tumor specimens compared to normal ovarian tissue [Denkert et al., 
2002] and we observed lower levels of MKP-l in SKOV-3 cells compared to benign lOSE 
cells. Steinmetz [Steinmetz et aI., 2004] demonstrated that forced overexpression of 
MKPl in malignant granulosa cells, which normally express low levels of MKPl and have 
elevated levels of active ERK, lowers basal levels of ERK phosphorylation to that seen in 
benign ovarian cells. They concluded that low levels of MKP-l result in enhanced ERK 
activity in these cells, which was supported by undetectable levels of active MEK 
[Steinmetz et al., 2004]. However, we observed normal kinetics of growth factor 
stimulation of ERK in adherent SKOV-3 cells by EGF, HGF, and serum and no difference 
in MKP-l protein levels in suspended versus adherent SKOV-3 cells. Moreover, we 
demonstrate a robust and sustained activation of MEK in suspended SKOV-3 cells and 
demonstrate that blocking upstream signaling from MEK to ERK by the addition of 
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U0126 for as little as 2 minutes resulted in a complete dephosphorylation of ERK. Thus, 
while MKP-l levels are lower in SKOV-3 cells compared to benign lOSE cells, there is 
sufficient phosphatase activity present from either M KPl or other ERK phosphatases 
[Camps et aI., 2000] to stimulate rapid turnover of ERK phosphorylation. Our results 
demonstrate that ERK activation in detached SKOV-3 cells is dynamically regulated by a 
skewed balance between robust upstream activation by MEK through an autocrine 
mechanism, which is favored over and counteracted by prevalent phosphatase activity. 
This balance is shifted towards MEK and ERK inactivation in adherent cells to allow for 
inactivation of MEK and ERK after cell stimulation. The signaling pathways that restore 
this balance upon cell adhesion will be an interesting area to investigate, as they 
regulate production of the autocrine factor or the way that the celt responds to the 
factor. 
Aplin et at. [Aplin et aI., 2001] demonstrated a requirement for cellular adhesion 
in order for ERK to signal to the nucleus in NIH3T3 cells, correlating with an inhibition of 
ERK activity in suspended cells. While co-transfection of a mutationally-activated form 
of Raf or MEK could stimulate ERK activity in suspended NIH3T3 cells, signaling to Elk! in 
the nucleus required cell attachment [Aplin et aI., 2001]. We demonstrate that the 
enhanced activation of MEK and ERK in suspended SKOV-3 cells allows for enhanced 
nuclear signaling to transcription factors compared to adherent cells. Overall 
transcription was greatly reduced in suspended cells, but ERK signaling to Elk! was 2.5 
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fold higher than in adherent cells. When endogenous ERK was artificially activated by 
co-transfection of a constitutively activated MEK, ERK nuclear signaling was not 
statistically significant between adherent and suspended cells. This suggests that some 
ovarian cancer cells have developed mechanisms to support nuclear translocation of 
activated ERK under conditions of anchorage independence. The enhanced gene 
transcription may then contribute to anchorage independent growth. The mechanism of 
ERK nuclear translocation under anchorage independent conditions has not been 
elucidated, but may provide novel targets for therapeutic intervention. 
The effects of ERK signaling in suspended cells may not only be transcriptional, 
but non-genomic as well. In MCF7 cells, arrest of cells at Gl/S results in transient 
activation of ERK in suspended cells, preventing apoptosis through suppression of Bim-
EL, which is pro-apoptotic [Collins et aI., 2005]. ERK phosphorylation of Bim-EL 
stimulates its degradation, promoting cell survival [Ley et aI., 2004; Luciano et aI., 2003; 
Marani et al., 2004]. However, the mechanism for anchorage-independent activation of 
ERK in ovarian cancer cells is apparently not due to Gl growth arrest, as MEK was 
inactive in the suspended MCF7 cells and activation of ERK was thought to occur 
through loss of phosphatase activity [Collins et aI., 2005]. 
We have shown that conditioned media from serum-starved suspended cells was 
able to stimulate ERK activation in serum-starved adherent cells, demonstrating the 
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presence of an autocrine pathway activated in detached cells. At present, the identity of 
the autocrine signal is unknown. Several mitogens, such as lysophosphatidic acid (LPA), 
platelet derived growth factor (PDGF) [Matei et aI., 2006] and others have been 
identified in ovarian ascites fluid. LPA was shown to be secreted by peritoneal 
mesothelial cells, stimulating the migration of ovarian cancer cells [Ren et aI., 2006]. It is 
doubtful that LPA is responsible for the autocrine signal, as LPA is the main mitogen in 
serum and serum was a weak stimulator of ERK activation in adherent SKOV-3 cells; 
however, we have not ruled out this possibility, as high levels of LPA may be produced 
from suspended cells. Signaling through the EGF receptor by either direct or indirect 
means could also be a possibility, as SKOV-3 cells overexpress EGF receptor family 
members and EGF stimulates robust ERK activation in these cells. EGFR and ErbB-2 are 
both overexpressed in a significant percentage of ovarian tumors and correlate with 
poor prognosis [Berchuck et aI., 1990]. The identification of the autocrine signal is 
currently under investigation in our laboratory, as it could serve as a marker for 
metastatic ovarian cancer. In addition, we are currently discerning the upstream 
intracellular signaling proteins that are utilized by the autocrine signal to enhance ERK 
activation, as these may give insight into signaling pathways induced by anchorage 
independent conditions of ovarian cancer cell growth in pleural and peritoneal ascites. 
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FIGURE LEGENDS 
Figure 1. Activation of ERK in suspended ovarian carcinoma cells. A: Adherent (Adh) 
SKOV-3 cells were detached with trypsin and treated with soybean trypsin inhibitor. The 
cells were centrifuged, resuspended in either serum free medium (SF) or media 
containing 10 % FBS, and put in suspension culture for 3 hr before harvest. Cell Iysates 
were immunoblotted for ERK2, MEK, FAK, and the activated forms of these proteins. B: 
Adherent SKOV-3 cells were detached with either trypsin or citric saline and put in 
suspension culture for 3 hr in serum-free media. C and 0: Adherent SKOV-3 cells were 
detached with trypsin (C) or citric saline (D) and put in suspension culture in serum free 
media for the indicated time. E: Adherent (A) lOSE and SKOV-3 cells were detached with 
trypsin and put in suspension (S) for 3 hr in serum free media. Lysates were 
immunoblotted for ERK2 and active ERK. F: Six adherent (A) ovarian cancer cell lines 
were detached with trypsin and placed in suspension in serum-free media for 1 or 3 hr. 
G: Adherent (Adh) SKOV-3 cells detached with trypsin and put in suspension for 3 hr in 
either serum-free media (-), or serum-free media containing 0.5% bovine serum albumin 
(BSA), 4 mM EGTA, or BSA and EGTAo 
Figure 2. Sustained activation of MEK and ERK in suspended cells. A: Adherent (Adh) 
SKOV-3 cells were trypsinized and suspended in serum-free media for the indicated 
time. Ceillysates were immunoblotted as indicated. The p-218 MEK antibody recognizes 
209 
the active form of the kinase, while the p-298 and p-292 antibodies recognize the PAK 
and ERK phosphorylation sites on MEK1, respectively. B: Adherent (Adh) SKOV-3 cells 
were put in suspension for 3, 24, or 48 hr in 10 % serum or serum-free media. Lysates 
were immunoblotted as indicated. 
Figure 3. A: Adherent SKOV-3 cells were serum-starved for 12 hr and then treated with 
either fresh serum free media {SF} or increasing concentrations of serum, EGF, or HGF 
for 10 min. Cell Iysates were immunoblotted for total and active ERK and MEK. B: 
Adherent (A) SKOV-3 cells were washed twice and incubated in serum-free (SF) media 
overnight. The cells were then stimulated for the indicated time with either 1 ng/ml EGF 
(top) or 5 ng/ml HGF (bottom). Ceillysates were immunoblotted for phosphorylated ERK 
and ERK2. C: Adherent cells were serum-starved overnight (SF) and then stimulated with 
10 % serum for the indicated times. Cell Iysates were immunoblotted for 
phosphorylated ERK and ERK2. 
Figure 4. Re-attachment of SKOV-3 cells to an extracellular matrix restores down-
regulation of ERK activity. A: Adherent (A) SKOV3 cells were detached with trypsin and 
suspended in serum-free media for 90 min or 3 hr. After 3 hr the cells were either left in 
suspension for the additional time indicated or replated onto fibronectin-coated dishes 
for the same amount of time. Cell Iysates were prepared and immunoblotted for total 
and the activated forms of ERK, MEK, and FAK. B: Adherent (A) lOSE and SKOV-3 cells 
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were detached with trypsin and put in suspension for 3 hr. The cells were either kept in 
suspension for the number of hours indicated or replated onto fibronectin-coated 
dishes for the number of hours indicated. Ceillysates were immunoblotted for total and 
the activated forms of ERK, MEK, and FAK as well as MKP-l and tubulin. 
Figure 5. Sustained activation of ERK in suspended cells is not due to loss of 
phosphatase activity. A: Adherent (Adh) SKOV3 cells were trypsinized and put in 
suspension in serum-free media for 3 hr. The MEK inhibitor U0126 was added to the 
media at a final concentration of 10 111M for the indicated number of minutes prior to 
harvest of the suspended cells. Ceillysates were immunoblotted for phosphorylated ERK 
and ERK2. B: Adherent (Adh) SKOV-3 cells were put in suspension culture for 3 hr, 24 hr, 
or 48 hr. Two minutes before harvest the cells were treated with either DMSO or 10 111M 
U0126. Ceillysates were immunoblotted for phosphorylated ERK and ERK2. 
Figure 6. Activation of ERK is suspended ovarian cells occurs through an autocrine 
mechanism. A: Adherent SKOV-3 cells (Adh) were put in suspension (Sus.) for 3 or 24 hr. 
The cells were harvested and conditioned media from these cells was collected. Either 
fresh serum-free media (SF) or conditioned media from the suspended cells was then 
added to serum-starved adherent SKOV-3 cells for 5, 15, or 60 minutes. Cells Iysates for 
the suspended and adherent cells were prepared and immunoblotted for ERK, MEK, and 
the activated forms of these proteins. B: Adherent {Adh} cells were put in suspension for 
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24 hr (Sus.). Conditioned media from the suspended cells was collected and added to 
serum-starved adherent SKOV-3 cells from 10 min. to 6 hr. Cell Iysates were 
immunoblotted with antibodies to ERK2 and phospho-ERK. 
Figure 7. ERK nuclear signaling is enhanced in suspended ovarian cancer cells. SKOV-3 
cells were co-transfected with GAL4-Elk1, SX GAL4 luciferase, TK Renilla luciferase, and 
either empty vector or mutationally-activated MEK1. After a 5 hr transfection in serum-
free media, the cells were incubated in 10% serum overnight. The following day, the 
cells were washed twice with PBS and either incubated in serum free media or 
trypsinized and incubated in serum-free media in suspension. After 24 hr all cells were 
harvested and both Renilla and firefly luciferase determined using a dual luciferase 
assay kit (Promega). Firefly luciferase activity was normalized to Renilla. Solid bars 
represent adherent cells and checked bars represent suspended cells. The results from 
the adherent cells transfected with the reporter construct, GaI4-Elk1, TK Renilla and 
empty vector (first column) was set at 100%. The results are an average of 5 
experiments performed in duplicate. There was a significant difference (*, p<O.OS) 
between normalized firefly luciferase activity between adherent and suspended cells 
(left columns). There was not a significant difference in normalized firefly luciferase 
activity between the adherent and suspended cells that were transfected with 
mutationally activated MEKI. 
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Figure 8. Inhibition of ERK activation impairs anchorage independent growth. A: SKOV-
3 and lOSE cells were plated in triplicate at a density of 1 X 104 cells per well in 12 well 
dishes in 10% serum-containing media. The following day the cells were treated with 
either 10 111M U0126 or DMSO control. MIT reagent was added for 2 hrs before cell 
harvest for the next 4 days. MTT activity was measured after harvest. The data shown is 
a representative experiment that was performed 3 times. (*, p< 0.05). B: Adherent 
SKOV-3 cells were trypsinized and placed in 1ml of soft agar containing 10% serum at a 
density of 5000 cells per ml. The assay was performed 3 times in triplicate. Cells were 
treated every 3 days with either 10 IlIM U0126 or DMSO control. Four random fields 
were photographed using a 2.5 objective. A representative field from each treatment is 
shown. C. Colony count (>400 [1]m 2) and size was determined using Image J software. 
Quantitation of the total colony count from 4 photographed fields per dish were 
averaged and then compared within each group. There was a statistical significant 
difference (*, p< 0.05) between U0126 and the DMSO control. 
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